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RÉSUMÉ
Dans notre environnement, il y a une multitude de substances toxiques potentiellement
absorbables par les êtres vivants, incluant les humains. Les organismes
gouvernementaux doivent se doter d’outils fiables pour identifier, évaluer et gérer les
risques toxicologiques associés à ces substances afin de prévenir les problèmes de
santé humaine.
Cette thèse présente des outils de surveillance biologique facilement applicables pour
analyser les risques toxicologiques chez les humains exposés à cinq contaminants
environnementaux trois insecticides de ta famille des organophosphotés (parathion,
malathion et chlorpyrifos), un phytocide largement utilisé comme herbicide (triclopyr),
et finalement le méthylmercure. Ces outils visent à évaluer avec suffisamment de
précision les quantités de substance qu’un individu a absorbées à partir de la mesure
des niveaux de ta substance-mère ou de ses métabolites dans une ou plusieurs matrices
biologiques. Une analyse de sensibilité des paramètres impliqués a permis de proposer
une procédure d’utilisation optimale de chaque outil dans le cadre de programmes
d’évaluation et de prévention des risques toxicologiques.
Un modèle cinétique a été développé ou adapté pour chacune des substances étudiées
afin d’établir les liens entre les niveaux de biornarqueurs, les charges corporelles de la
substance-mère et de ses métabolites et les doses absoi-bées suite à différents scénarios
d’exposition (unique, répété, chronique, intermittent ; cutané, oral et pulmonaire) et
différentes stratégies d’échantillonnage des matrices biologiques. Ces outils
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mathématiques se basent sur des systèmes d’équations différentielles qui assurent en
tout temps la conservation des masses molaires.
Pour chacun des quatre pesticides ciblés, un modèle cinétique spécifique a servi à
déterminer des niveaux de biornarqueurs urinaires en-dessous desquels aucun effet
toxique n’est susceptible de se développer. Ces valeurs de référence biologiques
correspondent aux quantités de la substance-mère, ou de ses métabolites, mesurées
dans les urines collectées durant une période donnée chez un individu ayant absorbé,
lors de son quart de travail, une dose pour laquelle il n’y a pas eu d’effets observés
(DSEO). Une analyse de sensibilité des paramètres des modèles cinétiques a montré
que l’hypothèse d’absorption entièrement par la peau donne des valeurs de référence
biologiques plus conservatrices que l’hypothèse d’absorption par les autres voies
possibles d’entrée. L’application de ces valeurs de référence assure ainsi une bonne
protection des personnes exposées quelle que soit la voie d’absorption de ces
substances.
Les outils développés dans cette thèse ont été utilisés pour estimer l’exposition et les
risques encourus par des travailleurs exposés au malathion ou au triclopyr ainsi que
pour des populations autochtones exposées au méthylmercure. Les comparaisons entre
les niveaux de biomarqueurs mesurés chez les travailleurs et les valeurs de référence
biologiques ont démontré que les risques découlant de cette exposition étaient
négligeables ou nuls au moment de cette évaluation. D’autre part, les apports
quotidiens en méthylmercure estimés à partit’ du modèle cinétique et des concentrations
Vde mercure total mesurées dans les segments consécutifs coupés dans les mèches de
cheveux se sont avérés plus bas et plus cohérents avec les données biologiques que
ceux estimés à partir de questionnaires alimentaires.
Mots clés surveillance biologique, analyse des risques, exposition, biomarqueur,
toxicocinétique, parathion, malathion, chlorpyrifos, triclopyr, méthylmercure.
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ABSTRACT
In our environment, there is a multitude of toxic chernicals that may be absorbed by
living organisrns, including humans. Governrnent agencies must thus obtain reliable
tools to identify, evaluate and manage the toxicological risks associated with these
chemicals in order to prevent damages to human health.
This thesis presents easily applicable biological monitoring tools to analyze the
toxicological risks for hurnans exposed to five environrnental contaminants: three
insecticides of the organophosphate family (parathion, malathion and chlorpyrifos), a
phytocide largely used as herbicide (triclopyr), and flnally rnethylrnercury. These tools
allow estimation ofthe absorbed arnounts ofchemical with sufficient precision starting
from the levels of the substance or its metabolites in one or several biological matrices
of the exposed individual. A sensitivity analysis of the relevant model pararneters Ied
to the proposai of an optimal method for utilizing each tool as part of a program for the
evaluation and prevention oftoxicological risks.
A kinetic model was developed or adapted for each studied substance in order to
establish die links between die levels ofbiornarkers, the body burdens ofthe substance
and its metabolites and the cumulative intake foliowing various exposure scenarios
(single, intermittent, repeated, chronic; dermal, oral and pulrnonary) and any collection
period of the biological matrices. These mathernatical tools are based on systems of
differential equations which ensure at any tirne the conservation ofthe molar masses.
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For each ofthe four targeted pesticides, a specific kinetic model vas used to determine
the levels of urinary biomarkers below which toxic effects are flot likely to appear.
These biological reference values correspond to the amounts ofthe substance, or their
metabolites, rneasured in cirines collected over a chosen period for a worker having
absorbed, during the work shift, a dose for which no toxic effect lias been observed
ENOEL). An anaÏysis on the pararneters of the kinetic models showed that the
hypothesis of absorption entirely by the skin gives more conservative biological
reference values than assurning that absorption occurred through the other possible
absorption routes. Use of these reference values thus ensures a good protection for the
exposed persons, and this whatever the route-of-entry.
The tools developed in this thesis were applied to estirnate the exposure and the risks
for workers exposed to malathion or to triclopyr and for indigenous populations
exposed to methylrnercury. Comparisons between rneasured levels of hiornarkers in
workers and the reference values showed that the risk related to this exposition were
negligible at the moment of the evaluation. The daily intakes of methylmercury
estimated with the kinetic model and starting from the total mercury concentrations
rneasured in hair segments turn out to be lower and more consistent with the biological
data than those estimated from dietary questionnaires.
Key words : biological monitoring, risk analysis, exposure, biornarker, toxicokinetics,
parath ion, malath ion, chlorpyri fos, triclopyr, rnethylrnercury.
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CHAPITRE 1: INTRODUCTION
PROBLÉMA TIQUE
Notre environnement est contaminé par une multitude de substances toxiques, résultat
d’activités humaines: production de biens, transport, chauffage, élimination et
récupération de déchets industriels et domestiques ainsi que les activités agricole,
horticole et forestière. Cette contamination atteint tous les milieux avec lesquels les
êtres vivants sont en contact (air, eau, sol, nourriture) et, conséquemment, l’être
humain lui—même est atteint. Les travailleurs qui manipulent des substances toxiques
sont généralement les plus susceptibles d’être exposés à ces produits, mais personne n’y
échappe. Il existe malheureusement des situations, accidentelles ou non, lors desquelles
les êtres humains absorbent des quantités de substances toxiques à des niveaux qui
induisent des problèmes de santé. Afin de prévenir ces problèmes, les organismes
gouvernementaux doivent établir des moyens d’identification, d’évaluation et de
gestion des risques tant à l’égard de l’environnement qu’à l’égard des êtres vivants.
Pour répondre à cette préoccupation, la communauté scientifique consacre de plus en
plus d’efforts au développement de différentes approches méthodologiques pour
l’analyse des risques toxicologiques pour la santé humaine. Cette analyse se définit
comme étant la somme des processus qui permettent de déterminer la probabilité que
des effets indésirables sur la santé se produisent à la suite d’une exposition donnée.
L’analyse des risques comprend, entre autres, deux volets complémentaires
l’évaluation de l’exposition et l’évaluation de la réponse toxique des êtres humains à
cette exposition. Pour être utiles, il importe donc que les méthodes utilisées pour ces
3évaluations soient les plus précises, car une mauvaise évaluation peut entraîner des
conséquences néfastes pour la société en général. Une bonne analyse des risques reliés
à une substance toxique ou à une famille de substances toxiqcles doit aussi s’appliquer à
n’importe quelle condition d’exposition en situation réelle.
En matière d’évaluation de l’exposition, le défi est d’estimer avec suffisamment de
précision les quantités de substances absorbées par les personnes exposées en tenant
compte de toutes les voies d’entrée dans l’organisme et de tous les types
d’exposition. Bien qu’idéalement, la part de la quantité absorbée attribuable à une
source spécifique par rapport à l’ensemble des sources d’exposition devrait être
déterminée, c’est souvent l’exposition interne totale qui est estimée lors d’une analyse
des risques toxicologiques. Il est bon de rappeler que, dans le jargon des toxicologues,
la quantité absorbée est souvent appelée dose absorbée ou exposition interne. Dans la
présente étude, les outils concernant l’évaluation de l’exposition sont développés pour
la détermination de la dose absorbée totale.
Pour évaluer la dose absorbée totale des personnes à des substances toxiques, deux
procédures de surveillance sont souvent employées. La première, appelée évaluation
environnementale, estime l’exposition interne de façon indirecte en deux temps : 1) par
la mesure de la contamination dans les échantillons collectés dans les divers milieux
(air, eau, sol, nourriture) et 2) par l’estimation de l’exposition de ces individus à ces
milieux et du degré d’absorption des quantités de substances avec lesquelles ils sont en
contact lors de leur présence dans ces milieux. La seconde procédure, appelée
4surveillance biologique, est plus directe puisqu’elle estime les doses absorbées au
moyen de mesures de cette contamination dans des échantillons biologiques (p.ex..
sang, urine, cheveux) prélevés directement chez les personnes en contact avec la
substance à l’étude.
Pour estimer l’exposition des personnes à l’étude sur la base de mesures
environnementales, il faut recueillir une quantité importante d’échantillons individuels
afin d’assurer une représentation fidèle de l’exposition réelle. Cette représentation se
réalise à l’aide d’analyses statistiques des données recueillies. Par exemple, pocir
effectuei- l’évaluation de l’exposition d’un travailleur exposé par inhalation ou par voie
cutanée à une substance quelconque, la fréquence et la durée de l’échantillonnage
doivent être adéquates. Les données recueillies doivent en fait tenir compte du temps
passé dans tin site donné par le travailleur, de sa mobilité dans les lieux fréquentés, des
différentes tâches effectuées par ce travailleur, de la fréquence de ces tâches, de la
variation des émissions de polluants d’une tâche à l’autre, de la variation des
concentrations dans le milieu au cours d’une même journée, d’une journée à l’autre et
d’une saison à l’autre. Aux nombreux facteurs de variabilité décrits ci-dessus s’ajoutent
la variation des mesures de protection prises par les individus et la variation du degré
d’absorption d’un individu à l’autre. Devant tous ces paramètres impliqués dans
l’estimation de l’exposition interne, il apparaît donc difficile d’estimer avec précision
les doses absorbées par les individus exposés en utilisant uniquement l’échantillonnage
environneinental.
5En revanche, l’évaluation biologique de l’exposition interne évite les considérants
environnementaux et les facteurs d’absorption. Elle vise la reconstruction, à postériori,
de la dose absorbée à partir de mesures effectuées dans des matrices biologiques
appropriées telles que l’urine, les cheveux, le sang ou l’air exhalé. Les niveaux de
biornarqueurs sont en fait les quantités mesurées du contaminant lui-même (substance
mère) ou d’une ou des substances dérivées des processus de biotransformation
(métabolites) présents dans les échantillons biologiques.
La caractérisation du risque par l’une ou l’autre de ces deux procédures de surveillance
s’établit en comparant les doses absorbées avec des données sur la relation « dose
absorbée-réponse toxique chez l’humain ». En général, compte tenu que le but
recherché est de prévenir tout risque, on cherche à connaître les niveaux d’exposition
en-dessous desquels des effets toxiques n’ont jamais été constatés chez l’humain. Ces
niveaux permissibles se définissent à l’aide des doses DSENO (dose sans effet nocif
observé) ou DMENO (dose minimale avec un effet nocif observé). De ces doses
résultent des valeurs de référence qui sont, pour la plupart, déterminées en divisant la
DSENO ou la DMENO par des facteurs de sécurité. En principe, ces valeurs de
référence ainsi calculées assurent la protection de tout le monde, même les plus
susceptibles. Conséquemment, en comparant la dose absorbée par un individu avec la
valeur de référence spécifique à une substance, on possède un outil de surveillance utile
pour prévenir les risques de développer des effets nuisibles sur la santé humaine.
6Les valeurs de référence basées sur l’absence d’effets s’appliquent généralement aux
doses visant la prévention d’effets non cancérigènes, Quand une substance est
considérée posséder un potentiel cancérigène, il y a absence de consensus dans la
communauté scientifique sur l’existence d’un seuil sans effet. Les limites admissibles
d’exposition sont souvent établies, principalement en Amérique, à un niveau
représentant un excès de risque jugé socialement acceptable. Cependant, puisque la
détermination de ces limites dépend de nombreux facteurs autres que scientifiques, une
discussion sur la caractérisation du risque pour les effets cancérigènes dépasse
largement le cadre de ce travail.
Au Québec, les valeurs limites admissibles font généralement référence à des
évaluations environnementales. Le Ministère de l’environnement établit les normes
pour la contamination de l’air, l’eau et les sols (L.R.Q., c. Q-2), le Ministère de
l’agriculture, pêcheries et alimentation détermine celles de la contamination des
aliments (L.R.Q., c., P-29), alors que la Commission de la santé et de la sécurité du
travail (RQMT, 2001) établit les normes pour le milieu de travail. Pour ce dernier
milieu, à quelques exceptions près, les valeurs de référence sont exprimées en
concentrations mesurées dans l’air ambiant.
7OBJECTIFS
Objectifprincipal
Les objectifs principaux de cette recherche sont de développer des outils de
sLlrvelllance biologique pour cinq contaminants, le méthylmercure (MeHg) et quatre
pesticides (parathion, malathion, chlorpyrifos et triclopyr), et de proposer pour chacun
une procédure pour déterminer ou utiliser adéquatement des valeurs de référence dans
te cadre de programmes d’évaluation et de prévention des risques pour la santé
humaine. Ces outils doivent être facilement applicables en situations réelles et être plus
précis que ceux déjà existants pour estimer l’exposition humaine à ces substances,
autant chez les travailleurs que chez la population générale.
Obledifsecondaire
L’objectif secondaire de cette recherche est d’appliquer ces outils pour étudier
l’exposition et les risques en situations réelles. Les applications portent sur l’exposition
de travailleurs exposés au malathion et au triclopyr alors que pour le méthylmercure, il
porte sur l’exposition de populations autochtones du Canada et du Brésil.
STR UCTURE DE LA THÈSE
Dans ce qui suit, une description sommaire des chapitres de la présente thèse est offerte
en fonction des objectifs spécifiques à atteindre pour chaque substance ciblée.
$Chapitre 2: Généralités sur la surveillance biologique
Dans ce chapitre est présentée une brève discussion sur les caractéristiques d’une étude
de surveillance biologique, sur différentes stratégies pour évaluer la dose absorbée et
pour déterminer les valeurs repères ainsi que sur les approches de modélisation
cinétique. Ce chapitre permet de mieux cerner les enjeux, les mérites et les exigences
d’une analyse de risques toxicologiques basée sur des mesures biologiques.
Chapitre 3, 4 et S : Pesticides de type organophosphoré (ARTIc’LES 1, 2 et 3)
Ces trois chapitres présentent le développement d’outils d’évaluation biologique
d’exposition et les propositions de valeurs de référence des marqueurs biologiques
utilisés pour trois pesticides organophosphorés : le parathion, le malathion et le
chlorpyrifos. PoLir ce faire, un modèle cinétique chez l’humain a dû être développé
pour chaque organophosphoré à partir de profils temporels, présentés dans la
littérature, de la substance-mère et de ses métabolites dans le sang et l’urine collectés
chez des humains. Ces modèles permettent d’établir des liens entre la dose absorbée,
les charges corporelles et les niveaux de biornarqueurs et ce, pour tous scénarios
d’exposition et d’échantillonnage probables. Ensuite, pour chaque substance, le modèle
cinétique a été utilisé pour déterminer des valeurs de référence biologiques en milieu
de travail sous forme de biomarqueurs urinaires accurncilés lors d’une période
d’échantillonnage déterminée. Ces valeurs se basent sur les relations entre les quantités
absorbées de l’insecticide et l’inhibition des acétylcholinestérases dans le sang; ces
9relations « dose absorbée-réponse toxique)), établies à partir d’expériences chez des
humains, sont aussi tirées de la littérature scientifique.
Chapitre 6: Pesticide de type pyridine (ARTICLE 4)
Pour le triclopyr, herbicide de la famille des pyridines, il existait déjà dans la littérature
un modèle cinétique développé à partir d’une étude expérimentale chez l’humain
(Carmichael et col!., 1989). Dans le présent ouvrage, ce modèle a été adapté pour
travailler avec des charges plutôt que des concentrations dans le but de reconstruire la
charge corporelle et les quantités de triclopyr absorbées à partir de la mesure du
biomarqueur accumulé dans t’urine. Ce modèle a aussi été modifié afin de permettre
cette reconstruction lors de divers scénarios d’exposition. Une fois adapté, ce modèle a
été utilisé pour quantifier la dose absorbée afin d’estimer le risque de dépassement
d’une dose de référence chez dix travailleurs québécois qui appliquaient du triclopyr
sur la végétation sous des lignes de haute tension.
Chapitre 7: liéthytmercure (ARTICLE 5)
Un modèle de la cinétique du MeHg chez l’humain avait déjà été publié (Carrier et
col!., 2001). Ce modèle possède déjà les attributs nécessaires pour une reconstruction
des profils temporels de charges et de concentrations de mercure organique et
inorganique dans le corps. le sang et autres tissus sur la base des concentrations de
mercure total mesurées dans les segments consécutifs coupés dans les mèches de
cheveux. La contribution originale dans le cadre de cette thèse a principalement
consisté à développer des moyens pour reconstruire l’historique des taux d’exposition
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par ajustements statistiques des projections du modèle aux concentrations de mercure
observées dans les cheveux. Ce travail a été réalisé à partir de données déjà publiées
sur les concentrations de mercure total mesurées dans les mèches de cheveux provenant
de populations autochtones du Canada et du Brésil (Lebel et cou., 1996, 199$ ; Dolbec
et cou.. 2000 Walker et coll.. 2002). L’apport en MeHg ainsi reconstruit a permis
d’estimer l’évolution du risqcie pour la santé en comparaison avec les apports
recommandés par Santé Canada. Ce travail a également permis de proposer des
stratégies concernant les collectes des matrices biologiques (cheveux et sang) selon le
type d’exposition des individus échantillonnés.
Chapitre 8: conclusion générale
Dans ce chapitre sont énoncées les conclusions des résultats de cette thèse ainsi que
leurs principales contributions pour le domaine de la surveillance biologique.
CHAPITRE 2 : GÉNÉRALITÉS SUR LA SURVEILLANCE
BIOLOGIQUE
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Ce chapitre présente une synthèse de connaissances sur la problématique d’utilisation
des biornarqueurs pour l’évaluation des risques associés à l’exposition des êtres
humains aux substances toxiques. Une analyse critique de ces connaissances est
réalisée dans le but de dégager les principaux concepts à la base des différentes
approches mises en oeuvre pour atteindre les objectifs de la présente recherche.
LES CONDITIONS D’UTILISATION DE LA SURVEILLANCE
BIOLOGIQUE
Il faut d’emblée préciser que la surveillance biologique n’est pas applicable à tous les
contaminants environnementaux ; il est nécessaire d’avoir accès à des mesures
biologiques qui permettront une reconstruction fiable de la dose absorbée. C’est le
devenir de la substance absorbée dans la circulation sanguine qui dicte quel est le
meilleur biomarqueur d’exposition à retenir lors d’une étude d’analyse des risques. En
effet, connaître les métabolites potentiels de la substance-mère, les tissus dans lesquels
la substance-mère et les métabolites sont plausiblement stockés de nième que connaître
leurs principales voies d’élimination aident à déterminer, d’une part, la molécule à
mesurer et, d’autre part, la matrice biologique où seront faits les prélèvements. De plus,
la connaissance de la cinétique du contaminant est essentielle pour établir des liens
quantitatifs entre la dose absorbée et son taux d’absorption, d’élimination ou de
stockage. Ces liens permettent particulièrement de choisir l’horaire idéal pour effectuer
les prélèvements dans la matrice biologique retenue.
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LES CARACTÉRISTIQUES D’UN BON BIOMARQUEUR
D ‘EXPOSITION
Un bon biornarqueur d’exposition doit satisfaire un certain nombre de critères : 1) être
le plus spécifique possible au contaminant étudié, 2) permettre sa mesure par une
méthode analytique fiable et peu dispendieuse, 3) être facilement accessible et 4)
fournir des mesures suffisamment sensibles pour permettre une détection de
l’exposition bien inférieure au niveau pour lequel des effets toxiques apparaissent chez
les plus sensibles. De plus, il faut que la molécule quantifiée soit assez stable dans la
matrice échantillonnée pour permettre des mesures reproductibles.
LES VALEURS DE RÉFÉRENCE
American Conference of Governmenta! Industrial Hvgienists (A CGHÏ°,)
Au Canada, pour les milieux de travail, les recommandations sur les niveaux
d’exposition à ne pas dépasser sont principalement celles proposées par l’Arnerican
Conference of Govemmental Industrial Hygienists (ACGIH©). L’ACGIH© est un
organisme sans but lucratif créé il y a plus de 60 ans qui joue aujourd’hui un rôle
primordial à travers le monde dans la prévention des maladies professionnelles. Une de
ses missions est l’établissement de valeurs limites d’exposition (VLE) à des agents
toxiques pour assurer la protection des travailleurs de l’industrie. Cet organisme
produit un guide contenant des valeurs seuils de concentrations de contarninants en
milieu ambiant (Threshold Limit Values t TLV©) et, lorsque possible, des indices
biologiques d’exposition (Biological Exposure Indices BEIs©). S’appuyant sur la
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littérature scientifique. des spécialistes voient à la mise à jour des connaissances et à la
révision périodique de ces valeurs guides. Cette agence américaine proposait, en 2003,
des indices biologiques d’exposition (BEI©) pour 39 substances ou groupes de
substances (ACGIH, 2003). Ces indices identifient les niveaux de biomarqueurs en
deçà desquels les travailleurs ne devraient pas subir d’effets délétères pour leur santé.
Les BEI© sont généralement établis en considérant que l’exposition se fait
exclusivement par inhalation. Les valeurs ainsi proposées sont déterminées en utilisant
rarement des modèles cinétiques qui simulent une exposition pendant une semaine de 5
journées de travail de $ heures à une concentration de la substance dans l’air ambiant
équivalente à la valeur limite d’exposition moyenne pondérée sur huit heures (TLV
TWA©) (ACGIH, 2003). Toutefois, de tels liens entre les TLV-TWA© et les BEI© ne
sont pas valables pour les contaminants dont la TLVTWA© protège le travailleur
contre des effets locaux (p.ex., irritation des yeux et de la gorge) ou pour ceux dont la
principale voie d’absorption est autre que les voies respiratoires (ACGIH, 2003). Dans
ces cas, les valeurs des BEI© sont déterminées à partir du lien direct entre l’apparition
d’effets néfastes sur la santé et les niveaux de biomarqueurs mesurés chez des
individus exposés sous des conditions professionnelles. Les BEI© du plomb, du
cadmium et du parathion ont été établis à partir de tels liens directs. Il faut de plus
mentionner que lACGIH© propose un BEI© sur la base d’un biornarqueur d’effets
mesurables suite à l’exposition aux pesticides des familles des organophosphorés et des
carbamates. Ce BEI© correspond à un niveau d’inhibition de 3O% de l’activité normale
de l’acétylcholinestérase érythrocytaire. Pour se servir de cette approche, il est alors
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nécessaire de faire au moins deux prélèvements sanguins, soit avant et après la période
d’application de la substance étudiée.
Les BEI© urinaires proposés par cet organisme sont basés sur la concentration de la
substance-mère ou ses métabolites mesurée dans l’urine d’une seule miction collectée à
un moment donné (ACGIH, 2003). Le moment approprié pour recueillir celte-ci est
mentionné pour chaque BEJ©; selon les caractéristiques cinétiques de la substance à
l’étude, la miction doit être échantillonnée au commencement, pendant ou à la fin du
quart de travail. Lorsque la molécule à mesurer est principalement éliminée par
filtration glomérulaire, la concentration du biomarqueur dans l’échantillon est ajustée
en fonction de la quantité de créatinine qui y est mesurée. Selon l’ACGIH, cet
ajustement permet d’obtenir une concentration indépendante du débit urinaire, jugé très
variable en comparaison de l’excrétion de la créatinine, et permet ainsi d’obtenir un
meilleur lien entre les mesures de biomarqueurs et les niveaux d’exposition (ACGIH,
2003). Par contre, plusieurs études expérimentales chez les humains rapportent
d’importantes variations quant à l’excrétion de la créatinine. En effet, son taux
d’excrétion varie beaucoup d’un sujet à l’autre (0,5 3 g/jour), sans compter que ce
taux chez un même individu est sujet à des variations inter-journalières (63 — 244%) et
intra-journalières (200%) (Curtis et Fogel, 1970: Greenblatt et colt., 1976; Alesio et
colI., 1985; Boeniger et colt., 1993). Ces variations, combinées avec l’incertitude et la
variabilité inhérentes à la cinétique des substances, contribuent à réduire la fiabilité des
estimations de l’exposition interne obtenues à partir d’un seul échantillon urinaire.
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Proposition d’une nouvelle approche
Une approche différente de celle préconisée par l’ACGIH© a été proposée par Carrier
et Brunet (1999) dans le but de déterminer des valeurs de référence biologiques visant
la prévention d’effets toxiques chez les humains exposés à l’azinphosméthyle, un
pesticide de la famille des organophosphorés. La démarche proposée par ces auteurs
s’est faite en deux étapes: 1) le développement d’un modèle mathématique de la
cinétique de cette substance et de ses métabolites chez l’humain capable, entre autres,
de reconstruire la dose absorbée et l’évolution des charges dans le corps à partir de
mesures des biomarqueurs appropriés dans l’urine et 2) la mise à profit des travaux
d’autres chercheurs ayant réalisé des études de toxicité chez l’humain. Cette approche a
permis de définir pour l’azinphosrnéthyle les relations entre la dose absorbée, les
niveaux de biornarqueurs et le risque de développer des effets nciisibles sur la santé
humaine (voir f igure 1) et ce, pour tout scénario d’exposition probable. C’est sur la
base de ces relations que Carrier et Brunet (1999) ont déterminé des niveaux de
biornarqueurs en deçà desquels on évite l’apparition d’effets toxiques.
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Cette démarche se distingue de l’approche de l’ACGIH© par l’utilisation du modèle
cinétique ainsi que par le choix de la période de collecte urinaire. D’une part,
lACGIH© utilise les modèles cinétiques principalement pour établir les liens entre
l’exposition externe à la TLV-TWA© et les niveaux de biomarqueurs (ACGIH, 2003)
alors que l’approche de Carrier et Brunet (1999) a été utilisée pour déduire la relation
entre niveaux de biomarqueurs et effets nocifs telle que présentée à la Figure 1. En fait,
le modèle de Carrier et Brunet (1999) sert à reconstruire les doses absorbées à partir
des niveaux de biomarqueurs urinaires accumulés durant une certaine période
prédéfinie ainsi qu’à estimer les niveaux de biomarqueurs correspondant à la dose sans
effet nocif (DSENO) absorbée sous des conditions d’exposition habituellement vécues
en milieu professionnel. Ayant constaté que, sur le plan cinétique, l’estimation de
l’exposition à partir d’une seule mesure du biornarqueur était très peu précise, la
reconstruction de la dose absorbée avec une précision acceptable est, selon eux,
possible seulement sur la base des biornarqueurs urinaires accumulés sur une période
Effets nocifs sur
santé humaine
f igure 1. Schéma général des relations entre la dose absorbée dans l’organisme, les
biomarqueurs et les effets nocifs sur la santé humaine.
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relativement longue. Ainsi, au lieu de collecter une seule miction à un temps spécifié et
d’y mescirer la concentration de biomarqueurs, normalisée ou non sur ta créatinine, tel
que proposé par l’ACGIH©, Carrier et Brunet (1999) suggèrent pour t’azinphosméthyte
d’effectuer une collecte urinaire pendant 24 heures consécutives depuis le début d’une
journée d’exposition et d’y mesctrer la quantité totale des biomarqueurs excrétée sur
cette période. Cette stratégie de collecte n’est plus ainsi soumise à l’influence du débit
urinaire ou de l’excrétion de la créatinine lors de la reconstruction de l’exposition
interne à partir des niveaux de biomarqueurs urinaires.
Avec leur approche, les valecirs de référence de biornarqueurs correspondant aux doses
jugées sécuritaires ont été déterminées selon l’hypothèse que l’absorption se fait
uniquement par la peau, voie d’absorption la plus importante chez les travailleurs
exposés aux pesticides (Temple et Srnith, 1996). En effet, une analyse par simulations
des paramètres du modèle cinétique a montré que l’absorption par la peau donne des
valeurs de référence biologiques plus conservatrices que par les autres voies d’entrée.
L’application de ces valeurs en vue de prévenir les risqcles assure ainsi une bonne
protection des personnes exposées, quelque soit la voie d’absorption de ces substances.
LA MODÉLISA TION CINÉTIQUE
La cinétique des substances chimiques dans un organisme vivant est modélisée par une
ou l’autre de deux approches compartirnentales t soit les modèles classiques à multi
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compartiments (MCK), soit les modèles à base physiologique (PBPK). Pour simuler la
cinétique des substances, ces deux approches reposent sur la mise au point de systèmes
d’équations différentielles qui assurent ta conservation des masses. Ce principe, sur
lequel repose théoriquement les modèles MCK et PBPK, respecte une règle d’or en
physico-chimie après l’exposition, la dose absorbée est égale (en moles) à la somme
des charges de la substance—mère biodisponibles dans les organes ou tissus
d’absorption (poumons, tube digestif, peau) plus les charges absorbées de la substance-
mère et de tous ses métabolites contenues dans l’organisme ainsi qu’accumulées dans
les excréta (urine, fèces, air expiré, sueur). Dans ces deux types de modèles, ces
charges sont représentées par des compartiments représentant des organes ou
regroupement d’organes et tissus. À chaque compartiment est associée une équation
différentielle qui décrit la différence, par unité de temps, entre les quantités entrantes
de la substance-mère ou des métabolites et les quantités sortantes.
Les divergences entre les approches de modélisation MCK et PBPK reposent sur ta
manière de construire les modèles (représentation des organes ou regroupement
d’organes et unités des paramètres) et sur la manière de déterminer les paramètres
impliqués dans le modèle (Leung, 1991 ; Gosselin, 2001 ; Dixit et coll., 2003). Dans
les modèles PBPK, les paramètres impliqués représentent, entre aLitres, des
caractéristiques physiologiques (p.ex., le débit sanguin et le volume des organes et
tissus) de même que des caractéristiques biochimiques (p.ex., le coefficient de
partition). Les valeurs de ces derniers paramètres sont souvent déterminées à l’aide
d’expériences in vitro (sur des cellules ou tissus) ou in vivo chez l’animal et, ensuite,
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extrapolées à des valeurs correspondantes chez l’humain. Par ailleurs, avec les modèles
MCK, les valeurs des paramètres sont déterminées par ajustement optimal entre les
profils temporels simulés par le modèle et ceux observés directement chez l’humain.
Les profils de la substance-mère et/ou de ses métabolites mesurés dans le sang et dans
les excrétas (urine, fèces, air exhalé) sont obtenus expérimentalement ou en clinique.
En cinétique, il importe qcte les modèles utilisés représentent les principaux facteurs
gouvernant la cinétique de la substance-mère et de ses métabolites dans l’organisme et
surtout, que le modèle permette de répondre à l’objectif visé. Ainsi, si on veut
reconstruire la charge corporelle ou la dose absorbée à partir de mesures sur un ou des
métabolites d’une substance à laquelle on est exposé, il est primordial que le modèle
intègre aussi la cinétique de ces métabolites. C’est même essentiel pour garantir la
conservation des masses du système en tout temps. Notre analyse de la littérature nous
amène à constater qu’il est très rare qu’un modèle de type PBPK intègre la cinétique de
la substance-mère et celle de ses métabolites. En effet, ces modèles considèrent la
cinétique de biotransformation de la substance en ses métabolites (généralement au
niveau du foie) comme moyen d’élimination sans toutefois décrire la cinétique de ces
métabolites. En théorie, l’intégration de cette cinétique dans les modèles PBPK est
possible, mais difficile à cause de la nécessité de déterminer les paramètres des
métabo lites impliqués pour établir leur distribution dans l’ensemble des compartiments
classiques des PBPK (i.e., sang artériel et veineux, regroupement de tissus faiblement
perfusés et hautement perfusés, foie, tissus adipeux).
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L’équipe de la Chaire en analyse des risques toxicologiques pour la santé humaine de
l’Université de Montréal a développé des modèles qui permettent l’intégration des
principaux facteurs cinétiques avec une approche modifiée des MCK. Les modèles
MCK suivants ont été développés principalement pour satisfaire les besoins d’une
étude de surveillance biologique: polychloro-dibenzo-p-dioxines et potychloro
dibenzofurannes (PCDD/PCDf) (Carrier et colI.. 1995), azinphosméthyle (Carrier et
Brunet. 1999), MeHg (Carrier et coIl.. 2001) et méthanol (Bouchard et colI., 2001). Ce
qui distingue ces modèles de la plupart des modèles MCK classiques tient à son
insistance d’assurer ta conservation des masses molaires ; dans ce but, les
compartiments de ces modèles représentent une charge et non une concentration. Ceci
favorise l’établissement des liens entre les quantités de biomarqueurs accumulées dans
les excréta, les charges corporelles et la dose totale absorbée. De plus, ces modèles ont
été développés à partir de données expérimentales chez l’humain tirées de différentes
expériences ou différents cas cliniques rapportés dans la littérature. Cet éventail de
données a donc permis de valider ces modèles pour diverses voies d’entrées, périodes
d’exposition et quantités absorbées. Ainsi, une fois les valeurs paramétriques validées
chez lhumain, ces modèles ont la capacité d’estimer l’évolution dans le temps des
niveaux de biornarqueurs suite à différents scénarios d’exposition (unique, répété,
chronique, intermittent ; cutanée, orale et pulmonaire). Ces estimations se font
simplement en variant les taux d’entrée de la substance lors de la résolution des
systèmes d’équations différentielles.
Notre analyse mathématique des modèles cinétiques nous amène à constater que
l’approche de modélisation MCK tire avantage des différences entre les échelles de
temps des processus cinétiques de la substance et de ses métabotites pour faire des
regroupements de tissus. C’est effectivement à cause de ces différences d’échelle de
temps qu’il existe souvent un équilibre dynamique entre les quantités de la substance-
mère et/ou de ses rnétabo]ites mesurées dans le sang et celles mesurées dans certains
fluides corporels, tissus et organes. Cet état de quasi-équilibre amène l’apparition
rapide d’un rapport constant entre des quantités variables dans le temps; ce qui permet
alors le regroupement de ces quantités dans un même compartiment (Seget, 1988;
Segel et Slemrod, 1989) et ainsi une simplification du modèle sans fausser la cinétique
général e.
Les modèles cinétiqcles développés dans cette thèse sont basés sur les principes de
modélisation proposés dans le cadre des travaux de la Chaire en analyse des risques
toxicologiques pour la santé humaine. Cette approche a été retenue principalement à
cause de l’accessibilité à de nombreuses données dans la littérature sur les profils
temporels des substances-mères et de leurs métabolites mesurés dans le sang et J’urine
collectés chez des humains.
CHAPITRE 3: ARTICLE 1, MALATHION
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ABSTRACT
A toxicoldnetic model is proposed to predict the time evolution of malathion and its
metabolites, mono- and di-carboxylic acids (MCA, DCA) and phosphoric derivatives
(dimethyl dithiophosphate (DMDTP), dimethyl thiophosphate (DMTP) and dimethyl
phosphate (DMP)), in the human body and excreta, under a variety of exposure routes
and scenarios. The biological determinants of the kinetics were established from
published data on the in vivo time profiles of malathion and its metabolites in the blood
and urine of human volunteers exposed by intravenous, oral and dermal routes. In the
mode!, body and excreta compartments were used to represent the time varying
amounts of each of the following: malathion, MCA, DCA, DMDTP, DMTP and DMP.
The dynamic of inter-compartment exchanges was described mathematically by a
differentiai equation system that ensures conservation of mass at ail times. The model
parameters were determined by adjusting statistically the explicit solution of the
differential equations to the experimentai human data. Simulations provide a close
approximation to kinetic data available in the published literature. When simulating a
dermal exposure to malathion, the main route-of-entry for workers, the mode! predïcts
that it takes on average 11.8 h to recover half of the absorbed dose of maiathion
eventualiy excreted in urine as metaboiites compared to 3.2 h foliowing an intravenous
injection and 4.0 h after oral administration. This shows that, following a dermal
exposure, the absorption rate govems the urinary excretion rate of ma]athion
metabolites, because the dermai absorption rate is much slower than biotransformation
and renal clearance processes. The model served to estabiish biological reference
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values for malathion metabolites in urine since it allows links to be made between the
absorbed dose of malathion and the time course of cumulative amounts of metabolites
excreted in urine. From the “no observed effect level” (NOEL) of 0.61 mo1/kg/day
derived from the data of Moeller and Rider (1962), the model predicts corresponding
biological reference values for MCA, DCA and phosphoric derivatives of 44, 13 and
62 nmol/kg, respectively, in 24-h urine samples. The latter were used to assess the
health risk of workers exposed to malathion in botanical greenhouses starting from
urinary measurements of MCA and DCA metabolites.
Key Words: malathion; mono-carboxylic acids; di-carbox ylic acids; phosphoric
deriv atives; toxicokinetics; risk assessment.
27
INTRODUCTION
Malathion (0,0-dimethyl S-1,2-di(ethoxycarbonyl)ethyl phosphorodithioate) is an
organophosphate tOP) insecticide widely used in agriculture and residential settings as
well as in public health programs for mosquito-bome disease control (Environnement
Québec, 2002; U.S. EPA, 2000). It is also used in some countries for the treatment of
head lice (Roberts, 2002). Like other OP insecticides, malathion exerts its neurotoxic
action in humans, as in insects, through cholinesterase (ChE) inhibition. This resuits in
the accumulation of acetylcho]ine within synapses leading to over-stimulation of
postsynaptic receptors (Liu and Pope, 1998). In acutely exposed individuals, clinical
signs of OP intoxication usually appear at inhibition of 60-70% of acetylcholinesterase
(AChE) activÏty in red blood celis (RBC). However, light clinical signs and symptoms
were reported in subjects with 30 to 60% reduction in RBC-AChE activity (Sideli,
1994).
The American Conference of Governmental Industrial Hygienists proposed a
biological exposure index (BEI®) for AChE inhibiting pesticides to prevent
cholinergic health effects (ACGN, 2002). A RBC-AChE activity of 70% of the
individual’s baseline (i.e. 30% inhibition of the activity) is proposed as a biological
reference. However, a BEI® based on the measurement of urinary biomarkers of
malathion bas not been proposed so far although this is desirable since it would give an
earlier warning of possible effects than AChE inhibition. Indeed, it is clearly
established that urinary biomarkers of exposure to malathion are more sensitive
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exposure indices since they can be measured at exposure doses lower than those
necessary to induce a measurable inhibition of AChE activity.
Experimental studies in animais and humans show that maiathion is oxidized by
cytochrome P-450, in small amounts (4-6% in rats), to malaoxon which is responsible
for ChE inhibition (U.S. EPA, 2000). Both malathion and malaoxon are rapidly
detoxified by carboxylesterases to mono-acid and di-acid derivatives, which are
excreted mainly in urine; these acids can further be metabolically converted to
phosphoric derivatives, also primarily excreted in urine (Ecobichon, 1992; Feldmann
and Maibach, 1974; Jellinek et al., 2000; U.S. EPA, 2000).
To assess exposure to maiathion in field studies, malathion mono- and di-carboxylic
acids (MCA and DCA) in urine are thus used as specific biomarkers (Adgate et al.,
2001; MacIntosh et al., 1999; Màrquez et al., 2001) while the phosphoric derivatives
dimethyl dithiophosphate (DMDTP), dimethyl thiophosphate (DMTP) and dimethyl
phosphate (DMP) serve as non specific urinary biomarkers (Cocker et aI., 2002; Coyes
et al., 1986; Fenske, 198$; Fenske and Leffingwell, 1989).
The use of these urinary biomarkers to assess risk is dependent on the establishment of
a link between their measurements and cnticai biological effects. Some authors
established a relationship between the exposure dose and urinary biomarkers in
controlled human studies (Feidmann and Maibach, 1974; Jellinek et al., 2000) whule
others studied links between the exposure dose and the inhibition of AChE activity in
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volunteers (Moeller and Rider, 1962). In some reports, attempts were also made to link
urinary biomarkers to the appearance of early biological effects under experimental
conditions but the administered doses were not sufficient to induce an inhibition of
AChE activity (Dennis and Lee, 1999; Jellinek et al., 2000). In field studies in exposed
workers, these relationships cannot be established directly on the basis of
measurements of extemal doses (ambient air concentrations or skin deposits). In the
context of malathion exposure in occupational settings, which occurs mainly through
dermal contact (ACGIH, 2002; Tuomainen et aI., 2002), knowledge of the kinetics is
essential since dermal absorption is subject to large variations among individuals and
depending on the exposed skin site (Cohen and Rice, 2001; feldmann and Maibach,
1974).
If links can be established between (i) the cumulative amounts of urinary biomarkers
and the absorbed dose of malathion whatever the exposure route (oral, dermal,
pulmonary) or scenario (single, repeated, intermittent or continuous exposure) and (ii)
the absorbed dose and the appearance of biological effects, it then becomes possible to
use urinary biomarkers to assess risk in workers exposed to malathion. These links can
be made through toxicokinetic modeling provided appropriate experimental data on the
metabolism and disposition of malathion and its metabolites are available. A
physiologically-based pharmacokinetic model has been developed to describe the
human dermal absorption, metabolism and excretion of malathion (Rabovsky and
Brown, 1993). This model did not however seek to describe the urinary excretion
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ldnetics of specific metabolites, and thus does flot aÏÏow reconstruction of the absorbed
dose starting from urinary measurements.
The objectives of this study were (i) to develop a toxicokinetic model for humans
linking the dose of malathion absorbed under different exposure routes and scenarios to
the time courses of malathion metabolites in urine and (ii) to use this model as a
framework to relate published human “no observed effect level” (NOEL) to associated
amounts of metabolites in urine, which are to be proposed as convenient biological
reference values to prevent health effects.
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METHOD AND MODEL PRESENTATION
Mode! devetopmeut
Conceptual and functional representation. The disposition kinetics of malathion and
its metabolites following intravenous, oral or dermal exposure was modeled using a
multi-compartment dynamical system, described mathematically by a mass balance
differential equation system (see Appendix). The model conceptual and functional
representation was designed to describe the data provided by feldmann arid Maibach
(1974) and JelÏinek et al. (2000) on the kinetics of malathion and its metabolites in
human volunteers.
The model conceptual representation is depicted in Figure 1. Symbols and
abbreviations used in this study are described in Table 1. The mode] uses a specific
body compartment for the malathion burden in blood and tissues in dynamical
equilibrium with blood, i.e. tissues that rapidly reach and maintain a fixed ratio with
blood (referred to later as the blood compartment B(t) for simplicity). Another
compartment regroups the malathion stored in tissues S(t), i.e. malathion in lipids or
bound to tissue proteins. A compartment M(t) is also used to describe the whole body
burden of total metabolites. In addition, different compartments are introduced for
cumulative amounts of each specific malathion metabolites in either urine or feces, that
is for malathion mono-carboxylic acids (MCA), di-carboxylic acids (DCA), and for the
phosphoric derivatives dimethyl dithiophosphate (DMDTP), dimethyl thiophosphate
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(DMTP) and dimethyl phosphate (DMP). The route-of-entry, gastro-intestinal tract or
skin, is also represented as a separate input compartment. In the model, ail amounts are
initially expressed on a mole basis.
The compartment M(t) regroups unconjugated MCA, DCA, DMDTP, DMTP and DMP
metabolites, which are generated in cascade, together with their conjugates, in
accordance with the metaboiism described by Ecobichon (1992). Since phase I and II
biotransformation processes occur on a much more rapid time-scale than renal and
fecal clearance of the metabolites, the fractions of total body metabolites excreted from
the body as specific metabolites are mainly function of the competition between phase
II conjugation and further phase I metabolism. For instance, the amounts of MCA
eliminated from the body are dependent on the competition between conjugation and
biotransformation to DCA, DMDTP and DMTP. Consequently, if 36% of an absorbed
dose is recovered in excreta as MCA and 4% of malathion is metabolized to malaoxon,
it indicates that 36% of the absorbed dose lias been metabolized to MCA and
conjugated while 60% lias been biotransformed to other metabolites. Without
competition between conjugation and the biotransformation cascade, unconjugated
metabolites would ail be metabolized to DMP.
In the model, the rates of change in the amounts of a substance in a given compartment
are described mathematically as the difference between compartment rates of uptake
and loss. Exchange rates between compartments represent either the physical transfer
of the same substance or the transfer (on a mole to mole basis) through
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biotransformation of malathion to its metabolites or one metabolite to another. Solving
the system of differential equations yields the mathematical function of the time
courses of malathion and its metabolites in the different compartments.
Determination of parameters. The model parameters were determined from the in
vivo time profiles provided by feldmann and Maibach (1974) and Jellinek et al.
(2000). The parameters were determined by: (j) statistical best-fits of the explicit
solutions of differential equations to experimental human time course data, or (ii) log
linear regression on the time profile data (using in both cases reported average values).
A professional edition of a MathCad software was used for this purpose (MathSoft
Inc., Cambridge, MA).
Extensive use was made of the different time scales involved in the biological
processes to simplify differential equations, using quasi steady state approximations
(QSSA) (Segel, 1988; Segel and Slemrod, 1989). This enabled no more than two model
parameters to be estimated per fit. In short, QSSA predicts that compartments with
rapid attrition reach a dynamic equilibrium with their slow varying “feeder”
compartment. For instance, the output transfer rate, kBM + kBs, of malathion in blood
B(t) to total body metabolites M(t) and to storage tissues S(t) was considered large
compared to the rates of change of its feeder compartments: R(t) for absorption or S(t)
for storage release, because the burden of malathion in blood is quickly depleted under
a oral dose (Jellinek et al., 2000).
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The transfer rate constant of total metabolites in the body to urine, kMu, was estimated
by least square fit adjustment of the model general solution to the data of Feldmann
and Maibach (1974) on the urinary excretion time course of average total 14C in male
human volunteers (n = 6) exposed intravenously (iv) to 1 Ci of ‘4C-labeled malathion
(dose in mole or g flot specified). These authors reported the time course of total 14C
urinary excretion rate (% of the administered dose per h). For the fitting of
experimentaÏ data and to determine the kMu parameter, the experimental values were
converted to cumulative burdens expressed as a fraction of the administered dose. Log
linear regression on the time course of average total 14C urinary excretion rate reported
by Feldmann and Maibach (1974) during the 24- to 120-h period following the iv
injection also served to determine the low transfer rate constant ksB of malathion from
storage tissues to blood.
The transfer rate constants of malathion in blood to total body metabolites, kBM, and to
storage tissues, k5, could not be detemiined precisely for lack of available detailed
time profile data of malathion in blood shortly following malathion exposure in human
volunteers. However, the sum of kBM + kBs could be approximated from the data of
Jellinek et al. (2000). These authors showed that 1 h following a single oral dose of 15
mgfkg of malathion in human volunteers, blood concentrations of malathion were
below the limit of detection (102 ng/ml). This corresponds to an attrition half-lïfe of
blood malathion of at most 12 mm, which is consistent with a very rapid distribution or
biotransformation of malathion. These findings indicate that the rate value of the sum
1n2 .
of kBM + kBs must be greater or equal to 12 min or
3.47 h . The individual values of
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kBM and kBs parameters were determined by adjustment of the numerical solution of the
system of differential equations to the data of Feldmann and Maibach (1974) in
volunteers exposed iv to ‘4C-malathion.
The data of Jellinek et al. (2000) were used to determine the fractions of total body
metabolites recovered as each of the five metabolites: MCA, DCA, DMDTP, DMTP
and DMP (fMu-McA, fMuDcA, fMu-DMDTp, fMu-DMTP and fMu-DMp, respectively). These
authors reported mean urinary excretion of these metabolites (as a % of the
administered dose) for the 0-12, 12-24 and 24-48 h periods following a single oral
malathion dose of 0.5, 1.5, 10 and 15 mg/kg of body weight in male human volunteers
as well as 15 rng/kg in female volunteers (n 5 per group). The fractions of specific
body metabolites to total body metabolites were thus obtained from the molar ratio of
specific metabolites excreted in urine to total metabolites in urine. This amounts to
assuming that the metabolites are produced in different proportions, but are excreted in
urine at the same kMu rate. This simplification was necessary given the lack of detailed
blood and urinary excretion time profiles for each metabolite and the paucity of data on
the conjugation reactions of malathion metabolites and their renal clearance. However,
the data of Feldmann and Maibach (1974), from which the kMU was derived, together
with the data of Jeflinek et al. (2000) show that elimination of the metabolites to urine
is almost complete 12 to 24 h following an iv or oral exposure. k is thus reasonable to
assume that the renal clearance of the different conjugated malathion metabolites is
more or less the same.
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The oral absorption fraction used in simulations was that reported by Jellinek et al.
(2000). The experimental data did flot allow for the exact determination of the oral
absorption rate constant; a range of values was tested, consistent with data from studies
on related compounds (Nolan et al., 1984; Carmichael et al., 1989) together with the
duration of intestinal transit up to the main absorption site of malathion (jejunum). For
dermal exposures, the absorption fraction and the absorption rate constant were
estimated by least square fit adjustment of the model general solution to the data of
Feldmann and Maibach (1974) on the urinary excretion time course of average total
14C in male human volunteers (n 6) exposed dermally to 1 Ci of ‘4C-labeled
malathion on the forearms.
Model simulations. Once the parameters were estimated as described above,
numerical solution of the complete model was performed by the Runge-Kutta method
on the differential equation system. Simulations were conducted using a professional
edition of a Mathcad Software (MathSoft Inc., Cambridge, MA). The model predicts
the amounts of malathion and its metabolites in the body and in excreta at any time
point postexposure for any route of exposure and scenario.
Simulations of exposure scenarios, where continuous or repeated intermittent doses are
administered through time, were performed by introducing a non-homogenous term,
g(t), describing these varying inputs (see Appendix).
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Mode! validation
The model developed using the previously mentioned data was validated using
different sets of experimental data: Maibach et al. (1971), Wester et al. (1983) and
Dennis and Lee (1999). Only in the study of Dennis and Lee (1999) were the data
presented in graphical form. Those graphs were thus scanned and the data were read
using a Sigma Plot Graphing Software (Jandel Corporation, San Rafael, CA).
Deteriniization of biological reference values
BioÏogical reference values for MCA, DCA and phosphoric derivatives amounts in 24-
h urine samples are proposed here based on model predictions and the data of Moeller
and Rider (1962). These authors exposed male human volunteers repeatedly, once a
day, to gelatin capsules containing malathion. The dosage regimen was $ mglday (0.1
mglkg/day) for 32 days, 16 mglday (0.2 mglkg/day) for 47 days or 24 mg/day (0.3
mg/kgfday) for 56 days (n = 5 per exposure group). Plasma and erythrocyte
cholinesterase activities were measured twice weekly before, during and after
administration. No clinical signs or symptoms of toxicity were observed during the
study period at ail dose levels. The exposure doses “no observed effect level” (NOEL)
and “lowest observed effect level” (LOEL) were estimated by Moeller and Rider
(1962) to be 0.2 and 0.3 mglkglday, respectively, based on a >10% inhibition of both
plasma and erythrocyte cholinesterases as compared to baseline values. We reanalyzed
the data of Moeller and Rider (1962) considering as significant an inhibition of 19%
plasma and 12% erythrocyte cholinesterases in two successive measurements, as
proposed by several authors (Gage, 1967; Heath and Vale, 1992; Larsen et al., 1982).
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Though we used a different criterion, the NOEL and LOEL alTived at are identical to
those of Moeller and Rider (1962). From the NOEL value of 0.2 mg/kg/day, the
corresponding absorbed dose was estimated and, using the model, associated urinary
amounts of MCA, DCA and phosphoric denvatives were obtained.
To determine biological reference values starting from the amounts of MCA, DCA and
phosphoric derivatïves accumulated in urine 0-24 h following the onset of exposure,
the model input conditions were set to generate biological reference values with a
safety margin. This was achieved with an 8-hlday absorbed NOEL dose using the
slowest absorption rate constant found compatible with the various experimental data
available. The fractions of total metabolites recovered in urine as MCA, DCA and
phosphoric derivatives were also attributed the smallest individual values determined
using data from the study of Krieger and Dinoff (1999) who were the only authors to
report individual values of MCA, DCA and phosphoric derivatives in urine. These
input conditions ensure a “minimal” urinary excretion of the metabolites for a given
dose. This provides a safety margin through a possible overestimation of the dose
absorbed when starting from urinary measurements.
Application
The proposed biological reference values were applied to assess health risk in workers
exposed to malathion. Unpublished urinary excretion data from botanical garden
workers, collected by the Institut national de santé publique du Québec (INSPQ),
Direction de la toxicologie humaine (Québec, Canada), were used. Twenty-four-hour
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urine samples were collected in male and female subjects (n = 9 and 2, respectively)
following a 2- to 3-h workshift in greenhouses which had been sprayed with malathion
12 to 15 h earlier. The workers studied had not participated in the application of
malathion.
Samples were analyzed for Œ- and 3-MCA and DCA metabolite contents at the INSPQ.
Urinary levels were determined by capillary gas chromatography/mass spectrometry
(GCIMS) after acidification, extraction on C18 micro-columns and derivatization with
diazomethane. Analysis was performed using a model 5890 gas chromatography
system (Hewlett Packard), a model 5972 mass spectrometer (Hewlett Packard) and a
fused silica capillary column HP-5MS (30 m X 0.32 mm, 0.25 km). The limit of
detection for MCA and DCA was respectively 2 and 1 ig/l. Average recovery of urine
samples spiked with 10 igI1 of authentic reference standards was 113% and 108% for
MCA and DCA, respectively (n = 10 samples). Inter-day coefficient of variation for
replicate analysis of the same urine sample spiked with 10 pg/l of reference standard
was 5.6% and 4.8% for MCA and DCA, respectively (n = 10 days).
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RESULT$
Mode! devetoprnent
Table 2 presents parameter values of the model determined using the data of Feldmann
and Maibach (1974) and Jellinek et al. (2000). Figure 2 shows that with these
parameter values, the model reproduces closely the data of Feldmann and Maibach
(1974) on the cumulative urinary excretion time course of total 14C in human
volunteers exposed intravenously and dermally to ‘4C-labeled malathion. The model,
with the same parameters, also simulates well the data of Jellinek et al. (2000) on the
cumulative unnary excretion of malathion metabolites 0-12, 0-24 and 0-4$ h following
an oral exposure to malathion in human volunteers (see Table 3). Asymptotically, the
model predicts that 90% of the absorbed dose is excreted in urine; the rest is predicted
to be excreted in feces, which is compatible with the rat data of Lechner and Abdel
Rahman (1986).
Mode! validation
The proposed model was applied to the data collected by Maibach et al. (1971) (Fig. 3)
and Wester et al. (1983) (data not shown) on the urinary excretion time profile of
average total ‘4C in male human volunteers following a single dermal application of
‘4C-labeled malathion at different anatomical regions of the body. The parameter
values in Table 2 were used for these model simulations except for the dermal
absorption fraction and rate constant, which are known to vary largely according to the
exposed region of the skin as well as from one individual to another. To simulate the
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experimental data of Maibach et al. (1971), the best fit values for the dermal absorption
fraction were: 0.075, 0.062, 0.134 and 0.25 for applications to the forearm, the paim of
the hand, the hand dorsum and the forehead, respectively. The corresponding values for
the absorption rate constant were: 0.103, 0.05, 0.11 and 0.11 h’. To simulate the data
of Wester et aÏ. (1983) in volunteers exposed dermally to 6.25 tLCi of ‘4C-malathion on
the forearm, the dermal absorption fraction was found to be 0.04 and the absorption
rate constant 0.05 h’.
The model was also validated through simulations of the data of Dennis and Lee (1999)
on the urinary excretion time course of phosphoric derivative metabolites (the sum of
DMDTP, DMTP and DMP) in volunteers exposed to an aqueous or alcohol-based head
lice formulation containing malathion (Fig. 4). The model provided a close
approximation to the data presented by these authors using the model pararneter values
in Table 2, except for the dermal absorption fraction and rate constant. For the
simulation of exposure to the aqueous-based formulation, the absorption fraction was
set equal to 0.075; the value of the absorption rate constant was left as that reported in
Table 2. For the simulation of exposure to the alcohol-based solution, the absorption
fraction was set equal to 0.068 and the absorption rate constant to 0.123 h’.
Iïtferences ofthe mode!
Prediction of the tïme course of malathion and ïts metabolites in the body and
excreta under different exposure scenarios. The model was used to predict the time
course of malathion and its metabolites in the body and in accessible biological
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matrices (blood, urine) under different exposure scenarios likely to occur in practice.
Figures 5 and 6 show model predictions of the time profiles of malathion and its
metabolites in the body and urine that would resuit from a single oral or dermai
exposure to malathion. Following oral exposure, with an absorption fraction of 0.73$
and absorption rate constant of 1.373 h1 (haif-life of 30 mm) as reported in Table 2, the
predicted time course of malathion in blood B(t) shows maximum level 19 min
postexposure, which represents 10.6% of the exposure dose (14.4% of the absorbed
dose). Because of an early partial storage in tissues and a slow retum from these tissues
to blood, elimination of m&athion from blood follows a bi-exponential pattem with a
more rapid phase followed by a siower phase (Fig. 5A). Model simulations predict a
low transfer of blood malathion to storage tissues S(t), where the maximum storage
level represents 2.6% of the exposure dose (3.5% of the absorbed dose) (Fig. SA). As
mentioned above, retum to blood from S(t) is however relatively slow; the predicted
haif-life for this process is 19.8 h. Malathion is also readily and extensively
metabolized in the body and its metabolites are rapidly eliminated once formed; the
maximum level of total metabolites M(t) is reached 1.7 h postexposure and represents
48.9% of the exposure dose (66.3% of the absorbed dose) (Fig. SA). The cumulative
urinary excretion time courses of malathion metabolites show that the different
metabolites are rapidly eliminated (Fig. 5B); the model predicts that 79, 90 and 98% of
total axnounts recovered in urine are excreted during the first 8, 12 and 24 h
postexposure, respectively. Asymptotically, urinary MCA, DCA and phosphoric
derivatives represent respectively 36.1, 8.7 and 21.6% of the exposure dose (48.9, 11.8
and 29.2% of the absorbed dose).
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Following a single dermal exposure, using an absorption fraction of 0.070 and an
absorption rate constant of 0.103 h’ (half-life of 6.7 h) as reported in Table 2, the
predicted time courses of malathion in blood 11(t) and in storage tissues S(t), and the
total metabolites in the body M(t) show respective peak levels 0.67, 16.1, 6.5 h
postexposure (Fig. 6A). Since the dermal absorption of malathion is small and
relatively slow compared to metabolism cum elimination, maximum values for 11(t),
S(t) and M(t) only amount to 0.11, 0.16 and 1.55% of the exposure dose, respectively
(1.6, 2,3 and 22.0% of the absorbed dose). Also, because dermal absorption of
malathion is slow compared to its biotransformation, a dynamic equilibrium is quickly
reached between the skin compartment R(t) and blood compartment B(t).
Consequently, B(t) begins its attrition at the rate of the absorption rate constant of
0.103 h’ (haif-life of 6.7 h), which is flot the case following an oral exposure where
absorption is more rapid than elimination processes (see Fig. SA).
From the cumulative urinary excretion time courses of malathion metabolites (Fig. 611),
the model predicts that 32, 51 and 83% of total amounts recovered in urine are excreted
during the first 8, 12 and 24 h, respectively, following a dermal exposure.
Asymptotically, urinary MCA, DCA and phosphoric derivatives represent 3.45, 0.83
and 2.06% of exposure dose (48.9, 11.8 and 29.2% of the absorbed dose; these latter
excretions are identical to those after oral exposure, as should be). These simulations
show that following a dermal exposure to malathion, the absorption rate constant
govems the overali urinary excretion rate of the metabolites, because the dermal
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absorption rate, kabsdermal, is small compared to the biotransformation rate and renal
clearance (represented in the model by kBM and kMu, respectively). According to model
predictions, to recover haif of the absorbed dose of malathion eventually excreted in
urine as metabolites takes 11.8 h following a single dermal application compared to 3.2
h following an intravenous injection and 4.0 h after oral exposure. furthermore, as
mentioned previously, the dermal absorption rate constant varies among individuals
and depends on the skin region exposed to malathion. Table 4 shows that, for dermal
exposure to malathion, varying the absorption rate constant affects markedly the
cumulative urinary excretion time course of total metabolites (the sum of MCA, DCA
and phosphoric derivatives).
The proposed model can also predict the time evolution of malathion and its
metabolites in the body and excreta following repeated exposures to malathion.
Simulations of an 8 h per day dermal exposure, 5 days a week for 4 consecutive weeks
are shown in Fig. 7. With the parameter values given in Table 2, during a week of
exposure, there is a slight increase from day to day in peak burdens of malathion in
blood B(t) and in storage tissues 5(t) and total body metabolites M(t) (measured as a
fraction of the absorbed daily dose). However, there is no sigriificant week to week
increase in daily maximum levels because, at the end of a 2-day break in exposure, the
elimination is nearly complete.
45
Reconstruction of the absorbed dose of maathion starting from urinary
measurements of the metabolites. The model can help estimate, through back
calculations, the absorbed dose of malathion starting from urinary measurements of the
metabolites provided the periods of exposure and urine collection are known. Table 5
shows simulations of the cumulative urinary excretion of total metabolites, expressed
as a fraction of the absorbed dose, at different time periods following the onset of an 8-
h workshift, assuming zero background levels. Simulations are performed under two
dermal exposure scenarios: one with a high value for the absorption rate constant (0.12
W’) and another with a low value (0.05 h1). Given the importance of the absorption
rate constant in determining dermal exposure, the excretion values, reported in Table 5,
can be viewed as “best” and “worst” case scenarios. From Table 5, the dose absorbed
by workers can be inferred from measurements of the arnounts of metabolites in urine,
when the urine collection time period following the beginnïng of a workshift is known
as well as the workshift duration.
Biological reference values. The model also served to establish biological reference
values for malathion metabolites in urine since it Iinks the absorbed dose to the
amounts of metabolites excreted in urine over different time periods. From the data of
Moeller and Rider (1962), a NOEL oral exposure dose of 0.61 molJkg/day (0.2
mglkg/day) was derived. With the estimated oral absorption fraction (see Table 2), this
corresponds to an absorbed dose NOEL of 0.45 /Lmol/kg/day (0.15 mg/kglday). The
corresponding biological reference values for MCA, DCA, phosphoric derivatives are
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then 44, 13 and 62 nmol/kg, respectively, in 24-h urine samples. The values for the
sum of acids or total metabolites are thus 57 and 119 nmolfkg, respectively.
Application
The model was used to assess the health risk related to malathion exposure in botanical
garden workers starting from measurements of the amounts of MCA and DCA
metabolites in 24-h urine samples (as described in the Method section). The workers
exhibited excretion values of MCA and DCA in their 24-h urine samples conesponding
to a range of 0.017 to 0.210 times the biological reference value proposed for MCA
and a range of 0.011 to 0.324 times the value proposed for DCA, indicating a
negligible health risk for those workers (see Table 6).
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DISCUSSION
A heuristic toxicokinetic model was developed, which integrates a weaÏth of
experimental in vivo time profile data, to uncover the critical biological determinants of
the ldnetics of malathion and its metabolites in humans. The model provides a good
understanding of the time evolution of malathion and its metabolites in the body and in
urine, under different exposure scenarios (single, repeated, continuous or intermittent
exposure). With this model, it is also possible to assess the effect of the route-of-entry
on time course data. In the context of biological monitoring, the model facilitates the
interpretation of urinary measurements collected over different time periods. It can also
be used to propose optimum sampling strategies for routine biological monitoring.
The model showed that, upon absorption, malathion in blood is either readily
biotransformed or transferred to storage tissues, though only a small fraction of the
absorbed dose of malathion is in fact transferred to storage tissues. Metabolites are also
rapidly excreted in urine and feces. Consequently, the exposure route determines the
time-dependent urinary excretion rate of malathion metabolites, because different
routes-of-entry imply different absorption rates. for example, when simulating a single
oral exposure, 80-89% of the absorbed dose is eliminated from the body within 12 h,
whereas, after a single dermal application, only between 29-53% of the absorbed dose
is excreted during the same time penod. (These value ranges are obtained by
considering the Iowest and highest absorption rate constant used to simulate the various
available data.) In workers, who are typically exposed to malathion mainly through the
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skin, the absorption rate thus limits the output rates of metabolites in urine, because
dermal absorption is much siower than biofransformation rate and renal clearance. This
is flot the case in individuals exposed by the oral or pulmonary routes, where the
absorption rate is not a limiting step in the excretion ldnetics.
Considering a continuous 8-h dermal exposure during a workday, the model predicts
that 52-80% of the absorbed dose will 5e eliminated from the body within the 24-h
period following the onset of exposure as compared to 84-98% within 48 h.
Consequently, for the biological monitoring of worker exposure to malathion through
measurements of the amounts of urinary metabolites, collection of 24-h urine samples,
starting at the beginning of the workshift, appears as an adequate sampling strategy. In
the case of workers subjected to exposure day after day, malathion is predicted by the
model to build up in storage tissues during the course of a workweek, thus resulting in
a progressive increase in total body burden. Repeating the exposure from week to week
does flot however cause any significant increase in maximum and minimum body
burdens. In this situation, it is best to collect the 24-h urine samples on the last day of a
workweek. Measurements should be repeated periodically when exposure levels are
suspected to vary significantly with time.
It is interesting to note that based on the data of Jellinek et al. (2000), cumulative
amounts of metabolites in urine (expressed as a percentage of the malathion exposure
dose) appear in the following order: MCA > phosphoric derivatives > DCA. These
findings combined with the fact that the MCA metabolite is specific to malathion
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exposure (Mdrquez et al., 2001; Tuomainen et al., 2002), suggest that MCA in urine is
the most useful individual biological indicator of exposure to malathion. 0f course,
measurements of phosphoric derivatives can also be of interest as non specifïc
bioindicators of exposure to organophosphate compounds (Cocker et al., 2002; Coye et
al., 1986).
The model enables iinks to be established at ail times between the dose, the body
burden of malathion and that of its metabolites and the amounts of specific metabolites
excreted in urine. The model can thus be used to reconstruct, through back calculatïons,
the absorbed dose of malathion following oral or dermal exposure, starting from
measurements of cumulative amounts of a specific metabolite excreted in urine over a
given period of time. Reconstructing the absorbed dose from metabolites in urine
avoids unnecessary assumptions or approximations about the absorption fraction,
which is known to be subject to large inter-individuai variations and, in the case of
dermal exposure, to vary according to anatomical skin regions (ACGII{, 2002; Cohen
and Rice, 2001; Feidmann and Maibach, 1974).
It was aiso possible, with the model, to propose biological reference values with a
margin of safety by simulating a dermal exposure scenario typical of a daily worker
exposure and using a combination of ldnetic parameters that overestimates the
reconstructed absorbed dose starting from urinary measurements. The establishment of
biological reference values based on a dermal exposure scenario rather than an oral or
pulmonary exposure contributes to safe estimates whatever the exposure route. Indeed,
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in an individual exposed to ma]athion mainly by inhalation or ingestion, the urinary
excretion of metabolites is more rapid than following a dennal exposure and hence
urinary excretion values in 24-h urine samples collected at the beginning of an
exposure period are more important. It should also be reminded that the biological
reference values were determined with the model using the slowest absorption rate
found compatible with the available literature data on excretions, together with the
lowest individual values found for the fractions of total metabolites recovered in urine
as MCA, DCA or phosphoric derivatives. This was to consider the variations in the
absorption rate among individuals and depending on the exposed skin regions
(feldmann and Maibach, 1974) as well as the reported variations from one study to
another in the fractions of total metabolites recovered in urine as MCA, DCA and
phosphoric derivatives (Bradway and Shafik, 1977; Jellinek et al., 2000; Krieger and
Dinoff, 2000). However, the study of Jellinek et aÏ. (2000) showed that over the 0.5 to
15 mg/kg oral dose range, the fraction of total metabolites recovered in urine as MCA,
DCA and phosphoric derivatives was independent of the dose.
To assess the risk of exposure to mal athion, the amounts of MCA, DCA and
phosphoric derivatives in the 24-h urine samples of exposed subjects can be compared
to the proposed reference values. Ideally, it is best to establish the risk from
measurements of the sum of acids rather than MCA or DCA individually, for a specific
but more precise estimate. Otherwise, the risk can be estimated from measurements of
the sum of ail metabolites in urine which, despite flot being entirely specific to
malathion exposure, allows to bypass uncertainties about the relative weights of each
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metabolite in total excretion. Also, when 24-h urine samples cannot be collected for
practical reasons, collection periods can be shortened; the Table 5 can be used to
estimate the 24-h urinary excretion in exposed subjects starting from measurements
over other urine collection periods. For a “safe side” estimation, excretion values in
Table 5 obtained from the slowest absorption rate should be used. However, to
minimïze the effects of inter-individual and inter-site variations of absorption rates on
urinary outputs, it is best to collect urine samples over the longest possible time period.
The model and proposed biological reference values were used in this study to assess
the risk for workers exposed to malathion in a botanical garden. The risk was predicted
to 5e negligible given that the measurements of MCA and DCA in 24-h urine samples
were lower than the proposed biological reference values. In general, these workers
appear to be less exposed than the greenhouse workers of a recent Spanish report
(Marquez et aÏ., 2001) where MCA was measured in the urine of three individuals
following applications of malathion. The total amounts of MCA excreted during the
24-h period following applications were calculated to be 134, 182 and 671 1ug,
corresponding to 3 1.7, 8.6, and 6.3 nmol/kg, assuming a body weight of 70 kg. These
values represent respectively 0.72, 0.20 and 0.14 of the proposed biological reference
value.
In summary, the toxicokinetic model was developed that accounts for the constraints
related to significant variations in some of the parameters: (i) variations in the dermal
absorption fraction and the rate of absorption among individuals and according to the
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exposed skin regions and (ii) variations from one report to another in the fractions of
total metabolites recovered in urine as MCA, DCA and phosphoric derivatives. In this
study, the model was used to reconsti-uct the absorbed dose starting from measurements
of urinary biomarkers; the effect of varying absorption fractions was thus bypassed.
Variations in the absorption rate constant and relative proportions of the different
metabolites in urine can impair accurate estimation of the absorbed dose starting from
the amounts of biomarker in urine. Under these conditions, to calculate biological
reference values with a margin of safety, the smallest rate values for the latter
parameters afforded by the literature were used. This leads to a possible overestimation
of the corresponding values for the reconstructed dose. The model also assumes the
absence of saturation in the metabolism and clearance processes. Over the exposure
dose range modeled in this study, the available data in volunteers and workers were
accurately predicted without having to introduce saturation. The model cannot,
however, be used to predict the kinetics in the saturating exposure dose ranges, as
expected in the case of intoxicated subjects. The available literature data remained
sufficient to bujld a robust model to better understand the ldnetics of malathion and its
metabolites and to propose convenient biological reference values together with
sampling strategies. These can be of use immediately for the biological monitoring of
malathion exposure through measurements of metabolites in urine.
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APPENDIX
First order tinear differentiat equations for each cornpartmeut
From Figure 1, the following differential equations are obtained (see Table 1 for
definitions of symbols and abbreviations):
dR(t)
=g(t)—k35 xR(t)
where g(t) is the absorbed oral or dermal dose Dabs per unit of time. Dabs D X
where fat,s is the absorption fraction and Dexp is tlie exposure dose.
For intravenous injection, g(t) = O for t>O and at time t = O: B(O) = Dabs.
dB(t)
= k5bS xR(t)+ ksb xS(t)(k8s + kBM)XB(t)
dS(t)
=kBsxB(t)—ksB xS(t)
dM(t)
=kBM XB(t)—(kMU +kMF)XM(t)
dF(t)
= kMf x M(t)
dM(t) f XkBM xB(t)—(kMU +kMF)xMÎ(t)
dU1(t)
=kxM(t)
where: j{MCA-C,DCA-C,DMDTP-C,DMTP-C,DMP-C}, 1 and
M(t) = M(t)
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Table 2. Numerical Values of Parameters Used in the Model
Constant parameters Values
Absorption fractions fabsoral 0.738
a
labs-dermal 0.0705
Transfer rates (W’) kabs-oral1’ 0.345 - 1.373
kabs..del’1 0.103
kBM’ 6.000
1 C
KBS
ksB 0.035
kMu 0.215
kMf 0.0239
Metabolite fractions fMcA 0.544
fDcA 0.131
fDMDTP 0.019
fDMTP 0.182
fDMP 0.124
Note. The description of constant parameters is given in Table 1. Absorption fractions
and transfer rates were determined in this study by statistical best-fits; metabolite
fractions were obtained from the literature.
aThese values were determined from the data of Feldmann and Maibach (1974).
However, the dermal absorption fraction and absorption rate constants are known to be
subject to variations among individuals and depending on the exposed skin region. To
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simulate the various data presented in this article, the value range for fabs-dermal WS
found to be 0.04 - 0.25 and for kabderI 0.05 - 0.123 h’.
bDiffefent values for kabsora1 were used, corresponding to absorption haif-lives between
30 min and2h.
cusing the kMu value of 0.215 W’ determined from the data of Feldmann and Maibach
(1974), the best fit was obtained for a Jt ratio equal to 25 and a rate value for the
sum of kBM + kBs equal to 6.24 W’, indicating that (kBM + kBs)» kMU and malathion
biotransformation is a very rapid process (kBM = 6 W1).
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Table 4. Effect of Variations in the Absorptïon Rate Constant on the Sïmulated
Cumulative Urinary Excretion of Total Metabolites Over Different Time Periods
Following a Single Dermal Exposure to Malathion
Urine collection Cumulative urinary excretion of total metabo
lites
.
(fraction of the absorbed dose)
period
postexposure (h) kabs = 0.12 h’ kabs = 0.10 h’ kabs = 0.07 h’ kabs = 0.0
5 h1
0-4 0.09 0.08 0.06 0.04
0-8 0.30 0.26 0.20 0.15
O-12 0.48 0.43 0.34 0.26
O-16 0.62 0.56 0.46 0.37
O-24 0.77 0.73 0.64 0.53
O-36 0.86 0.84 0.7$ 0.69
O-4$ 0.88 0.87 0.84 0.78
0-200 0.90 0.90 0.90 0.90
Note. kabs = dermal absorption rate constant values, which are in the range of those
used for simulations of the vanous dermal data presented in this article.
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Table 5. Predicted Cumulative Urinary Excretion of Total Metabolites (the Sum
of Mono- and Di-Carboxylic Acids and Phosphoric Derivatives) at Different Time
Periods Following the Onset of an 8-h Dermal Exposure to Malathion
Urine collection Cumulative urinary excretion of total metabolites
period following the (fraction of the absorbed dose)
onset of exposure (h)
kabs = 0.12 h’ kabs = 0.05 h’
0-4 0.02 0.01
0-6 0.06 0.03
0-8 0.13 0.06
0-12 0.32 0.16
O-16 0.49 0.27
O-20 0.62 0.38
O-24 0.72 0.46
O-36 0.84 0.65
O-48 0.88 0.76
0-60 0.89 0.82
0-72 0.89 0.85
Note. The predicted cumulative urinary excretion of total metabolites over different
time periods is given considering two dermal exposure scenarios, with a relatively high
and low absorption rate constants (0.12 and 0.05 Ii’, respectively). Background urinary
70
excretion is considered negligible. Also note that, eventually, no more than 90% of
absorbed dose wiII be excreted in urine. kabs = Dermal absorption rate constant.
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Table 6. Excretion of Mono- and Di-Carboxylic Acids in 24-li Urine Samples of
Botanical Garden Workers Exposed to Malathion and Comparison With the
Biological Reference Values Proposed in This Study
Subjects Sex a Cumulative 24-h urinary Fraction of the proposed
excretion (nrnol) biological reference values”
MCA DCA MCA DCA
1 F 47.3 7.9 0.020 0.011
2 F 159.4 69.4 0.066 0.097
3 F 205.0 75.5 0.085 0.106
4 F 80.8 12.9 0.033 0.018
5 F 42.2 10.3 0.017 0.014
6 F 113.4 23.8 0.047 0.033
7 M 51.4 31.5 0.017 0.035
$ F 98.5 45.5 0.041 0.064
9 M 228.7 105.9 0.074 0.116
10 F 62.4 15.5 0.026 0.022
11 F 509.0 231.7 0.210 0.324
Note. MCA = malathion mono-carboxylic acids; DCA = malathion di-carboxylic acids.
af
= female and M = male, which are considered to weigh, as default values, 55 and 70
kg of body weight, respectively.
72
bBiological reference values proposed in this study for MCA and DCA are respectively
44 and 13 nmol/kg in 24-h urine samples.
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CAPTIONS TO FIGURES
Figure 1. Conceptual representation of the kinetics of malathion and its metabolites.
Symbols are described in Table 1.
Figure 2. Mode] simulations (unes) compared with experimental data of feldmann and
Maibach (1974) (symbols) on the cumulative urinary excretion time course of total ‘4C
(% of administered dose) in male human volunteers following an intravenous (A) and
dermal (B) exposure to 1 Ci of 14C-malathion. Each point represents mean value of
experimental data (n = 6 per exposure group).
Figure 3. Mode! simulations (lines) compared with experimental data of Maibach et ai.
(1971) (symbols) on the cumulative urinary excretion time course of total 14C (% of
administered dose) in male human volunteers following a dermal exposure to
malathion (4 g/cm2) on the forearm (x), the palm of the hand (+), the hand dorsum (o)
and the forehead (O). Each point represents mean value of experimental data (n = 6 per
exposure group).
Figure 4. Model simulations (lines) compared with experimental data of Dennis and
Lee (1999) (symbols) on the cumulative urinary excretion time course ofphosphoric
derivative metabolites (the sum of DMDTP, DMTP and DMP) (nmol) in human
volunteers following a dermal exposure (on an intact skin) to an aqueous-based head
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lice formulation containing on average 0.126 g ofmalathion (O) and an alcohol-based
head lice formulation containing on average 0.089 g of malathion (u). Each point
represents mean value of experimental data (n = 5 to 10 volunteers per treatment
group).
Figure 5. Simulation of the time course of malathion and its metabolites (% of
administered dose) in body (A) and excreta (B) compartments of the model following a
single oral exposure to malathion. B(t), malathion in blood and tissues in dynamical
equilibrium with blood as a function of time; S(t), malathion in storage tissues as a
function of lime; M(t), total metabolites in the body as a function of time; Q(t),
systemic body burden of malathion and its metabolites as a function of time; UMCA(t),
MCA metabolite in urine as a function of time, UDCA(t), DCA metabolite in urine as a
function of time, UMP(t), phosphoric derivative metabolites in urine as a function of
time. For comparison purposes, Figure 5B also shows the average urinary excretion of
MCA (X), DCA (O) and phosphoric derivatives (u) during the 0-12, 0-24 and 0-4$ h
following an oral administration ofOE5, 1.5, 10 and 15 mg/kg of malathion in
volunteers, as determined from the data of Jellinek et al. (2000).
Figure 6. Simulation of the time course of malathion and its metabolites (% of
administered dose) in the model compartments following a single dermal exposure to
malathion. B(t), malathion in blood and tissues in dynamical equilibiium with blood as
a function of time; S(t), malathion in storage tissues as a function of time; M(t), total
metabolites in the body as a function of time; Q(t), systemic body burden of malathion
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and its metabolites as a function of time; UMCA(t), MCA metabolite in urine as a
function of time, UDCA(t), DCA metabolite in urine as a function of time, UMp(t),
phosphoric derivative metabolites in urine as a function of time.
Figure 7. Simulation of the time course of malathion and its metabolites (fraction of
absorbed daily dose) in the mode] compartments following a repeated dermal exposure
to malathion, 8 hlday, 5 consecutive days/week for 4 weeks. B(t), malathion in blood
and tissues in dynamical equilibrium with blood as a function of time; 5(t), malathion
in storage tissues as a function of time; M(t), total metabolites in the body as a function
of time.
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ABSTRACT
A multi-compartment kinetic mode! was developed to describe the kinetics of
parathion and its metabolites, p-nitrophenol (p-NP) and aikyl phosphates (AP), in order
to assess worker exposure and heaith risks. Model compartments represent body
burdens and excreta of parathion and its metabolites; to minimize the number of
compartments and free parameters, regrouping was carried out on the basis of the time
scales of the ldnetic processes involved. Burden variations in time were described
mathematically by differentiai equations that ensure conservation of mass on a mole
basis. Mode! parameter values were determined from statisticai fits to published in vivo
kinetic data in humans. Except for the derma! absorption fraction and absorption rate,
which are known to be subject to wide intra- and inter-individual variabiiity, a single
set of parameter values for the internai body ldnetics enabled the model to simulate
accurateiy the available ldnetic data. For dermal exposure to parathion, with a typical
absorption rate of 0.085 W’, model simulations show that it takes 20 h to recover haif
of the total amounts of p-NP eventually excreted in urine and 30 h for the AP. The
mode! can be used to estimate the dose of parathion absorbed under different exposure
routes and temporal scenarios, based on measurements of amounts of metabolites
accumuiated in urine over given time periods. Using the above dose-excreta iinks and
the human no-observed-effect leve! for parathion reported in the literature for the
inhibition of cholinesterase activities, biological reference values are proposed in the
form of specific amounts of urinary metabolites excreted over chosen time periods.
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INTRODUCTION
Parathion (0,0-diethyl O-p-nitrophenyl phosphorothioate) is an organophosphorus
insecticide widely used in agriculture. In humans, as in insects, this pesticide exerts its
neurotoxic action by inhibiting nervous system acetylcholinesterases (AChE), enzymes
responsible for the degradation of acetylcholine. Clinical signs of intoxication usually
occur at an inhibition of 60-70% of the cholinesterase activity in red blood celis (RBC
AChE), an enzyme closely related to nervous system cholinesterases (SidelI, 1994).
Some clinical signs and symptoms were however reported in subjects with a RBC
AChE inhibition of 30-60% (SidelI, 1994).
In 1991, due to the high toxicity of parathion, the U.S. EPA and most of the registrants
of products containing parathion reached an agreement to restrict the application of
parathion to agricultural crops of alfalfa, barley, com, cotton, canola, sorghum,
soybean, sunflower and wheat (U.S. EPA, 1999). Additional label restrictions which
include aerial-only application and mechanical-only harvesting were further agreed
upon to reduce health risks in workers (U.S. EPA, 1999). Yet, following these
restrictions, some exposure incidents related to parathion spray drift or equipment
maintenance have stili been documented. The 1999 U.S. EPA Human Health Risk
Assessment Report also states that postapplication exposure of agricultural workers
remains a concem in the United States (U.S. EPA, 1999). The use of parathion is stiil a
concern in many other countries (Denga et al., 1995; Akgiir et al., 1999).
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Most plausibly, occupational exposure to parathion occurs mainly through the skin due
to the iow volatility and high lipophilic properties of this substance. Given the large
variations and uncertainties in dermal absorption. to estimate the dose of parathion that
actually penetrates in the body, and consequently to assess the health risks, the
measurement of biomarkers is more accurate than environmental monitoring (ACGIH,
2002).
The ACGIH®, NIOSH® and the German Commission for the Investigation of Health
Hazards of Chemicai Compounds in the Work Area (GCIHH) ail proposed biological
reference values based on the prevention of RBC-AChE inhibition. A 30% inhibition
of the RBC-AChE activity compared to the individual’s baseline was proposed by
these three organizations as a biological limit value. However, the inhibition of RBC
AChE activity is flot specific to parathion exposure but rather to the whole class of
acetylcholinesterase inhibiting pesticides, namely organophosphorus and carbamate
pesticides. The ACGIH® and GCIHH proposed more specific biological reference
values based on the urinary concentration of p-nitrophenol (p-NP), a metabolite of
parathion but also of other pesticides such as methyl parathion (O,O-dimethyi O-p
nitrophenyl phosphorothioate) and EPN (phen ylphosphonothioic aci d 0-ethyl O-p
nitrophenyl ester). The ACGIII® proposed a biological exposure index (BEI®) of 0.5
mg of p-NP/g of creatinine (0.34 mmol p-NP/mol creatinine) and the GCIRH
suggested a biologicai tolerance value (BAT) of 0.5 mg of p-NP/L of urine. Both
organizations recommended collecting a spot urine sample as soon as possible after
work. The p-N? urinary biomarker gives an earlier warning of possible adverse
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cholinergic effects than the inhibition of RBC-AChE activity since p-NP in urine is
detectable far before any inhibition of enzymatic activity occurs (Arterbeny et al.,
1961; Richter et al., 1992).
The proposed BEI® and BAT are expressed in concentrations, either adjusted or not for
creatinine contents. For the interpretation of measurements of p-NP in a spot urine
sample, the timing of sample collection is critical since urinary concentration values
vary significantly with time. For chemicals eliminated through the kidneys by
glomerular filtration or active secretion and flot passively reabsorbed, as is the case for
parathion metabolites (Michalke, 1984; Jokanovié, 2001), the urinary concentrations
decrease with increasing urinary flow rate (Boeniger et al., 1993). Although creatinine
is often taken to be excreted in urine at a constant rate, several authors reported that its
excretion rate is subjected to significant inter-individual variations (0.5 — 3 glday) as
well as inter-day (63 — 244%) and intra-day (200%) variations in the same individual
(Curtis & Fogel, 1970; Greenblatt et al., 1976; Alesio et al., 1985; Boeniger et al.,
1993). The main factors influencing the urinary excretion rate of creatinine are diumal
variations, body mass index, gender, age, pregnancy, diet, exercise and diuresis. These
important variations with time, in either metabolite concentrations or creatinine
excretion rate, suggest that the measurement of amounts of metabolites accumulated in
urine over a given period of time is a more reliable means of assessing occupational
health risks.
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In order to make good use of amounts of urinary biomarkers as a means of determining
exposure and health risks, it appears important to develop a toxicokinetic model that
would permit reconstruction of the absorbed dose from biomarker measurements, and
the choice of any convenient urine collection periods. This modeling should also allow
simulation of different temporal scenarios (single, repeated intermittent or continuous
exposures) and exposure routes (oral, dermal, respiratory). Models have been
developed to describe the toxicokinetics of parathion in rodents (Sultatos, 1990;
Gearbart et al., 1994) but these models did not describe the kinetics of parathion
metabolites excreted in urine and were flot adapted nor validated for humans.
After systemic absorption, parathion is either stored in lipids or biotransformed mainly
in the liver; the biotransformation is a rapid hydrolysis to p-N? and
diethylphosphorothioic acid (DETP), which are excreted in urine and feces, or an
oxidation to paraoxon, the metabolite responsible for the inhibition of cholinesterases
(Menzie, 1969; Poore & Neal, 1972; Hayes, 1982; Jokanovié, 2001). According to an
in vitro study with human liver microsomes (Mutch et al., 1999), the rate of
detoxification of parathion into p-NP is 4 to 7 times greater than the rate of activation
of parathion into paraoxon, indicating that roughly 80% of the biotransformed
parathion is directly hydrolyzed to p-NP while 20% of parathion is converted to
paraoxon. Once formed. paraoxon is either broken down by a A-esterase into p-N? and
diethylphosphoric acid (DEP), which are excreted in urine and feces, or it binds to
proteins such as AChE (Menzie, 1969; Hayes, 1982; Jokanovié, 2001). Hence, less
than 20% of the parathion absorbed dose forms AChE bound oxon. In rats, about 65-
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74% of the amount of AChE bound oxon undergoes spontaneous hydrolysis (reversible
binding) while the rest undergoes aging (irreversible binding) (Carr & Chambers,
1996). Upon binding with AChE, paraoxon releases a p-NP molecule (Gallo &
Lawryk, 1991; Lotti, 1991; Zhang & Sultatos, 1991). In tum, the oxon reversibly
bound to AChE, during hydrolysis, gives rise ta DEP (Gallo & Lawryk, 1991; Lotti,
1991). The ineversibly bound oxon, upon turnover of the AChE enzyme, releases an
aikyl residue, a monoethyl phosphate (Gallo & Lawryk, 1991; Lotti, 1991). The main
metabolites of parathion found in urine are therefore p-NP and aikyl phosphates (AP):
essentially DETP and DEP (see Figure 1).
The objectives of this study were thus: i) to develop a toxicokinetic model predicting
the time course of p-NP and AP metabolites in human urine associated with a given
absorbed amount of parathion under various exposure routes and temporal scenarios
and ii) ta propose, using model predictions, biological reference values for parathion
metabolites, p-NP and AP, based on the measurement of cumulative amounts of
metabolites in successive urine collections following the onset of occupational
exposure.
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METHOD
Model Devetopment
Conceptual and Functional Representation The urinary excretion kinetics of
parathion and its metabolites was modeled using a multi-compartment dynamical
system. The conceptuai model is depicted in Figure 2 and symbois and abbreviations
are described in Table 1. Compartments represent the burdens or cumulative excreta of
parathion or its metabolites as a function of time and arrows stand for the rates of
transfer or biotransformation of parathion and its metabolites. The evolution of burdens
is described mathematicaily by differential equations where the rate of change of the
amounts in each compartment is the difference between the incoming and outgoing
transfer rates (see Appendix for differential equations). Once the parameters of the
internai dynamics of parathion have been determined using time course data under
controlled exposure conditions, the differential equation system can then be solved for
other time moduiated inputs and absorption rates. The model can thus be used to
predict the time courses of parathion and its metabolites under different exposure
scenarios (intravenous (iv), oral, dermai andlor inhalation, single or repeated
intermittent or continuous exposures).
The model uses specific input compartments, D(t), GI(t), RT(t), to describe the
amounts of parathion bioavaiiable at the skin surface, the gastrointestinal tract and the
respiratory tract, respectively. Tissue burdens of parathion and paraoxon that rapidly
reach and maintain a fixed ratio with the blood burden were regrouped with the biood
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burden in a single compartment, B(t), since ail these quantities evolve in unison.
Another compartment, $(t), regroups storage tissue burdens of parathion and paraoxon
that are slowly retumed to blood. This S(t) compartment was introduced in the model
to account for the biphasic elimination Idnetics of parathion metabolites in the urine of
volunteers intravenously exposed to parathion (Feldmann & Maibach, 1974). The
terminal elimination phase of this urinary time course curve is most plausibly due to
the slow release to blood of parathion and paraoxon accumulated in lipids or covalently
bound to tissue proteins.
To simulate the time courses of the urinary biomarkers, there are two key elements to
consider in the biotransformation process. The first one: each mole of parathion in the
body is eventually broken down into one mole of p-NP arid one mole of AP (DETP,
DEP or other alkyl phosphates), either directly or through the formation of paraoxon
(Menzie, 1969; Gallo & Lawryk, 1991; Lotti, 1991; Zhang & Sultatos, 1991;
Jokanovié, 2001). This requires two distinct mass balance differential equation systems
(on a mole basis), one for the production and elimination ofp-NP and another for AP
(see the Appendix for differential equations). The second one: phase I and phase II
biotransformation of parathion and paraoxon into p-NP or AP occurs on a much more
rapid time-scale than renal and fecal clearance of the metabolites (Michalke, 1984).
Consequently, the rate of formation of p-NP or AP, directly from parathion or through
the formation of paraoxon, is very rapid compared to the relatively slow metabolite
elimination.
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It was also considered that as soon as the AP or p-NP metabolites are formed, they
rapidly undergo phase II conjugations (Michaike, 1984) and become highly
hydrosoluble. Single metabolite specific cornpartments, MAp(t) or MNp(t), were thus
used to represent either AP (the sum of DETP and DEP) or p-NP burdens in blood and
in tissues in dynamic equilibrium with blood (for short, compartments MAp(t), MNp(t)
and B(t) will usually be referred to as blood burden compartments). The compartments
MAp(t) and MNp(t) comprise the sum of free and conjugated forms of the metabolites
since, in the studies used to develop the model, total p-NP and AP were measured
analytically, after acidic or enzymatic hydrolysis of samples (Elliott et al., 1960; Shafik
et al., 1973a,b; Michaike, 1984).
Analysis of the experimental data of Feldmann and Maibach (1974) and Michaike
(1984) further served to detail the part of the model representing the kinetics of p-NP
and AP metabolites. Michaike (1984) reported the concentration-time course of p-NP
in the blood and urine of a subject intoxicated with parathion. The first two biological
specimens were collected 30 min and 10 hr after parathion ingestion. Maximum
concentration of p-NP in blood was observed in the first collection sample, whereas,
maximum concentration in urine was seen in the second sample. This shows that: j) p
NP is formed rapidly from parathion and paraoxon and ii) its subsequent rapid
disappearance from blood but long delay before recovery in urine stems most plausibly
from a retention of p-NP in the kidney. This delay was also observed in animal studies
on the detailed time courses of [4C]-p-NP in blood and urine (Qiao et al., 1994, 2000;
Abu-Qare et al., 2000). This delayed excretion is modeled by the introduction of a
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holding compartment KNp(t) that retains p-NP prior to excretion in urine. In a similar
matter, the available urinary excretion kinetic data on AP, reported by Feldmann and
Maibach (1974), show that peak excretion rate of A? in urine was not reached until 10
hr following an iv injection of labeled parathion in volunteers, indicating a long delay
between the rapid biotransformation of parathion and the excretion of its AP
metabolites. Indeed, these authors described the time course of total ethyl-’4C excretion
rate in the urine of 6 volunteers exposed iv to 1 /LCi of ethyl-’4C-labeled parathion
(dose in mole or in gram was not specified). Given that parathion was marked on the
aikyl group, the kinetics of AP was followed in that study. In the model, a holding
compartment KAp(t) that retains AP prior to excretion in urine was therefore introduced
to account for the observed time of maximum urinary excretion rate of AP.
The compartment UAp(t) represents the cumulative excretion of total AP observed in
urine and fAp(t) the cumulative excretion of total AP excreted otherwise and not
measured, similarÏy for total p-NP with UNp(t) and FNp(t). The metabolite burdens not
excreted through urine are likely excreted via feces, as evidenced from mass-balance
data in animais (Nye & Dorough, 1976; Prakashchandra & Guthrie, 1983; Carver &
Riviere, 1989).
Determination of the Parameters The studies of Feldmann and Maibach (1974),
Hayes et al. (1964), Hartwell et al. (1964), Maïbach et al. (1971) and Morgan et al.
(1977) were used to detemiine model parameter values. figures reported in those
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studies were scanned and the experimental values were read using a Sigma Plot
Graphing Software (Jandel Corporation, San Rafael, CA).
Most of the model parameter values were first estimated by least square fits of the
approximate analytical solutions of the differential equations to the appropriate human
time course data available in the literature. The different time scales involved in the
biological processes provided these approximate solutions following the quasi steady
state theory (Segel, 1988; Segel & Slemrod, 1989). Starting with these first
estimations, the model parameter values were further adjusted by least square fits of
exact numerical solutions of the differential equation system to the experimental time
course data. A professional edition of a MathCad software was used for this purpose
(MathSoft Inc., Cambridge, MA). In the following, the published data used for the
determination of each model parameter value are presented.
Parathion and Paraoxon Kinetics: The parameter kBM represents the rate of
appearance of p-NP or AP in the blood compartment, i.e., the rate at which blood
parathion and paraoxon are broken down into p-NP and AP. It was determined from
the data of Michalke (1984) on the time course of blood p-NP in a subject exposed to
parathion. According to these data, the maximum concentration of p-NP in blood was
observed during the initial sampling, that is 30 min postexposure, suggesting that most
of the parathion is metabolized by that time. The half-life for the appearance ofp-NP in
blood is thus of the order of 6 min and hence the kBM biotransformation rate was taken
to be 6.93 h’. This rapid biotransformation is supported by the animal data of Sultatos
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(1990) on the concentration-time course of parathion in blood, liver, lungs and brain of
mice exposed iv to parathion.
The slow transfer rate ks8 of stored parathion and paraoxon back to the blood
compartment B(t) was determined from the data of feldmann and Maibach (1974) by
log-linear regression of the time course of average total ethyl-’4C urinary excretion rate
during the terminal phase (36 to 120 h) following an iv injection of ethyl-’4C parathion
in volunteers. The parathion and paraoxon storage rate kBs was also estimated from the
iv data of Feldmann and Maibach (1974) by least square fits of the numerical solution
of the differential equation system to the time course of average total ethyl-’4C urinary
excretion rate 0-120 h postexposure.
AF Kinetics: The proportion of blood AP that is eventually excreted in urine as
compared to feces, = kMK , was determined also from the iv data of
kMKM, +kMFAP
Feldmann and Maibach (1974) on the average amounts of total ethyl-’4C recovered
overail in the urine of volunteers during the 120-h collection period, assuming that the
urinary excretion of AP is complete at that time. The transfer rates kMK..Ap and kKuAp
describing the ldnetics of urinary AP were estimated by least square fits of the
differential equation solution to the iv time course data reported by Feldmann and
Maibach (1974) on the urinary excretion rate 0-120 h postexposure.
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p-NP Kinetics. The proportion of blood p-NP that is eventually excreted in urine as
compared to feces, = kMK , was obtained from the study of Morgan et
kMK + kMF
al. (1977), which reports the percent ofp-NP excreted in the urine of volunteers (n = 4)
following an oral administration of 1 or 2 mg ofparathion.
The transfer rates kMKNp and kKUNp describing the kinetics of urinary p-NP were
estimated by least square fits of the differential equation solution to the data of
Hartwell et aI. (1964) on the time course of average p-NP urinary excretion rate in a
volunteer following a 2.5-h inhalation exposure to parathion vapors at 38°C.
Respiratory exposure was considered, for input to the model, as equivalent to a drop by
drop exposure with instantaneous absorption of inhaled vapors.
Dermal Absorption Parameters for Parathion: The parameter fabs-clermal describes the
fraction of the exposure dose that will be absorbed into the systemic circulation. The
parameter kabs.dermal describes the dermal absorption rate of parathion from skin layers,
epidermis or dermis, to the systemic circulation. There are known intra- and inter
individual variations in the skin absorption of chemicals depending on the anatomical
region of the skin exposed, the skin condition and the environmental temperature and
humidity (Maibach et al., 1971; Bronaugh & Maibach, 1999; ACGIH, 2002). These
variations appear important for parathion absorption according to the data of Maibach
et al. (1971). b account for this variability, the absorption parameter values, kabsdert
and fabs-dermat, were adjusted to the different dermal data sets. However, to ensure the
unity of the model, a single set of parameter values was used to describe the kinetics of
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parathion and its metabolites once parathion is absorbed in the blood stream. A
sensitivity analysis was achieved to study the impact of variations in the dermal
absorption rate on metabolites urinary excretion.
The model was used to simulate the data of Feldmann and Maibach (1974) along with
the data of Maibach et al. (1971) both on the urinary time course of average ethyl-’4C
equivalents in volunteers exposed to dermal doses of ethyl-’4C parathion. Feldmann
and Maibach (1974) applied 1 fLCi of ethyl-’4C parathion on the foreanns of 6 male
volunteers (dose in mole or in gram flot specified). Maibach et al. (1971) applied 1 tCi
of ethyl-’4C parathion on 13 skin regions of male volunteers (n = 6 per exposure group;
dose in mole or g flot specified). The most common dermal exposure scenarios
reported by these authors were simulated with the model, i.e. exposures either on the
forearm, the paim, the hand dorsum or the scalp.
The data of Hayes et al. (1964) on the urinary excretion kinetics of p-N? was also
simulated. These authors established the time course ofp-NP excretion rate in the urine
of a male volunteer exposed 2 h per day, on 5 successive days, to 5 g of 2% parathion
dust on the right hand and forearm secured in a polyethylene bag. During the 2-h daïly
exposure, the temperature was kept constant at 4 1°C.
Model Simulations Once the parameters of the model were determined as described
above, simulations of the time courses of parathion and its metabolites in the body and
in excreta were carried out by solving numerically the differential equation systems
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using the Runge-Kutta method incorporated in MathCad. The same set of parameter
values was used to describe the kinetics of parathion once absorbed and that of its
metabolites. Only the absorption rates were adjusted according to the site-of-entry.
Simulations of different temporal exposure scenarios, where continuous or repeated
intermittent doses are administered through time, were performed by introducing time
varying inputs (see Appendix).
$ensitivity Aitatysis
The capacity of each model parameter value to influence the predicted 12- and 24-h
urinary excretion was tested. The model parameter values, obtained above from fits to
published mean excretion data, were separately varied as far as ± 50%. The sensitivity
(02-01)101
tests were based on the followrng normahzed sensitlvity coefficient: R= (12—11)/11
where I is the default value of the parameter analyzed for sensitivity, ‘2 its modified
value and where 01 is the predicted 12- or 24-h cumulative urinary using default
parameter values, 02 its predicted value with the modified parameter values.
Establishment of Biologicat Refereitce Values
The biological reference values proposed in the current study are expressed as
cumulative amounts of p-NP or AP in urine collected over different periods of time
following the onset of an exposure to parathion. These values are generated by
simulating an 8-h dermal exposure, where the daily absorbed dose corresponds to a
human no-observed-effect level (NOEL) reported in the available literature on blood
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cholinesterase inhibition following controlled exposures. To provide a safety margin
and to protect the more susceptible workers, the slowest absorption rate compatible
with the various dermal experimental data presented above was used for these
simulations. further, background values were considered negligible.
Human NOEL for the Establishment of the Biological Reference Values Human
NOELs for parathion have been reported by Edson et al. (1964) and Rider et al. (1969),
based on the inhibition of plasma pseudocholinesterase (plasma-ChE) or RBC-AChE
activities in volunteers exposed orally to parathion. In ah these studies, volunteers were
repeatedly exposed to parathion over more than a month resulting in a response
representative of a worker exposure. The clinical signs or symptoms of toxicity were
monitored throughout the course of the experiment, but none were observed.
Data provided in the aforementioned studies was reanalyzed since the cholinesterase
activity reduction considered then as significant for the determination of the reported
NOELs was different from that suggested by several ôther authors. Given the large
inter- and intra-individual variability in baseline plasma-ChE and RBC-AChE activities
of unexposed individuals, the inhibition was considered as significant when the degree
of inhibition of exposed subjects compared to their baseline activity was 19% for
plasma-ChE and 12% for RBC-AChE (Gage, 1967; Larsen & Hanel, 1982; Heath &
Vale, 1992).
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Edson et al. (1964) exposed volunteers orally to parathion, once a day, 5 days per
week, during 5 to 14 consecutive weeks. The dosage regimens were 0, 0.6, 1.2, 2.4, 4.8
and 7.2 mglday (n = 4 per exposure group). Plasma-ChE and RBC-AChE activities
were measured before, during and after the exposure period. In the group exposed to
7.2 mglday, an inhibition of 33% of the plasma-ChE activity (Le., 67% of control
activity) and 16% of the RBC-AChE activity (i.e., 84% of control activity) was
observed after 6 weeks of exposure. For the other dose regimens, no significant
inhibition was reported. From these observations and the cholinesterase inhibition
criteria mentioned above, the human NOEL dose value retained for the establishment
of our suggested biological reference values was 4.8 mg/day (i.e., 58 igIdayIkg of
body weight (bw)) as determined by Edson et al. (1964). In the absence of adequate
human experimental data, the oral absorption fraction was assumed to be 100%, a
value observed in dogs (Braeckman et al., 1983).
The human NOEL dose value of 58 ug/kg-bw/day is corroborated by the experimental
study of Rider et al. (1969). The latter authors administered parathion orally to male
prisoners during approximately 30 consecutive days. Four groups of 5 volunteers
ingested 3, 4.5, 6 or 7.5 mg of parathion per day (or 40, 60, 80 and 100 ug1kg-bw,
assuming a body weight of 75 kg). The analysis of plasma-ChE and RBC-AChE
activities measured in volunteers shows that the NOEL dose of this study is 4.5 mglday
(or 60 g/kg-bw/day).
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RESULTS
Mode! Simulations
Table 2 presents parameter values of the model obtained from fits to available
experimental data. With these values, the model reproduced closely the data of
Feldmann and Maibach (1974) on the time course of total ethyï-14C excretion in the
urine of human volunteers exposed to either a single iv or a dermal dose of ethyl-’4C
parathion (Figure 3). The excretion rate data of Feldmann and Maibach (1974)
following iv injection, when converted to cumulative values, show that, at the end of
the observation period (120 h), 46% of the dose is excreted in urine as AP. Therefore,
in the model, the urinary fraction was set to 0.46; the rest is eliminated by other
means, most plausibly via the feces. In the data of feldmann and Maibach (1974) for a
dermal dose, only 10% is finally recovered in urine. Combining this with the results of
the iv experiment, indicating that only 46% of an absorbed dose is finally excreted as
AP in urine, leads te a dermal absorption fraction, fabs-dermat, equal te 0.21, Le. 0.21 x
0.46 = 0.10. The absorption rate compatible with the dermal data reported by these
authors was found to 5e kabsder, = 0.085 h1.
The proposed model, with the parameter values of Table 2 describing the ldnetics of
absorbed parathion and that of AP metabolites, was aise applied to the data of Maibach
et al. (1971) on the urinary excretion time profiles of total ethyl-’4C in human
volunteers te whom was applied ethyl-’4C parathion on different skin regions of the
body (Figure 4). The data of Maibach et al. (1971) indicated large variations in the
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dermal absorption fraction and rate depending on the exposed skin site. For proper
model simulations of these data, the average dermal absorption fractions compatible
with the data were 0.19, 0.26, 0.46 and 0.72 for applications to the forearm, the palm of
the hand, the hand dorsum and the scalp, respectively, while the corresponding
absorption rates were 0.06, 0.04, 0.15 and 0.07 h’.
The model, with the pararneter values of Table 2 describing the kinetics of absorbed
parathion and that ofp-NP, gave a good fit to the data of Hartwell et al. (1964) on the
time course of urinary p-NP in a volunteer exposed to parathion vapors by inhalation
(Figure 5). The model was also found to predict conectly the data of Hayes et al.
(1964) on the time course of p-NP excretion in the urine of a volunteer repeatedly
exposed to parathion dust through dermal contact at an exposure temperature of 41°C
(Figure 6). At this relatively high exposure temperature, the dermal absorption rate (0.5
W’) was found to be much greater than was the case in the studies of Feldmann and
Maibach (1974) and Maibach et al. (1971) mentioned above.
The model was also tentatively applied to the data of Michaike (1984) on the
cumulative urinary excretion time course of p-NP metabolite in a subject intoxicated
with parathion, to estimate the unknown absorbed dose. The model provided a close fit
to the data presented by this author using the model parameters reported in Table 2 for
the kinetics of absorbed parathion and that of p-NP along with an oral absorption rate
of 0.8 W’ (Figure 7). This oral absorption rate value is also compatible with the data on
chlorpyrifos, a related compound (Nolan et al., 1984). No saturation function was
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necessary to obtain a good fit. Using the value for the urinary p-N? fraction reported
by Morgan et al. (1977) fuNp = 0.37, the mode! estimates that the absorbed dose of this
intoxicated subject was 860 mol (250 mg).
The model was also used to reproduce the ldnetics of parathion and its metabolites
under the exposure conditions of agricultural and horticultural workers. Without regard
for the specific absorption fraction, the mode! can be used to reconstruct the actua!
dose of parathion absorbed in the body of a worker from the amounts of metabolites
excreted in urine. Figure $ compares mode! simulation to the data of Wolfe et al.
(1970) on the time course of p-NP cumulative excretion in the urine of an orchard
worker app!ying a formulation containing parathion during a single 8-h period. A good
fit to the time course data of this worker was achieved by considering that bioavai!able
parathion penetrated in the body at a constant rate of 0.3 h’ and that, although
absorption occurred most!y on the day of application, it continued to some extent on
the days following the spraying episode. The absorption rate used here is typical of a
derma! exposure under high ambient temperatures as reported by Wolfe et al. (1970). 11
is compatible with the study of Hayes et al. (1964), which suggests that hïgh exposure
temperature accelerates the passage of parathion through the skin. This absorption rate
value cou!d also reflect a combined derma! and respiratory exposure. from the
cumulative urinary excretion time course data depicted in figure 8, the overail dose of
parathion absorbed in the body of the worker was estimated to be 23 fLmol (6.7 mg).
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$ensitivity Aizatysis
Sensitivity analysis were conducted on mode! parameters using default values reported
in Table 2. Under typical worker exposure conditions, a daily dermal exposure over $
consecutive hours, sensitivity tests through model simulations (see Table 3) have
shown that the dermal absorption rate kabsdermal and the excretion rate parameter kKu
were the main parameters governing the 12- and 24-h cumulative urinary excretion.
The effect of variations in these latter rates was more important than the impact of
variations in parathion biotransformation rate kBM. In sensitivity tests, it was shown
that the exact value for the biotransformation rate kBM had littie bearing on metabolites
excretion kinetics provided parathion partitioning between storage and metabolism
(kflSflcflM) remained fixed.
Determination ofBiotogicat Reference Values
Biological reference values for p-NP and AP amounts in urine samples collected over
different time periods are presented in Table 4. To ensure that these biological
references values were derived with a safety margin, mode! inferences under different
input conditions are considered in the following.
Figure 9 shows that use of the s!owest possible dermal absorption rate (kabsderma1) 5
essential in establishing protective biological reference values. For example, when
simulating a dermal exposure to parathion where the absorbed dose over 8 h
corresponds to the NOEL dose, using a kabsdeI value of 0.3 h1, yields a 24-h
cumulative urinary amounts of 55 nmol/kg-bw for p-NP and 41 nmol/kg-bw for AP,
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whereas using a kabs-dermal value of 0.04 W’, the corresponding values are 24 nmol/kg
bw for p-NP and 15 nmol/kg-bw for AP. This illustrates that, for dermal exposure, the
absorption rates can strongly limit metabolite excretion rates. The effect of the
absorption rate on the cumulative urinary amounts reflects the importance of
establishing biological reference values based on the simulation of a dermal exposure
scenario rather than a pulmonary or oral exposure. In the latter exposures, absorption is
so rapid that excreted amounts over a period of time are much larger for a given
absorbed dose.
Table 5 illustrates that the determination of biological reference values without
consideration of a background also contributes to provide values with a safety margin.
As shown in Table 5, when simulating a repeated $ hlday dermal exposure to
parathion, 5 days per week, Monday to Friday, typical of a worker exposure, with an
absorption rate of 0.04 W’, daily urinary amounts of p-NP and AP are shown to
increase over the course of a work-week. Predicted daily urinary excretion ofp-NP and
AP on Friday is, respectively, about 3 and 6 times the values predicted on Monday.
This increase occurs because there is flot enough time available between the end of a
work-shift and the beginning of the next work-shift for the total excretion of
metabolites stemming from the daily absorbed dose.
Figure 1OA also shows that, when considering this typical worker exposure scenario
with a slow absorption rate, kabs-dermal = 0.04 li’, a significant fraction of the absorbed
daily dose from the previous day remains in the skin layers, epidermis or dermis, and
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has not yet reached the systemic circulation. Under this repeated exposure scenario,
accumulation of parathion or paraoxon in storage tissues S(t) further contributes to the
increase in the daily urinary excretion of parathion metabolites as the week progresses
(see figure lOB).
If a much faster dermal absorption rate is considered, kabs-dermal = 0.3 li’, for these
repeated exposures, Figure 1OA shows that there is no accumulation from one exposure
day to another in the skin burden of parathion. However, even with this rapid dermal
absorption, the daily urinary excretion tends to be higher at the end of the work-week,
due to the effect of the tissue storage build up and slow release to blood (see Figure
lOB). For instance, on the first exposure week, Monday daily urinary excretion of AP
is 20.7% of the absorbed daily dose as compared to 45.4% on Friday. It is also
noteworthy that, for any kabs-dermal values between 0.04 and 0.3 W1, after two weeks of
repeated exposures, 8 h/day, 5 days/week, there are no further week to week increase in
the daily urinary excretion values of either p-NP or AP.
Table 6 presents the cumulative urinary excretion of p-NP and AP generated from
simulations of either an instantaneous or a 4-h dermal exposure, where the total
absorbed dose corresponds to 58 pgIkg-bw. Since workers are rarely exposed to
pesticides for more than 8 consecutive hours, comparison of Table 4 and Table 6 shows
that consideration of an 8-h temporal exposure scenario rather than a shorter exposure
duration leads to smaller p-NP and AP urinary excretion values and thus safer
biological reference values based on urinary excretion.
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Figure 11 shows simulations of the concentration-time course of p-NP in urine
following a dermal absorption typical of a daily worker exposure, where the total
absorbed dose corresponds to the NOEL. The concentration was obtained by dividing
dUNp(t)the time-dependent p-NP urinary excretion rate ( dt ) by the average urinary
flow rate in man (equivalent to 1.5 llday reported by Boeniger et al., 1993). This Figure
indicates that urinary concentrations vary significantly with time in addition to being
influenced by the dermal absorption rate, the creatinine contents and the urinary flow
rate. Thus, to avoid being misled by these important variations in spot value
concentrations, it is best to propose a biological reference value expressed in terms of
cumulative amounts of the metabolite recovered in urine over a specified time period.
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DISCUSSION
Modet Devetoprnent
A toxicokinetic model was developed in this study to better assess health risks related
to parathion exposure in workers using urinary measurements of metabolites, AP or p
NP. The model describes the time courses of urinary biomarkers of parathion under
different exposure routes and temporal scenarios. The model was built for biologicai
monitoring purposes and flot, for instance, to uncover the links between the formation
of paraoxon and the appearance of health effects. It predicts the essential features of the
ldnetics of parathion and its metabolites in humans without the need for detailed
knowledge of internai physiological processes. To develop the model, extensive use
was made of the different time scales underlying the critical biologicai processes
governing the urinary excretion dynamics.
A single set of values were used for the model parameters describing the kinetics of
parathion, once absorbed, to its excretion as AP and p-NP in urine. Only the dermal
absorption rate, kabs-dermal, and the absorption fraction, fabs-dermal, needed to be adjusted
to provide good fits to ail the considered dermal data sets. These adjustments for the
absorption parameters reflect the known wide variations in absorption due to the
particularities of each exposed skin region and exposure temperature, as reported by
funckes et al. (1963) and observed from the data of Hayes et al. (1964) and Maibach et
al. (1971). The model showed that, depending on the absorption rate, the dynamics of
the urinary biomarkers can be markedly altered. For example, following an iv injection,
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to recover haif of the total amounts ofp-NP excreted in urine takes 7 h, for AP it takes
20 h, whereas, following a dermal exposure, the corresponding times are 20 h for p-NP
and 30 h for AP, considering a dermal absorption rate of 0.085 h’.
The model was flot validated with an entirely separate data set because such data was
flot forthcoming. However, a single set of parameter values was capable of describing
the internai dynamics of parathion and its metabolites over a variety of data sets with
different routes-of-entry and temporal scenarios. The model simulated closely
published data on the mean urinary time course of parathion metabolites in voiunteers
and workers following acute and repeated iv, pulmonary or dermal exposures (Hartwell
et al., 1964; Hayes et al., 1964; Wolfe et al., 1970; Maibach et al., 1971; Durham et al.,
1972; Feldmann & Maibach, 1974). This gives confidence that the model is a suitable
tool to assess exposure and hence heaith risks in workers using urinary biomarker
measurements.
The model can, through back calculations, serve to estimate the dose of parathion
absorbed by a worker. There are however constraints reiated to the wide variations in
the absorption rate according to the route of exposure and, in the case of dermal
exposure, upon the site of application, skin condition and exposure temperature.
Considering that these variations in the absorption rate largely influence the urinary
excretion rate (see sensitivity analysis), simulations of an exposure scenario with the
slowest and highest absorption rates compatible with the avaiiabie literature data on
excretions can provide a lower- and upper-bound value for the absorbed dose
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reconstructed from amounts of biomarkers in urine. In cases where some basic
information is available on the approximate time of exposure, the route of absorption
and the detailed urinary excretion time course, the model can provide a more accurate
estimation of the absorbed dose. This was carried out starting from the p-NP urinary
time course reported by Michalke (1984) in an intoxicated subject. Even for the
relatively high dose estimated for this subject, a good time profile prediction of the
urinary excretion data was afforded by the model without the need for any saturation
mechanism in the metabolism of parathion (figure 7). The estimated absorbed dose of
parathion for this intoxicated subject was from one to two orders of magnitude higher
than the absorbed dose estimated by the model for the orchard workers in Durham et
al. (1972) and Wolfe et al. (1970) (data shown only in one case). Attempts were also
made to simulate other data in intoxicated subjects (Kuo et al., 1979). However, for the
two cases reported in that study, marked saturation processes appeared to govern the
kinetics. The cumulative urinary excretion of these subjects were however assessed to
be 3.2 and 8.5 mmol, which-would correspond, according to the model, to absorbed
doses of at least 8.5 and 22.1 mmol, respectively. These are 10 and 26 times greater
than that calculated for the intoxicated subject of the study of Michaike (1984)
discussed above.
A temporary retention effect of parathion metabolites, prior to excretion in urine, was
however apparent from data in exposed volunteers (feldmann & Maibach, 1974) and
an intoxicated subject (Michaike, 1984); it was accounted for in the mode! by
introducing a holding compartment that retains parathion metabolites prior to their
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excretion in urine. This process may be due to a retention of actively secreted parathion
metabolites in renal tubular celis prior to their transport in the tubular lumen. The
mechanisms by which this occurs, possibly an inhibition of renal active transport as
reported for the herbicide 2,4,5-trichlorophenoxyacetic acid and for dinitrophenol
(Bemdt & Grote, 1968; Bemdt, 1982), remain to be documented in in vitro studies
using human ceils.
An important feature of the model lies with the detennination of its parameters solely
from human data in order to avoid uncertainties arising from animal to human
extrapolations. Indeed, comparison of the human data of Morgan et al. (1977) and the
animai data of Carver and Riviere (1989), Nye and Dorough (1976), and
Prakashchandra and Guthrie (1983) shows large differences between animais and
humans in the relative proportion of p-NP recovered in urine as compared to feces.
Morgan et al. (1977) reported that, on average, 37% of the p-NP appears to be
eliminated by the renal route in humans as compared to 87-90% in rats (Nye &
Dorough, 1976; Prakashchandra & Guthrie, 1983) and 96% in pigs (Carver & Riviere,
1989).
The model was built on the basis of a compilation of published mean urinary excretion
data for different exposure scenarios. It could be refined if, within a same experimental
framework, individual blood and urinary excretion data had been available from
volunteers exposed by different routes to a wide dose range of parathion. These data
would have helped establishing the inter-individual variability. In the absence of such
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data, a sensitivity analysis was impiemented for the model to simulate the variation in
outcomes under reasonable parameter variations. However, knowing the variations in
parameter values describing the internai kinetics is not essentiai for the purpose of this
study, which is the determination of reference values for p-NP and AP in urine. Indeed,
in the case of a dermai exposure, the main route-of-entry for workers, sensitivity
analyses conducted on the model parameter values showed that the absorption rate
contributes to a major part of the variability in the urinary excretion rate of parathion
metabolites. Within reasonable ranges, the parameters describing the internai kinetics
have generaily little influence on the 12- or 24-h urinary excretion for dermal
absorption.
Establishment ofBiotogical Reference Vatues
Biological references values for urinary parathion metabolites, p-NP and AP, are
estabiished in this study to prevent adverse heaith effects in exposed workers. The
proposed biological reference values are expressed as cumulative amounts of p-NP or
AP in urine over given periods of time rather than in the form of end-of-shift urine
samples as the ACGIII® suggests. End-of-shift urine concentrations are subject to the
influence of the rapid changes in metabolites transfer to urine (see Figure 11) and can
vary greatly for identicai exposures given that the time eiapsed since the previous
micturition is usually unknown. With the approach proposed in the current paper, the
integration of urinary excretion amounts over given periods of time reduces
significantiy these variations and avoids the impact of the known variations in urinary
flow rate. Furthermore, the ACGIH® approach relies on the concentration of
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metabolites in urine with respect to that of creatinine; with the proposed approach, it is
unnecessary to rely on creatinine, which excretion rate lias been documented to vary
(Boeniger et al., 1993). The expression of biological reference values in terms of
cumulative urinary amounts rather than spot urine sample measurements also facilitates
the detection of metabolites at lower exposure levels.
Inferences using the toxicokinetic model show that the worker exposure scenario used
to derive the biological reference values provide safe estimates that protect the more
susceptible workers. The biological reference values can also be considered protective
on the basis of the data of Hayes et al. (1964) in a volunteer dermally exposed to
parathion. For this volunteer, where the reported 24-h p-NP urinary excretion was 15.9
mo1, there was no significant inhibition of RBC-AChE (0%) and plasma-ChE (6%)
activities. Assuming a body weight of 70 kg for this volunteer, this excretion value is
approximately 10 times higher than the p-NP biological reference value proposed in
this study (24 nmolfkg-bw).
These biological reference values can serve to estimate health risks in exposed
workers. For instance, Wolfe et al. (1970) determined the urinary excretion ofp-NP in
7 spraymen exposed to parathion in orchards. It can be calculated from the reported
data that, assuming a constant daily exposure over the observation period and a body
weight of 70 kg, the p-NP daiÏy excretion of the different workers is 50, 230, 40, 60,
30, 20 and 47 nmolfkg-bw. On this basis, only the excretion in one worker is below the
biological reference value for p-NP (24 nmol/kg) proposed in the cunent study. These
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findings suggest significant occupational exposures for those workers. That study was
however conducted long before the U.S. EPA reached, in 1991, an agreement to limit
the usage of parathion in the USA and to increase parathion handiing and
postapplication restrictions (U.S. EPA, 1999). To our knowledge, the extent to which
these measures contributed to reduce the adverse health risks cannot be assessed for
Jack of relevant data published after 1991.
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APPENDIX
first order tinear differentiat equations for each colnpartrnent
Kinetics of parathion. From Figure 2, the following differential equations are
obtained (see Table 1 for definitions of symbols and abbreviations):
dD(t)
dt
= dermaI (t) — x D(t)
dGI(t)
gorai (t) — kabsor& x GI(t)
dRT(t)
=
g (t)
— kabsinh x RT(t)
where guer(t), gorai(t) and g0h(t) are the bioavailable dose Dabs per unit of time for
dermal, oral, or respiratory tract absorption, respectively.
For intravenous injection, g(t) = O for t O and at time t = O: B(O) = Dabs.
dB(t)
= kabs_Orai x GI(t) + kabs inh x RT(t) + kabs_dermal x D(t) + ksB xS(t) — (kBs + kBM ) x B(t)
dS(t)
=k5 XB(t)—ksB xS(t)
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Kinetics of the p-nitrophenol metabolite
dMNP(t) =
kBM XB(t)—(kMK_Np + kMF_Np)XMNP(t)dt
dKNP(t) =
kMK_Np x MNP(t) — kKUNP x KNP(t)dt
dUNP(t)
kKUNP XKNP(t)dt
dFNP(t)
=kMF_Np xMNP(t)dt
Kinetics of the aikyl phosphate metabolites
dMAP(t)
kBM xB(t)— (kMK_Ap + kMf_Ap)x MAP(t)dt
dK(t)
kMK_ xM(t)—kKU M. xKM.(t)dt
dUAP(t) =
kKU_M XKAP(t)dt
dfM.(t)
=kMFAP XMAP(t)dt
Mass balance verification
Kinetics of the p-nitrophenol metabolite
D(t)+ GI(t) + RT(t) + B(t) + S(t)+ MNp(t) + Kp(t) + Up(t) + fp(t) —
[D(o)+oI(o)+RT(o)+B(o)+s(o)+M(o)+K(o)+u(o)+F(o)]
= =
total absorbed dose tu time” t”
Kinetïcs of the aikyl phosphate metabolites
D(t) + GI(t) + RT(t) + B(t) + S(t) + M(t) + K(t) + U(t) + F(t) —
[D(o) + GI(0) + RT(O) + B(0) + S(0) + M(0) + K(0) + U(0) + f(0)j
= dea1(S)+ g(s) + (s)]x ds =
total absorbed dose tu time t”
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Table 1. Symbols Used in the Conceptual and Functional Representation of the
Model
Variables and
parameters
Description
Symbols or
abbreviations
Variables guj(t) Dermal dose bioavailable (mol) per unit of time (h) which can describe time
varying inputs
gorai(t) Oral dose bioavailable (mol) per unit of time (h) which can describe tïme
varying inputs
gflh(t) Inhaled dose bioavailable (mol) per unit of turne (h) which can describe time
varying inputs
D(t) Burden of parathion bioavailable (mol) at the skin surface as a function of time
GI(t) Burden of parathion bioavailable (mol) in the gastrointestinal tract as a
function of time
RT(t) Burden of parathion bioavailable (mol) in the respiratory tract as a function of
time
Q(t) Systemic body burden of parathion and its metabolites (mol) as a function of
time
B(t) Burden of parathion and paraoxon (mol) in blood and tissues in dynamical
equilibrium with blood as a function of time
5(t) Burden of parathion and paraoxon (mol) in storage tissues as a function of time
M(t) Burden of aikyl phosphates (mol) in blood and tissues in dynamical
equilibrium with blood as a function of time
M(t) Burden of p-nitrophenol (mol) in blood and tissues in dynamical equilibrium
with blood as a function of time
K,(t) Burden of alkyl phosphates (mol) in body reservoir as a function of time
KNP(t) Burden ofp-nitrophenol (mol) in body reservoir as a function of time
U(t) Cumulative burden of aikyl phosphates (mol) in urine as a function of time
UNp(t) Cumulative burden ofp-nitrophenol (mol) in urine as a function of time
Fy(t) Cumulative burden of alkyl phosphates (mol) in feces as a function of time
FNP(t) Cumulative burden ofp-nitrophenol (mol) in feces as a function oftime
Parameters kabsorl Oral absorption rate of parathion (h1)
kabsinh Pulmonary absorption rate of parathion (ht)
kabsdemial Dermal absorption rate of parathion (i.e., transfer rate from skin surface to
blood) (h1)
k5 Blood to storage tissues transfer coefficient of parathion and paraoxon (h’)
ksB Storage tissues to blood transfer coefficient of parathion and paraoxon (h’)
kBM Rate of body parathion and paraoxon biotransformation into p-nitrophenol and
aikyl phosphates (h’)
kMK]’ Blood to body reservoir transfer coefficient of aikyl phosphates (h’)
kMK Blood to body reservoir transfer coefficient ofp-nitrophenol (h’)
kKu Body reservoir to urine transfer coefficient of aikyl phosphates (h1)
kKu Body reservoir to urine transfer coefficient ofp-nitrophenol (h’)
kMF Blood to feces transfer coefficient of alkyl phosphates (h’)
kMF Blood to feces transfer coefficient ofp-nitrophenol (h1)
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Table 2. Parameter Values Used for Model Simulations of the Kinetïcs of
Parathion and That ofp-Nitrophenol and Aikyl Phosphate Metabolites
Transfer coefficients Values (h’)
Absorption parametersfor parathion
kabs.oral 0.8
kabsdermaI 0.04 - 0.5
Parathion and paraoxon kinetic pararneters
kBM 6.93
kBs 2.40
ksB 0.0457
Aikyt phosphate kinetic pararneters
kMKAp 0.0997
kKuAp 0.0749
kMfAp 0.117
p-Nitrophenot kinetic parameters
kMKNp 0.463
kKuNp 0.166
kMpNp 0.788
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Table 3. Ranges of Values of the Normalized Sensitivity Coefficient R
Normalized sensitivity coefficient R range a
(0201)/O1R= (12—11)111 , where 11;s the default value of the parameter given in Table 2, 12 its
modified value (± up to 50% Ii). 01 is the predicted 12- or 24-h cumulative urinary
using default parameter values and 02 its predicted value with the modified parameter
value. The cumulative urinary 0 and 02 were obtained by model simulations of an 8-h
dermal exposure to parathion, where the daily absorbed dose corresponds to a unit
dose.
b kBs and kaM are varied simultaneously but such as to maintain a constant partitioning
ratio between storage and metabolism (kBs/knM).
Model
parameters
p-Nitrophenol Alkyl phosphates
12-h cumulative 24-h cumulative 12-h cumulative 24-h cumulative
urinary excretion urinary excretionurinary excretion
(0.03, 0.03)
urinary excretion
(0.06, 0.07)ksB (0.03, 0.03) (0.05, 0.06)
k3 (-0.26, -0.20) (-0.21, -0.18) (-0.26, -0.20) (-0.23, -0.18)
kBM (0.18, 0.40) (0.14, 0.33) (0.19, 0.41) (0.15, 0.35)
kBM’’ (0.01, 0.04) (0.00, 0.01) (0.02, 0.06) (0.01, 0.02)
kMKC (0.10, 0.27) (0.03, 0.08) (0.50, 0.76) (0.23, 0.52)
kKu (0.5 1, 0.78) (0.21, 0.52) (0.75, 0.90) (0.5 1, 0.78)
kabsdermatd (0.59, 0.93) (0.28, 0.83) (0.64, 0.94) (0.36, 0.86)
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The proportion of blood metabolite that is eventually excreted in urine as compared to
feces is kept constant (kMK/kMK+kMf).
d The default parameter value is 0.085 W1, value determined from the data of Feldmann
and Maibach (1974) on the time course of total ethyl-14C urinary excretion rate in
volunteers following a percutaneous administration of ethyl-14C parathion.
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Table 4. Biological Reference Values for p-Nitrophenol and Aikyl Phosphates in
Urine
Proposed biological reference values
Period of urine collection
(h) following the onset of (nmol/kg of body weight)
exposure
p-Nitrophenol Aikyl phosphates
12 6 2
24 24 15
a Expressed as cumulative amounts over different periods of urine collection. These
amounts were obtained using model simulations of an 8-h dermal exposure to
parathion, where the daily absorbed dose corresponds to the human NOEL of 5$ pg/kg
of body weight and the denual absorption rate is equal to 0.04 h.
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Table 5 Predicted Daily Amounts ofp-Nitrophenol and Aikyl Phosphates in Urine
During a Repeated 8-h Daily Dermal Exposure to Parathion
24-h cumulative urinary excretiona
(% of absorbed daily molar dose)
Day of the onset of
_________________________________________________
the 24-h unne p-Nitrophenol Aikyl phosphates
collection
First week Second week first week Second week
of exposure of exposure of exposure of exposure
Monday 11.8 17.5 7.5 18.4
Tuesday 24.7 27.4 24.0 29.2
Wednesday 31.2 32.4 34.9 37.4
Thursday 34.3 34.9 40.7 41.8
friday 35.7 36.0 43.5 44.0
Saturday 24.6 24.7 37.3 37.6
Sunday 12.0 12.1 21.5 21.6
Obtained using model simulations of an 8-h dermal exposure to parathion, Monday to
Friday, repeated over two weeks, where the dermal absorption rate is equal to 0.04 h1.
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Table 6. Cumulative Urinary Amounts of p-Nitrophenol and Alkyl Phosphates
Over Different Collection Periods Following Either an Instantaneous Exposure or
the Onset of a 4-h Dermal Exposure to the Chosen NOEL Dose of Parathion
Cumulative urinary excretion a
Period of urine (nmol/kg of body weight)
collection (h)
following the onset p-Nitrophenol Aikyl phosphates
of exposure
Instantaneous Instantaneous4-h exposure 4-h exposure
exposure exposure
12 12 9 5 4
24 29 26 21 18
a Obtained using model simulations of a dermal exposure, where the daily absorbed
dose corresponds to the human NOEL of 58 pgIkg of body weight and the dermal
absorption rate is equal to 0.04 h.
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CAPTIONS TO FIGURES
Figure 1. Biotransformation pathways of parathion.
Figure 2. Conceptual representation of the kinetics of parathion and its metabolites.
Symbols and abbreviations are described in Table 1. One mole of parathion absorbed
in the body is broken down into one mole of aikyl phosphates and one mole of p
nitrophenol.
Figure 3. Model simulations (unes) compared with experimental data of Feldmann and
Maibach (1974) (symbols) on the time course of total ethyl-’4C urinary excretion rate
(% of administered dose/h) in male human volunteers following an intravenous (o) and
percutaneous (x) administration of ethyl-’4C parathion (1 MCi). Each point represents
mean value of experimental data (n 6 per exposure group).
Figure 4. Model simulations (unes) compared with experimental data of Maibach et al.
(1971) (symbols) on the time course of total ethyl-’4C cumulative urinary excretion (¾
of administered dose) in male human volunteers following a percutaneous
administration of ethyl-’4C parathion (4 ugIcm2) on the forearm (X), the paim of the
hand (+), the hand dorsum (o) and the scalp (O). Each point represents mean value of
experimental data (n = 6 per exposure group).
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Figure 5. Model simulation (une) compared with experimental data (symbols) of
Hartwell et al. (1964) on the time course of p-nitrophenol urinary excretion rate in a
human volunteer exposed by inhalation to parathïon vapors for 2.5 h, under an
exposure temperature of 3 8°C.
figure 6. Model simulation (line) compared with experimental data (symbols) of
Hayes et al. (1964) on the time course of p-nitrophenol urinary excretion rate in a
human volunteer exposed for 2 hours, on 5 consecutive days, to 5 g of 2% parathion
dust on a hand and forearm secured in a polyethylene bag, at a constant exposure
temperature of 4 1°C.
Figure 7. Model simulation (une) compared with experimental data (symbols) of
Michalke (1984) on the time course ofp-nitrophenol cumulative urinary excretion in a
human subject intoxicated orally with parathion.
Figure 8. Model simulation (fine) compared with experimental data (symbols) of
Wolfe et al. (1970) on the time course ofp-nitrophenol cumulative urinary excretion in
a worker following an 8-h application period, in orchards, of a formulation containing
parathion.
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Figure 9. Mode! simulations of the time course of (A) p-nitrophenol and (B) aikyl
phosphates cumulative excretion in urine (expressed as a fraction of total amounts
excreted in urine) following the onset of an 8-h exposure to parathion considering
different dermal absorption rate values: kabsdcrmal = 0.04 W’; kabsej = 0.09
Ll. 1 C1’Ll11 , abs-derma1 = U•3 11
Figure 10. Model simulations of the time course of (A) parathion burden at the site-of
entry R(t), and (B) parathion and paraoxon in storage tissues S(t) (expressed as a
fraction of absorbed daily dose) during and following a consecutive 5-day-per-week
dermal exposure to parathion, 8 h per day, repeated over two weeks, considering a
dermal absorption rate of 0.04 W’ ( ) or 0.3 W’ (
Figure 11. Model simulations (unes) of the concentration-time course ofp-nitrophenol
in urine following the onset of an 8-h dermal exposure to parathion where the daily
absorbed dose corresponds to the NOEL of 58 pg/kg of body weightlday with a urinary
flow rate of 1.5 l/day and different dermal absorption rate values: kabsermal = 0.04
—1
—1. —1h , kabsdermal = 0.09 h ,
.-.-.-.- kabs-dermal = 0.3 h
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ABSTRACT
Urinary biomarkers of chlorpyrifos (CPF) exposure are often measured in field studies
although biological guidelines are flot yet available to assess health risks in workers.
The aim of this study was to propose biological reference values (BRVs) for CPF
metabolites in urine based on a toxicokinetic approach. As a first step, a toxicoldnetic
mode! for CPF and its metabolites was developed and validated using the human
kinetic time course data available in the literature. The model was built to link the
absorbed dose of CPf under a vanety of exposure routes and temporal scenarios to the
urinary excretion of its major metabolites, 3,5,6-trichloro-2-pyridinol (3,5,6-TCP) and
aikyl phosphates (AP). The model was then used to propose BRVs of urinary
biomarkers of CPF exposure below which workers should not experience adverse
health effects, whatever their exposure conditions. This was achieved by linking j) a
literature reported repeated CPF no-observed-effect level (NOEL) daily exposure dose
for the inhibition of red-blood-cell acetylcholinesterase (RBC-AChE) activity to a
conesponding absorbed daily dose, on the one hand and ii) this absorbed daily dose to
the urinary excretion of CPF metabolites, on the other hand. Model simulations under a
variety of exposure scenarios showed that the safest BRVs are obtained from a dermal
exposure scenario with the slowest absorption rate compatible with the available
literature data rather than from respiratory or oral exposure scenarios. Also, model
simulations showed that, for a given total absorbed dose, absorption over 8 hours
resuits in smaller 3,5,6-TCP and AP urinary excretion rates than those obtained from
the same absorbed dose over shorter exposure durations, although eventually the
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cumulative amounts found in urine would be the same. from these considerations,
BRVs were derived by simulating an 8-hour dermal CPF exposure such that the total
absorbed daily dose corresponds to the absorbed NOEL. The reference values are
proposed in the form of total amounts of 3,5,6-TCP and AP metabolites excreted in
urine over chosen time periods (24 and 48 hours).
Keywords Chlorpyrifos, 3,5,6-Trichloro-2-Pyridinol, Aikyl Phosphates, Biological
Reference Values, Biomarkers, Toxicoldnetics, Occupational Exposure
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INTRODUCTION
Chlorpyrifos (O, O-diethyl-O-[3,5,6-trichloro-2-pyridylJphosphorothioate, CAS
Registry No. 2921-$8-2) is an organophosphorus (OP) pesticide used in LORSBAN®
and DURSBAN® formulations to control agricultural and horticultural insect pests.
Chlorpyrifos-induced toxicity resuits primarily from the inhibition of neuronal
acetylcholinesterase (AChE) activity by the chlorpyrifos (CPF) bioactivation product,
CPF-oxon.13
To prevent health risks from airborne exposures in occupational settings, a time
weighted average threshold limit value (TLV-TWA®) of 0.2 mg CPF/m3 of air has
been proposed.4 However, in the majority of occupational cases, respiratory exposure
to pesticides accounts for only a small fraction of the overail exposure.5 Like many
other OP insecticides, CPf’s lipophilic property favors its absorption through the
skin.4 fenske and Elkner’6 have estimated that, during structural control treatments of
houses with DURSBAN®, 73 percent of urinary CPF metabolite excretion was
attributable to dermal exposure.
Since occupational exposure to CPf potentially occurs through multiple routes,
particularly by skin contact, the assessment of health risks based on the compliance to
biological guidelines rather than environmental guidelines (TLV®) appears more
suitable.7’8 A Biological Exposure Index (BEI®) has been proposed based on the
measurement of the inhibition of red-blood-cell (RBC)-AChE activity by OP and
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carbamate insecticides.4 However. a BEI® based on the measurement of urinary
metabolites of CPF has flot been proposed so far; this is desirable since urinary
biomarkers give an earlier warning of exposure and biological effects than the
inhibition of AChE activity and are more specific.9
According to both animal and human studies, whatever the exposure route, CPF is
eventually nearly completely converted to equimolar amounts of 3,5,6-trichloro-2-
pyridinol (3,5,6-TCP) and aikyl phosphate (AP) metabolites (diethyl phosphate (DEP)
and diethyl thiophosphate (DETP)) (see Figure 1), which are essentially excreted
through the renal route.’°14 To assess exposure to CPF, urinary metabolites are thus
often being measured: 3,5,6-TCP as a more specific biomarker and AP as less specific
biomarkers6”5”6 Nonetheless, given the absence of biological guidelines for 3,5,6-
TCP and A? metabolites, these urinary biomarkers cannot currently be used to assess
health risks.
Most BEI5® are based on urinary biomarker concentrations at TLVTWA@ airborne
exposure.4 In the case of CPF, for which exposure occurs through multiple routes, the
establishment of a BEI® on the basis of airbome concentrations of CPF does flot ensure
a safe estimate for ah working conditions because of very different absorption fractions
and absorption rates arising from the different routes of exposure. BEIs® have also
been proposed based on ]inks between urinary biomarkers and effects under worker
exposure situations, but these hinks have not yet been established for CPF. Recently,
biological reference values (BRVs) have been proposed for the specific urinary
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metabolites of the following OP insecticides: azinphosmethy1’7, ma1athion’8 and
parathion°9. These BRVs are given as urinary excretions conesponding to safe levels
of absorption for workers, whatever the exposure scenario. This was accomplished
through the development, for each of these OP insecticides, of a toxicokinetic model
relating the dose of the parent compound absorbed in the body to j) the time course of
urinary biomarkers under different exposure scenarios, on the one hand, and ii) to OP
insecticides exposure doses causing inhibition of RBC-AChE activity, on the other
hand.
The objective of this study was to use a similar approach to propose BRVs for CPF
metabolites in urine, with a margin of safety. The model developed in the current work
links the absorbed dose of CPf to the urinary excretion of its major metabolites, 3,5,6-
TCP and aikyl phosphates (the sum of DEP and DETP). The modeling approach used
here, similar to that used in previous works on ma1athion’8 and parathion’9, is a
refinement of classical compartment models in that a biological significance is
attributed to each compartment and mass balance tracking is emphasized.
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METHODS
Mode! Devetopment and Validation
A multi-compartment dynamical model was developed to describe the biodisposition
ldnetics of CPF and its metabolites in humans. It seeks to predict the essential
biological features of the kinetics of CPF with a minimum number of compartments
and parameters. To limit the number of compartments, regrouping of tissues and
functions was carried out on the basis of the different time scales relevant to the
essential biological processes. Parameters were determined from direct fits to available
human data on the time courses of the parent compound and its metabolites in
biological matrices (blood and urine).
Mode! Functional Representation
The model functional representation was based on the available literature on the time
course data of CPF and its metabolites, 3,5,6-TCP and AP, in blood and urine of
individuals exposed orally and dermally to CPF. The model is depicted in Figure 2 and
symbols and abbreviations are described in Table I. Compartments represent burdens,
on a mole basis, of CPF or its metabolites in the body or cumulative excretion of CPF
metabolites as a function of time. Arrows stand for the transfer rate of CPF or its
metabolites from one compartment to another or the biotransformation rate of CPF to
one of its metabolites. The variations with time in compartment burdens were
described mathematically by systems of differential equations where the rate of change
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in a compartment burden is the difference between its input and output rates (see
Appendix for differential equations).
The amounts of CPF bioavailable at the skin surface, in the gastro-intestinal tract and
in the respiratory tract were each represented by a specific input compartment, D(t),
GI(t), RT(t), respectively. A specific compartment B(t) was used to descnbe the CPf
blood burden (i.e. arterial and venous blood including tissue blood). A storage
compartment S(t) was used to represent CPF in lipids or reversibly bound to tissue
proteins.
In the model, which aims at relating the absorbed dose of CPF to the excretion of 3,5,6-
TCP and AP metabolites, each mole of CPF in the body was taken to be eventually
broken down into one mole of 3,5,6-TCP and one mole of AP’0; this occurs directly or
through the formation of CPF-oxon (in vitro haif life of the oxon in human blood of 55
seconds)i2023 Thus, a mass-balance system of differential equations was developed for
CPF absorption, storage and metabolism into 3,5,6-TCP and AP. After CPF
breakdown, the ldnetics of 3,5,6-TCP and AP were described by two different mass
balance (on a mole basis) differential equation systems. Accordingly, metabolite
specific compartments MTcp(t) and MAp(t) were used to represent the body burden of
3,5,6-TCP and AP metabolites. Similarly, the cumulative urinary excretions of 3,5,6-
TCP and AP metabolites were represented by compartments Uicp(t) and UAP(t). The
model considers that excretion of CPF metabolites occurs through the renal route, as
indicated in the literature. O-14)
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Determinatio,z of Parameter Values
The model parameters were determined using the experimental data of Nolan et
and Drevenkar et a124 in individuals orally exposed to CPF. Nolan et al.’2 exposed 6
volunteers orally to 0.5 mg CPF per kg of body weight and established the detailed
blood concentration-time profile of 3,5,6-TCP along with the time course of 3,5,6-TCP
urinary excretion rate. These time profiles were shown to evolve in parallel on a semi
log plot, indicating that the 3,5,6-TCP urinary excretion rate is proportional to the
3,5,6-TCP body burden, a fact incorporated in the model ldnetics.
Drevenkar et aii24 determined the blood concentration-time profiles of CPF and AP as
well as the urinary excretion time course of AP metabolites in a subject oralÏy
intoxicated with CPF. After an initial disposition phase, blood concentration-time
profiles of CPF and AP are parallel on a semi-log plot. Peak blood concentration levels
were observed during the first sample collection (i.e. 2 to 5 hours after ingestion) and
concentration values dropped rapidly at subsequent time periods without the
observation of an initial zero-order elimination process. Although this subject ingested
a dose of CPF sufficiently large to induce signs of acute toxicity, the blood
concentration-time courses of CPF and AP metabolites measured after admission to
hospital suggest the absence of saturation processes. Also, it can be seen again from the
data that the AP urinary excretion rate follows, on a semi-log plot, a time course
parallel to the blood concentration of AP metabolites. However, although parallel,
these time courses are not straight unes, they rather show an initial rapid decrease
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followed by a siower decrease. The rapid decrease is due to two concomitant processes
both occurring in the same order of time-scale: the biotransformation of CPF into its
metabolites and the transfer of CPF from the blood compartment to a storage
compartment. The siower decrease reflects the release of CPF from the storage
compartment to blood, released CPF being biotransformed as soon as it reaches the
blood compartment.
For the determination of the model parameters, since CPF is eventually broken down
into one mole of 3,5,6-TCP and one mole of AP, the experimental data used from the
literature (exposure dose and blood and urinary time course data) were expressed in
moles. In addition, given that the model is based on the conservation of mass,
experimental data used from the literature on the urinary excretion profiles of CPf
metabolites which were presented as excretion rates were integrated over time to
provide the cumulative burdens necessary for mass conservation. Observed blood
concentration values of CPf and its metabolites reported in the literature were also
converted to burdens. Amounts of CPF in blood were obtained simply by multiplying
reported CPF concentrations in blood by the blood volume (0.08 times the body
weight25). Amounts of metabolites in the body were obtained by multiplying the
observed metabolites concentrations in blood by their apparent volume of distribution.
The latter was found to correspond to the blood volume in order to ensure conservation
of mass at ail times in the system i.e. that, at ail times, the total bioavailable CPF dose
equals the sum of CPF amounts remaining at the site-of-entry, amounts of CPF and its
metabolites in the body and amounts of metabolites excreted, in moles. Considering the
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blood volume as the volume of distribution of CPF metabolites is consistent with the
fact that CPF metabolites are unlikely to diffuse through vascular celis because they
rapidly undergo phase II conjugation once formed’11’12. More precisely, this
conjugation increases both the water-solubility and the molecular weight (MW of 375,
346 and 330 for the glucurono-conjugates of 3,5,6-TCP, DETP and DEP, respectively,
and of 277, 249 and 233 for the sulfo-conjugates of 3,5,6-TCP, DETP and DEP,
respectively), which limits the capacity to diffuse through lipid membranes of vascular
ceils or the passage through aqueous channels of the cellular membranes (this latter
process becomes negligible for substances with a MW>150-2O0).26
Parameters were determined essentially by least square fits of the explicit solution of
differential equations to the observed average blood time courses of CPF, 3,5,6-TCP
and AP metabolites (see Table II). The accuracy of parameter values was verified by
minimum least square fits to the observed urinary-excretion time courses of CPF
metabolites. No more than two parameters were detemiined per fit. A professional
edition of a MathCad software was used for this purpose (MathSoft© Inc., Cambridge,
MA).
Mode! Simulations
Once the parameters of the model were determined as described above, simulations of
the time courses of CPF and its metabolites in the body and in excreta were carried out
by solving numencally the whole differential equation systems using a fourth-order
Runge-Kutta algorithm incorporated in MathCad. The model was used to predict the
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time courses of CPF and its metabolites under different exposure routes (oral, dermal
andJor inhalation) and temporal scenarios (single or repeated intermittent or continuous
exposures). In ail these simulations, the same set of parameter values was used to
describe the kinetics of CPF, once absorbed, and that of its metabolites. Only the
absorption rate constant and the absorption fraction were adjusted according to the
route, site and mode of exposure.
To compare model simulations of blood concentrations of CPF and its metabolites with
reported experimental resuits, compartment burdens were simply divided by the blood
volume. To compare model simulations of urinary excretions to reported observed
data, both the observed excretion rates and the cumulative amounts were examined.
Mode! Validation
The model developed using the previously mentioned data was validated using
different sets of experimental data. The data of Nolan et al.’12 for dermally exposed
individuals (on the forearm), the oral data of Brzak et al.14 and that of Griffin et al.’3
were used for model validation.
Determination of Biotogicat Reference Values
BRVs are proposed in this study for 3,5,6-TCP and AP in urine. Since most regulatory
agencies and international organizations now rely on the measurement of RBC-AChE
inhibition as an early biomarker of cholinergic effects27’28, the proposed reference
values were derived using the available literature data on human exposure to no-
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observed-effect level (NOEL) doses for the inhibition of RBC-AChE activity. Plasma
cholinesterase activity was not considered because it is now generally accepted that it
should not be used for risk assessment since its inhibition is not indicative of an
adverse effect; this is weil documented by Carlock et ai.’28 in a review on regulating
and assessing risk of cholinesterase-inhibiting pesticides.
In the selection of the NOEL for the establishment of the proposed BRVs, repeated
dose controlled exposures were used since they most resemble worker exposure
conditions. The study of Couiston et al.29 is, to our knowledge, the oniy available
controlled study on the assessment of RBC-AChE activity in volunteers repeatedly
exposed to CPF. These authors determined RBC-AChE activity in volunteers oralÏy
administered tablets containing 0, 0.014, 0.03 and 0.1 mg of CPf per kg of body
weight per day for 27, 20 and 9 days, respectively (n = 4 adult male volunteers per
exposure group). for ail dose regimens, no significant inhibition of RBC-AChE
activity was observed. The NOEL for inhibition of RBC-AChE activity was thus taken
to be 0.1 mg/kglday, the highest dose tested. An anaiysis of the availabie repeated-dose
NOEL data carried out by Mattsson et ai.30 also ied them to conclude that the
repeated-dose human NOEL is 0.1 mglkglday. These authors used for their analysis
the human data of Couiston et a1.29 and conoborated their results with the data of
McCollister et ai.31 on dogs, which showed that dietary administration of 0.1 mg
CPf/kg/day for 1 year did flot produce any statisticaliy or clinically significant effect
on RBC-AChE activity.
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From this repeated exposure-dose NOEL value of 0.1 mg/kg/day (20 mol/day for a 70
kilogram individual), the correspondîng absorbed NOEL dose was estimated. BRVs in
the form of urinary excretion of metabolites were then derived by simulating with the
model an 8-hour dermal CPF exposure such that the total absorbed daily dose
corresponds to the absorbed NOEL dose. The proposed reference values are the total
amounts of 3,5,6-TCP and AP metabolites excreted in urine over chosen time periods
following the onset of exposure. To derive BRVs with a margin of safety, these
simulations were carried out: j) using the slowest absorption rate compatible with the
analyzed experimental time-course data and ii) without considering any baseline
excretion.
Sensitivity Aitatysis
The capacity of each model parameter value to influence the cumulative urinary
excretion over conveniently chosen time periods, 12, 24 and 4$ hour, was tested. The
model parameter values, obtained above from fits to published mean excretion data,
were separately varied. The sensitivity tests were based on the following normalized
sensitivity coefficient: R=2_O1)’Ot where I is the estimated value of the parameter(12—11)111
analyzed for sensitivity and 12 its locally modified value and where 0 is the predicted
12-, 24- or 48-hour cumulative urinary amount of metabolite using estimated parameter
values and O2its predicted value with the modified parameter value.
166
RESULTS
Mode! Simulations
Table II presents parameter values of the model determined using the data of Nolan et
a1’2 and Drevenkar et al.24 in orally exposed individuals. Figure 3 shows that the
model, with these parameter values, provided a close approximation to the data
collected by Nolan et a112 on the blood concentration-time profiles of 3,5,6-TCP as
well as the urinary excretion time course of 3,5,6-TCP in volunteers orally
administered 0.5 mg CPf per kg of body weight in the form of tablets. figure 4 shows
that the model also reproduced closely the data of Drevenkar et a1.24 on the blood
concentration-time profiles of CPF and AP together with the time dependent
cumulative urinary excretion time course of AP in a subject poisoned with CPF.
According to model simulation, the total absorbed dose of this intoxicated subject was
estimated to be 731 mol (the exposure dose was estimated to 5e 4.6 mg CPFIkg of
body weight).
The proposed model was applied to another set of data from Nolan et al.12 on the
blood and urinary lime profiles of 3,5,6-TCP in dermally exposed volunteers, on the
forearm. The parameter values reported in Table II, which describe the kinetics of
absorbed CPf and that of 3,5,6-TCP, were used for these simulations. To fit the data,
the dennal absorption fraction (fabs-dermal) was found to be 0.0 10 and the dermal
absorption rate (kabsjer,1), 0.04 hf’. These values are near those reported by Nolan et
al.”2 using a simpler compartment model: fabder1 = 0.013 and kabs-dermal = 0.03 hr’.
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With the values determined in the present study, Figure 5 shows that simulations of
time profiles were in close agreement with the observed data.
The model was further validated with the data of Brzak et al.’4 on the blood
concentration-time profiles of 3,5,6-TCP as well as on the cumulative urinary excretion
time course of 3,5,6-TCP in volunteers orally exposed to capsules containing 0.5, 1 and
2 mg CPF per kg of body weight (see figure 6). Ail the parameters of the internaI
kinetics were kept as determined with the data Nolan et al.02 in orally exposed
individuals (Table II). For good predictions of the experimental data, the average
absorption fraction was found to be 0.23, 0.23 and 0.19 for the 0.5, 1 and 2 mglkg
dose, respectively, and the absorption rate was found to be 0.1 hf1 for ail doses. This is
congruent with the oral absorption fraction estimate of 0.22 which can be infened from
the average, on ail treatment groups, 3,5,6-TCP cumulative excretion in urine reported
by Brzak et a1.’4. This small absorption rate fraction stems from the fact that CPF was
given in the form of capsules rather than in the form of tablets as in the study of Nolan
et ai.’2 and, it appears, the contents of some of the capsules was flot compietely
bioavailable.
The model describing the kinetics of absorbed CPf and that of AP was also applied to
the data of Griffin et al.’3 in volunteers orally exposed to a low dose of 1 mg of CPF
placed on a sugar cube. With the parameter values of Table II, the model predicts too
small a rate of elimination for AP in urine. However, a good fit was obtained (see
figure 7) by lowering the storage rate of CPF, ks, to 0.12 hf’ and by using the oral
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absorption fraction of 0.93 reported by Griffin et a1.t13 and an oral absorption rate of
0.13 hr’ while keeping the otherparameter values of Table II unchanged.
Sensitivily Anatysis
A sensitivity analysis was performed on model parameters using the values reported in
Table II (see Table III). It showed that, under typical worker exposure conditions
— an
8 hour per day dermal exposure
—, the dermal absorption rate kabsdermal and the urinary
excretion rate parameters, kMuTcp and kMuAp, were the main model parameters
governing the 12-, 24- and 48-hour cumulative urinary excretion. However, changes in
the dermal absorption rate had a greater influence on the cumulative urinary excretion
of CPF metabolites over the first 12-hour period than over the 0-24 and 0-48 hour
periods.
Changes in the dermal absorption rate kabsdej and the urinary excretion rate
parameters kMuTcp and kMuy had a larger effect on the excretion than changes in the
CPF biotransformation rate kBM. Varying the biotransformation rate kBM had little
impact on metabolites excretion kinetics provided CPF partitioning between storage
and metabolism (kBs/kBM) remained fixed, which is the case in our model. In other
words, the value of the kBsfkBM ratio is more important in governing the kinetics than
the values of the two parameters separately (kBs and kBM).
Determination of Biotogicat Reference Values
Using the model, which allows links to be made between the absorbed dose and the
urinary excretion of metabolites whatever the exposure scenario, BRVs for 3,5,6-TCP
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and AP in urine are proposed (see Table IV). These are expressed as cumulative
amounts of metabolites (nmol per kg of body weight) in 24- and 48-hour urine
collection periods. Although considered, in the interest of robustness, the possibility of
a BRV based on a O-12 hour collection period was excluded because it would be too
sensitive to the highly variable absorption rate, as shown by the sensitivity analysis.
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DISCUSSION
This report presents a toxicokinetic approach for the determination of BRVs for CPf
metabolites in urine. As a first step, a toxicokinetic model was developed that captures
the broad features of CPF kinetics and allows links to be made between the dose of
CPf absorbed in the body and the urinary excretion of its metabolites, for different
exposure routes and temporal scenarios. As a second step, this model was used to
propose reference values of urinary biomarkers of CPF exposure below which workers
should not experience adverse health effects.
Mode! Description of the Kinetics of Ch!orpyrfos and Its Metabotites
To describe the kinetics of CPP once absorbed and that of its metabolites, a single set
of parameter values was used (Table II); only the parameters pertaining to the
absorption process needed to be adjusted to meet the very different exposure situations
encountered (dermal, oral or inhalation routes). The mode] showed that the blood and
urinary excretion ldnetics of CPF and its metabolites were most dependent on the
absorption rate constant (kabs) and absorption fraction (fabs) of CPf. These parameters
are known to differ substantially among individuals ta 10-fold difference in the oral
absorption rate, according to Nolan et al.”2, i.e. from 0.3 to 3 hr’ (n = 6 individuals))
and from one exposure route to another. Also, for oral exposures, these parameters vary
depending on the mode of administration, e.g., tablets versus capsules°2’14, and for
dermal exposures, depending on the exposed skin site, the skin condition and the
ambient temperature and humidity.’4’32
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With these considerations, the mode! was shown capable of accurately simulating the
kinetics of CPF and its metabolites over a wide range of doses (12 to 95 pmol of
absorbed CPF) by different exposure routes.02”4 At the lower absorbed dose of 2.7
mol, as administered by Griffin et aiP3, the CPF storage rate kBs needed to be
reduced substantially for the mode! to provide a good fit to the urinary excretion time
course of AP metabolites reported by these authors. At low doses, one can surmise that
the reason for this low storage rate lies with the hepatic first-pass metabolic effect,
which is more important than at higher doses. If this is so, a significantly larger part of
the CPF dose would be metabolized prior to reaching the systemic circulation from
which storage occurs.
However, the model parameter values could flot ah be validated with an entirely
separate data set, under the same exposure conditions, because such data were flot
forthcoming. Since the model was built to derive BRVs by allowing links to be made
between an absorbed dai!y dose (therefore independent of the absorption fraction), the
cumulative urinary amounts of biomarkers and the appearance of critical biological
effects, it was not necessary to have the complete range of parameter values. In this
context, it is sufficient to use the most conservative parameter values compatible with
the available data.
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Comparison of the Current Modet with Oth ers Previousty Pubtished
The current model can be compared to other previously published models. Authors
have fitted their experimental time course data to one or two compartment models.12’24
In particular, Nolan et al.’2 described mathematically the blood concentration-time
profile of 3,5,6-TCP using a one compartment model with first-order elimination
leading to a prediction of mono-exponential decrease. In our model, 3,5,6-TCP in the
body was also represented by a single compartment; however, the introduction of a
storage compartment for the parent compound, S(t), resuits in a bi-exponential pattem
for the blood time course of CPF metabolites. This feature corresponds more closely to
the combined data of Nolan et al.’2 and Drevenkar et al.t24 (see Figures 3-5).
Timchalk et al.33 recently proposed a pharmacokinetic model for CPF, CPF-oxon and
its 3,5,6-TCP metabolite. These authors described the kinetics of the parent compound
using a model with $ compartments: skin, gastro-intestinal tract, liver, brain, fat,
diaphragm, richly and slowly perfused tissues. Their model for the 3,5,6-TCP ldnetics
was described by a single global compartment from which elimination occurs through
excretion in urine. The parameters of their model were determined from a combination
of animal data22’34’35, human data1225) and mathematical algorithms36. The model of
Timchalk et al.33 considers only the detoxification of CPF into 3,5,6-TCP, whereas
our model considers also the AP metabolites, which are as important in quantity since
one mole of CPF yields a mole of 3,5,6-TCP and a mole of AP. These authors do not
propose a BRV based on their model. Although structurally different, both our model
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and that of Timchalk et al.33 provided a close approximation to the data of Nolan et
a112 and Brzak et al.U4).
Proposed Biotogicat Reference Values
BRVs are proposed in this study for CPF urinary metabolites based on the links
between the dose of CPF absorbed and time varying metabolite excretion as provided
by the toxicokinetic model, on the one hand, and on experimental data relating CPF
exposure dose to the inhibition of RBC-AChE activity, on the other hand. They are
expressed as total amounts of 3,5,6-TCP and AP in urine over time periods chosen to
provide an accurate assessment of worker exposure, i.e., 24 and 48 hours following the
onset of a workshift.
Although it is more practical in field studies to determine concentrations of CPF
metabolites in spot urine samples and adjust for creatinine contents, this may lead to
serious biases because of important variations with time, in both CPf metabolite
concentrations and creatinine excretion rate (200% intra-day and 63 — 244% inter-day
variations in creatinine excretion rate in the same individual).3740 For a more accurate
assessment of health risks, it is better to determine total amounts of metabolites in urine
collected over the longest feasible period of time. Model simulations showed that it is
best to collect urine samples over at least 24 hours, as was done in several studies.6’
4143) This stems from the fact that i) the dermal absorption rate, which is known to be
subject to wide intra- and inter-individual variations32, has a larger influence on the
rate of appearance of CPF metabolites in urine at earlier time points than at later times
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(see Table III), and ii) when considering a kabsdermal of 0.04 hr’, a greater fraction of the
absorbed CPF dose is estimated to be excreted in urine as 3,5,6-TCP and AP during the
first 24 hours following the onset of an 8-hour dermal exposure to CPF (11.3% and
19.8%, respectively) than during the first 12 hours (2.5% and 5.7%, respectively).
The proposed BRVs aim at protecting the most susceptible workers. According to
several authors,27”’45 the establishment of guidelines on the basis of measurements of
RBC-AChE activity as a srnrogate for AChE in the nervous system contributes to
provide a margin of safety for protecting human health. Indeed, in a study conducted
by Nordstrandt et al.46 in rats administered a single oral dose of CPf, RBC-AChE was
inhibited at least 12-fold more than brain or peripherial tissue AChE. Chen et al.27
reported moreover that the inhibition of RBC-AChE activity consistently occurs at CPF
doses below those exerting any clinical signs of cholinergic toxicity.
Using the toxicoldnetic model developed, it was possible to explore the conditions
(exposure routes and time scenarios) under which an identical total CPF absorbed dose
would produce the lowest cumulative urinary excretion of CPF metabolites over
chosen time periods. Since the proposed BRVs are based on these cumulative urinary
outputs, they can be determined with a margin of safety by basing them on the slowest
output situations. It can thus be shown that reference values based on a workday
dermal exposure scenario, with slow absorption and thus slow urinary output, are safer
than those based on the faster urinary outputs of rapidly absorbed CPF from respiratory
or oral exposures. For example, simulation of an 8-hour dermal exposure to CPF leads
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to cumulative urinary amounts of 3,5,6-TCP over 24 hours equal to 11.3 percent of the
absorbed dose, whereas the corresponding value inferred from an 8-hour inhalation
exposure with instantaneous absorption equals 33.2 percent of the absorbed dose.
Similarly, simulation of an 8-hour dermal exposure to CPf Ïeads to cumulative urinary
amounts of AP over 24 hours equal to 19.8 percent of the absorbed dose, whereas the
conesponding value inferred from an 8-hour inhalation exposure equals 48.7 percent of
the absorbed dose. In addition, bearing in mmd that workers are rarely exposed to
pesticides for more than 8 consecutive hours, model simulations were conducted where
a given total dose is absorbed over different exposure durations up to 8 hours. These
showed that, for a given total absorbed dose, absorption over 8 hours results in smaller
3,5,6-TCP and AP urinary excretion rates than those obtained from shorter exposure
durations. This is reasonable since the same total input, when absorbed over a longer
period, leads to a lower input rate and consequently a lower output rate, although
eventually the cumulative amounts found in urine would be the same. Thus, urinary
BRVs based on the 8-hour exposure duration are the more conservative.
Model inferences further indicated that the smaller the absorption rate value, the slower
will metabolites be excreted in urine, for inhalation exposure, absorption is very rapid
and is similar to a drop by drop infusion; following oral exposure, the average
absorption rate compatible with the available data varies between 0.1 and 0.5 hr’ 02,14).
upon dermal application, the absorption rate was shown to be much siower, in the
vicinity of 0.04 hr*’2 In the case of a dermal exposure, the main route-of-entry for
workers, sensitivity analyses conducted on model parameter values (see Table III)
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showed that the absorption rate contributes to a major part of the variability in the
urinary excretion rate of CPF metabolites. The proposed BRVs, based on a dermal
exposure with the slowest absorption rate found, 0.04 hf’, are thus protective.
k was also found from model simulations that the derivation of BRVs without adding
the background contribution of prior exposure days also contributes to provide safer
estimates. Indeed, the daily urinary excretion of CPf metabolites, expressed as a
fraction of the absorbed daily dose, was predicted to increase upon repeated daily 8-
hour dermaÏ exposures. These findings indicate that for workers exposed to CPF on an
almost daily basis, it is best to collect urine at the end of a workweek to account for the
yet non-eliminated built up of previous days.
As a measure of their applicability to practical situations, the proposed BRVs were
used to assess the health risks of botanical garden workers applying CPF (n = 1) to
plants or manipulating treated plants (n = 3)•(43) The total amounts of 3,5,6-TCP
measured in a 0-24 hour urine sample following an application of CPF were 1.4 ug in
the person applying CPF and 6.5, 5.1, 4.5 jig in 3 individuals manipulating plants.
These values represent respectively 0.004, 0.018, 0.014 and 0.012 of the proposed
BRV, assuming a body weight of 70 ldlograms. The proposed BRVs were also used to
assess the health risks of workers in the Fenske and Elkner6 study, who were exposed
to CPF following structural control treatments of houses. These workers appear to be
more exposed than those of the study of Samuel et a1.43. However, from the values
shown in Table V, it appears that these workers were at low risk upon comparison of
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their 3,5,6-TCP cumulative urinary excretion values over 24 and 48 hours following
the onset of a workday to the proposed BRVs for each of these urine collection periods.
The proposed BRVs are convenient and robust. However, they could benefit from
further validation in the field for different occupational exposure conditions. This could
be achieved by comparing observed amounts of CPF biomarkers with levels of
cholinesterase activity in workers in contact with CPF. The accuracy of the proposed
BRVs could then be refined, aiways ensuring that any individual with a urinary
excretion value below the BRV lias an inhibition of RBC-AChE activity below the
BEI® of 30%, as proposed by the ACGIH®(4), and this whatever the exposure duration
(single or repeated).
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APPENDIX
first Order Linear Differentiat Equations for Each Modet Coinpartrnent
Kinetics of Chlorpyrifos
From Figure 2, the following differential equations are obtained (sec Table I for
definitions of symbols and abbreviations):
dD(t)
= gder1 (t) — kabsdet x D(t) [1]
dGI(t)
= gorai (t) — kabsorai x GI(t) [21
dRT(t)
= gfl(t) kabSiflh xRT(t) [3]
where gdermal(t), gorai(t) and gflh(t) are the bioavailable dose per unit of time for dermal,
oral, or respiratory tract absorption, respectïvely.
For intravenous injection, g(t) = O for t O and at time t = 0: 3(0) = Dabs.
dB(t)
kabs_orai X GI(t) + kabs inh x RT(t) + kabs_dei x D(t) + ksB xS(t) — (kBs + kaM ) x B(t)
[41
dS(t)
=kBs xB(t)—k8 xS(t) [5]
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Kinetics of 3,5,6-Trichloro-2-Pyridinol
dMTCP(t)
= kBM xB(t)
— kMUTCP XMTCP(t) [6]dt
dUTCP(t)
=kTcpxMTcp(t) [7]dt
Kinetics of the Aikyl Phosphates
dM (t)
=kBM XB(t)—kMUAP XMAP(t) [8]dt
dU(t)
=kMU_APXMAP(t) [9]dt
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Table 1. Symbots used in the functional representation of the model
Variables and
parameters
Description
Symbols or
abbreviations
Variables gd(t) Dermal dose bioavailable (mol) per unit of time (hr) which can describe time
varying inputs
gor(t) Oral dose bioavailabte (mol) per unit of time (hr) which can describe time
varying inputs
g11(t) Inhaled dose bioavailable (mol) per unit of time (hr) which can describe time
varying inputs
D(t) Burden of chlorpyrifos bioavailable (mol) at the skin surface as a function of
time
GI(t) Burden of chlorpyrifos bioavailable (mol) in the gastro-intestinal tract as a
function of time
RT(t) Burden of chlorpyrifos bioavailable (mot) in the respiratory tract as a function of
time
Q(t) Systemic body burden of chlorpyrifos and its metabolites (mol) as a function of
time
3(t) Blood burden of chlorpyrifos (mol) as a function of time
S(t) Burden of chlorpyrifos in storage tissues (mol) as a function of time
MTcp(t) Body burden of 3,5,6-trichloro-2-pyridinol (mol) as a function of time
M(t) Body burden of alkyl phosphates (mol) as a function of time
UTCP(t) Cumulative amount of 3,5,6-trichloro-2-pyridinol in urine (mol) as a function of
time
U(t) Cumulative amount of aikyl phosphates in urine (mol) as a function of time
Parameters fabs-QrdI Oral absorption fraction of chlorpyrifos
Pulmonary absorption fraction of chlorpyrifos
fabs.dermal Dermal absorption fraction of chlorpyrifos
Oral absorption rate of chlorpyrifos (hf’)
k3bsflh Pulmonary absorption rate ofchlorpyrifos (hr1)
kabsdenp.aI Dermal absorption rate of chlorpyrifos (i.e., transfer rate from skin surface to
blood) (hr’)
Blood to storage tissues transfer rate ofchlorpyrifos (hr1)
ksB Storage tissues to blood transfer rate of chlorpyrifos (hr’)
kBM Biotransformation rate of chlorpyrifos (hr’)
kMUTCP Transfer rate of 3,5,6-trichloro-2-pyridinol from the body to urine (hr’)
kMuAp Transfer rate of alkyl phosphates from the body to urine (hf’)
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Table 2. Model parameter values
ParametersA Values
Absorption fractions fabs-oral O.798’
fabs-dermal O.00995
C
Transfer rates (hf’) kabsoral
1 t’ f A
KabsdermaI U.U’+UU
kBM
ks
3061D
OE036 i’
1 1 E,F
KMUTCP
kMuAp
A The description of parameters is given in Table I.
B The oral absorption fraction and rate are known to vary according to the mode of
administration.’’2”4 These oral absorption fraction and rate values were determined
from the oral data of Nolan et al.12 on the average blood time profile of 3,5,6-
trichloro-2-pyridinol (3,5,6-TCP) along with the average time course of 3,5,6-TCP
cumulative urinary excretion calculated from the urinary excretion rate data presented
by these authors.
C The dermal absorption fraction and rate are known to vary according to the site of
application.3 These dermal absorption rate and fraction values were determined from
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the dermal data of Nolan et al.’2 on the average blood and urinary time courses of
3,5,6-TCP in volunteers exposed to CPF on the forearm.
D Determined from the data of Drevenkar et a1.24 on both the blood time courses of
chlorpyrifos and aikyl phosphates (AP).
E Based on the available human data’2’4, excretion of metabolites from the body was
taken to occur through the renal route.
F Determined from the average blood time course of 3,5,6-TCP reported by Nolan et
j(12) and accuracy was verified from the average urinary excretion time profile of
3,5,6-TCP reported by these authors.
G Determined from the blood time course of AP reported by Drevenkar et a1.24 and
accuracy was verified from the urinary excretion time profile of AP reported by these
authors.
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Table 3. Values of the normalized sensïtivity coefficient R
Normalized sensitivity coefficient R A
Model 3,5 ,6-Trichloro-2-pyndinol Aikyl phosphates
parameters O-12 hr O-24 hr O-48 hr O-12 hr O-24 hr O-48 h
urinary urinary urinary urinary urinary urinary
excretion excretion excretion excretion excretion excretion
ksB 0.06 0.13 0.23 0.06 0.14 0.25
kBs -0.56 -0.55 -0.48 -0.56 -0.54 -0.46
kBM 0.59 0.53 0.55 0.58 0.56 0.47
kBM3 0.05 0.02 0.01 0.04 0.02 0.01
kMu 0.83 0.66 0.40 0.57 0.29 0.10
kabs-dermal 0.88 0.75 0.52 0.88 0.72 0.47
A (02—01)/01 . .R= (12—11)/11 , where I is
the estimated value of the parameter as given in Table II,
12 its locally modified value. 0 is the predicted 12-, 24- or 48-hour cumulative urinary
excretion using the estimated parameter value and 02 the predicted value with the
modified parameter value. The cumulative urinary 01 and 02 were obtained by model
simulations of an 8-hour dermal exposure to chlorpyrifos, where the daily absorbed
dose corresponds to a unit dose.
B k5 and kBM are varied simultaneously but such as to maintain a constant partitioning
ratio between storage and biotransformation (kBs/kaM).
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Table 4. Biological reference values for 3,5,6-trichloro-2-pyridinol and aikyl
phosphates in urine: cumulative amounts over different collection periods from
the onset of exposure
Proposed biological reference values A,B
Urine collection period (nmol/lcg of body weight)
3,5 ,6-Trichloro-2-pyridinol Aikyl phosphates
0-24 26 45
0—48 76 99
A For comparison of urinary metabolite measurements to the proposed biological
reference values, workers should collect ail urines from the beginning of a workshift
for either of the proposed periods: 24 or 48 hours, preferably at the end of a workweek
to capture, for safety, non-eliminated doses from previous days.
B Obtained using model simulations of an 8-hour dermal exposure, where the daily
absorbed dose corresponds to the estimated human absorbed no-observed-effect level
(NOEL) dose of 0.08 mg/kg of body weight and where the dermal absorption rate is
equal to 0.04 hf’. The absorbed NOEL dose was obtained by multiplying the oral
exposure dose NOEL of 0.1 mg/kg determined by Couiston et ai.2 by the oral
absorption fraction of 0.798. This latter value was determined from the data of Nolan et
ai.’2 where volunteers were administered chlorpyrifos in the form of tablets as in the
study of Coulston et ai.29.
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Table 5. Comparison of the data of Fenske and E]kner6, on the cumulative
urinary excretion of 3,5,6-trichloro-2-pyridinol (3,5,6-TCP) over 24 and 48 hours
in workers exposed to chlorpyrifos following structural control treatments of
bouses, with the proposed biological reference valuesA
Urine Observed 3,5,6 - TCP cumulative urinary excretion over different urine collection periods
collection Biological reference value for same urine collection period
period
U) Worker 1 Worker 2 Worker 3 Worker 4 Worker 5 Worker 6 Worker $
O - 24 0.05 0.12 0.10 0.10 0.09 0.02 0.06
O - 48 0.04 0.06 0.08 0.08 0.09 0.02 0.04
A Sec Table III for the proposed biological reference values for 3,5,6-TCP in the 24- or
48-hour urine collection periods.
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CAPTIONS TO FIGURES
Figure 1. Chlorpyrifos biotransformation pathways.
Figure 2. Conceptual representation of the ldnetics of chlorpyrifos and its metabolites.
Symbols and abbreviations are described in Table 1. One mole of chlorpyrifos
absorbed in the body is eventually broken down into one mole of 3,5,6-trichloro-2-
pyridinol and one mole of aikyl phosphates (the sum of diethyl phosphate and diethyl
thiophosphate), either directly or through the formation of chlorpyrifos-oxon.
Figure 3. Model simulations (unes) compared with experimental data of Nolan et al.12
(symbols) on (A) the blood concentration-time course of 3,5,6-trichloro-2-pyridinol
(X), the urinary excretion rate time course of 3,5,6-trichloro-2-pyridinol (o) and (B) the
cumulative urinary-excretion time course of 3,5,6-trichloro-2-pyridinol in male
volunteers orally administered 0.5 mg chlorpyrifos per kg of body weight deposited
onto lactose tablets. Each point represents mean value of experimental data (n = 6).
Figure 4. Model simulations (lines) compared with experimental data (symbols) of
Drevenkar et al.24 on (A) the blood concentration-time course of chlorpyrifos (u) and
alkyl phosphates (X), the urinary excretion rate time course of aikyl phosphates (o) and
(B) the cumulative urinary-excretion time course of alkyl phosphates (the sum of
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diethyl phosphate and diethyl thiophosphate) in a poisoned subject who ingested a
commercial insecticide formulation containing chlorpyrifos.
Figure 5. Model simulations (unes) compared with experimental data of Nolan et ai.’2
(symbols) on (A) the blood concentration-time course of 3,5,6-trichloro-2-pyridinol
and (B) the cumulative urinary excretion time course of 3,5,6-trichloro-2-pyridinol in
male volunteers dermally applied 5 mg chlorpyrifos per kg of body weight on the
forearm. Each point represents mean value of experimental data (n = 5).
Figure 6. Model simulations (lines) compared with experimental data of Brzak et a1.’4
(symbols) on (A) the blood concentration-time course of 3,5,6-trichloro-2-pyridinol
and (B) the cumulative urinary excretion time course of 3,5,6-trichloro-2-pyridinol in 6
male and 6 female volunteers orally administered 0.5 (o), 1 (x) and 2 (n) mg
chlorpyrifos per kg of body weight in capsule form. Each point represents mean
experimental value and en-or bars are standard deviations.
Figure 7. Model simulations compared with experimental data (symbols) of Griffin et
al. t3) on the cumulative urinary excretion time course of alkyl phosphates (the sum of
diethyl phosphate and diethyl thiophosphate) in volunteers orally administered 1 mg of
chlorpyrifos placed on a sugar cube. Each point represents mean value of experimental
data (n = 5, four men and one women). The solid une represents model simulation
using an oral absorption fraction of 0.93 as reported by Griffin et an oral
19$
absorption rate of 0.13 hr1, a CPF storage rate, kBs, of 0.12 hr’ and the other
parameters as reported in Table 2.
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WORKER EXPOSURES TO TRICLOPYR: RISK ASSESSMENT
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ABSTRACT
In the province of Quebec (Canada), the phytocide Garlon 4®, whose active ingredient
is triclopyr, is often used to prevent trees reaching electrical conductors. The object of
this paper is to assess the potential health risks in workers coming into contact with
Garlon 4®. Ten workers collected their micturations during the 22 hours following the
beginning of a work-shift. Measured urinary amounts of triclopyr varied between 1 and
13 mg. The absorbed daily doses were estimated from the amounts of triclopyr in urine
through the use of a kinetic model that Iinks the rates of triclopyr elimination to
absorbed doses. These estimated doses were compared to the no-observed-effect level
(NOEL) observed in rats: 5 mg/kg-bw. The upper-bound estimations of the worker
daily absorbed doses were found to be 13.3% or less of the rat NOEL.
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INTRODUCTION
Garlon 4® is a phytocide employed to control the undesirable growth of woody plants
and broadleaf weeds. The active ingredient of Garlon 4® is triclopyr (3,5,6-trichloro-2-
pyridinyloxyacetic acid), present as a butoxyethyl ester form with a concentration of
61.6%. Its mode of action occurs through imitation of auxin, a natural growth
regulating hormone found in plants, which resuits in acceleration of the plant’s
maturation. Since the plant’s energy supply is not sufficient to support this rapid
growth, the plant dies prematurely. Garlon 4® is used on a variety of sites, in particular
on power une rights-of-ways to reduce the risk of power outages and to allow safe
access to transmission facilities. In the province of Quebec (Canada), this phytocide is,
together with Tordon 101®, the principal product applied in summer for controlling the
growth of trees capable of reaching electrical conductors. Concem for the workers
applying the pesticides led the electric utility company to undertake a field study in
2001 to assess the potential ocdupational health risks from the seasonal application of
Garlon 4®.
To evaluate occupational exposure to pesticides, biological monitoring through
collection and analysis of urine to establish levels of the parent substance or its
metabolites is a direct and accurate means. It integrates ail routes of exposure and,
comparèd to environmental monitoring, is independent of the absorption fractions of
exposed surfaces, the protective equipments used and the climatic conditions. The use
of biomarkers to assess health risks is however possible only if the link between their
210
levels in urinary samples and the critical biological effects is established. This can be
achieved by a two step procedure: first, relate absorbed dose to biornarkers levels with
a validated toxicokinetic model; second, compare this absorbed dose with a toxicity
dose establlshed from observed biological effects. This procedure, retained for the
health risk assessment of triclopyr, was already used for other pesticides (Carrier and
Brunet, 1999; Bouchard et al., 2003; Gosselin et al., 2005). Since triclopyr, once
absorbed by humans, is principally excreted without biotransformation (Carmichael et
al., 1989), the suitable biomarker for the biological monitoring of Garlon 4® is triclopyr
itself in urine. The object of this paper is to assess the health risks incurred by workers
through measurements of the amounts of triclopyr in their urine.
211
METHODS
Field study
Studied Workers: At the end of lune 2001, ten male workers were recruited to
participate in a survey of biological monitoring. From lune to August 2001, these
workers sprayed Garion 4® under high voltage transmission unes in the province of
Quebec. Eight of them applied diluted Garlon 4© with a backpack unit directly on the
stumps of recently cut trees. The diluted solution in the backpack unit was 20% Garlon
4® and 80% mineraI ou. Dilution manipulations were carried out by the managers of
the project; each worker loaded its backpack unit with this solution. The personal
protective equipments of these $ workers were long pants, rubber boots and a helmet.
Their work-schedule was an 8-hour day with two 15-minute breaks in the moming and
in the afternoon and a 30-minute lunch break. The two other workers pulverized diluted
Garlon 4® over the leaves under transmission unes from a tractor-mounted boom spray.
The tractor reservoir was filled by these two workers with 12.6 liters of Garlon 4® and
1800 liters of water. These two workers wore rubber boots, gioves, an overail and a
helmet. Their work-schedule was an 11.5-hour day with two 15-minute breaks in the
morning and a 30-minute break in the aftemoon.
Urinary sample collection : On the ultimate day of a 5 day work-week, the workers
were instructed to coliect ail their micturitions into a plastic container from the onset of
their workday (8 o’clock) until the first micturition of the next day (6 o’clock). Thus
the amounts of triclopyr measured in these samples represented the cumulative urinary
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excretion of triclopyr during the 22-hr period from the beginning of that day’s
exposure. The body weight of each worker was recorded at the same time.
Urine samples were analyzed at the Laboratoire du Centre de toxicologie humaine of
the Institut national de santé publique du Québec which is accredited by the Canadian
Association for Environmental Analytical Laboratories. Samples were kept frozen at —
20°C until analysis. The sum of free and conjugated triclopyr was measured after acidic
hydrolysis and extraction with a hexane/ether mixture. The extracts were evaporated to
dryness and redissolved in a 25% acetonitrile : 75% ammonium acetate solution. The
samples were then analyzed using a Micromass Quattro liquid chromatography
electrospray ionization-mass spectrometry (LC-ESI-MS) system operated in negative
MRM mode. The LC system was equipped with a Waters Symmetry C1$ column
(51cm, 50 mm x 2.1 mm). The limit of detection of triclopyr was 0.3 g/L and the limit
of quantification was 0.9 cg/L. Average recovery of triclopyr from urine samples
spiked with a 10 g/L of reference standard was 97%. Intra-day coefficient of variation
for replicate analysis of the same urine sample spiked with 2 gfl of reference standard
was 4% (n = 10 samples).
Health Risk Analysis
Determrnation of the daily absorbed dose : The daily absorbed dose of triclopyr for
each worker was reconstructed from the following equation:
Cumulative amount of triclopyr in the urine collected over T hours
Daily absorbed dose =
F (T)
(1)
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Where Fexc(T) is the fraction of the daily absorbed dose of triclopyr recovered in the
cumulative urinary sample during T hours following the onset of exposure.
The resuits of the pharmacokinetic study of Carmichael et al. (1989) were adapted to
estimate fexc(22 hrs). These authors exposed five healthy male volunteers to triclopyr
via the oral and dermal routes. The dietary doses were 0.1 mglkg-bw followed three
weeks later by 0.5 mg!kg-bw of triclopyr. The five volunteers were later exposed to a
dermal dose equivalent to 3.7 mg/kg-bw of triclopyr. After each administration, bÏood
and urinary samples were collected over a period of 72 hours. To fit these time-course
data, Carmichael et aÏ. (1989) used an open two-compartment pharmacokinetic model.
A different set of model parameters was estimated for each administration and for each
volunteer.
The original ldnetic model of Carmichael et al. (1989) was modified in order to assess,
for the gradual exposure occulTing in typical work shifts, the absorbed dose starting
from cumulative amounts of triclopyr excreted in urinary samples collected during the
given period of time (see Fig. 1). Since the skin and the lungs are the significant route
of-entries for workers exposed to triclopyr (Middendorf et al., 1994), two functions
were included in the model to describe the input dose per unit of time bioavailable at
each site of absorption (g5kfl(t) and giungs(t)). These two time dependent input functions
allow one to simulate the different time tables of exposure encountered in occupational
conditions. For skin absorption, an input compartment was necessary to account for the
accumulation in skin followed by the slow release of triclopyr to the blood stream. On
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the other hand, simulations show that it is flot necessary to add an input compartment
for lungs, since the absorption is too rapid to observe a sizable time-delay to the blood
stream; the pulmonary absorption is in fact similar to a drop by drop intravenous
exposure. The differential equation system for this kinetic model is described in the
Appendix. The model simulations were performed by solving numerically this system
using the Runge-Kutta method incorporated in MathCad 2000 Professional.
In the current study, absorption of triclopyr occurs gradually during the work day and
for five consecutive days; the input functions used to simulate this occupational
exposure were based on the specified work-schedules for each of the two groups of
workers, those with a backpack unit and those using a tractor-mounted boom spray.
Estimations of Fexc(22 hrs), specific to each work-schedule, were obtained by solving
the differential equation system with the appropriate input conditions (see the
Appendix). For a unit of absorbed dose, under a given time-table of exposure, the
numerical solution of the model predicts a cumulative amount of triclopyr to be
observed in the urine collected during the 22 hours following the beginning of
exposure. From formula #1, the relevant F(22 hrs) is then easily obtained.
Since the relative contributions of the dennal route and the pulmonary route cannot be
determined by a simple measurement of triclopyr in urine, model simulations with
input functions gkjfl(t) and giungs(t) giving different fractions of the daily absorbed dose
arising from the skin and from the lungs (fkj and fiungs) were carried out in order to
determine their impact on outcome in urine. For each choice of and fiungs, the daily
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absorbed dose, the peak of blood concentration and the area under the blood
concentration time-curve were estimated by simulating an 8-hr exposure to triclopyr
without break time resulting in a 22-hr cumulative urinary excretion of triclopyr equai
to the average of triclopyr measured in the urinary samples of workers.
In model simulations, the sets of pararneters describing the internai ldnetics of triclopyr
(ks, kBs, ke, f, Vd, see the descriptions in Table 1) were the ones estimated from the
time-courses of triciopyr in each of the five volunteers orally exposed to 0.1 and 0.5
mg/kg-bw of triclopyr in Carmichael et al. (1989). The rates ofdermal absorption (kabs)
used were the ones estimated from the time-courses of dermally absorbed triclopyr in
the corresponding volunteers. An average set of parameters was also obtained from the
average of these ten individual data sets. Consequently, for each assumed values of
skin versus lungs fractions contributing to daily dose (fk and fiungs), the parameter sets
derived from the individual sets presented in Carmichael et al. (1989) enabled eleven
estimations of Fexc(22 hrs) for the workers with backpack units as well as for the
workers with a tractor-mounted boom spray.
Determination of the toxicity dose s b assess the health risks associated with
occupational exposure to triclopyr, the estimated daily absorbed dose was compared
with the no-observed-effect level (NOEL) proposed by U.S.EPA for chronic exposure
(U.S. EPA, 1998). The critical effect used to define it is an increased incidence of
proximal tubular degeneration of the lddneys in P1 and P2 parental rats observed in a
two-generation dietary reproduction study in Sprague-Dawley rats (U.$. EPA, 1998).
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In that experimental study, 30 rat-couples per dosage were exposed respectively to 0, 5,
25 and 250 mglkg-bw/day of triclopyr. The first and second generations P1 and P2
ingested triclopyr during respectively 10 and 12 weeks before mating. The NOEL was
found to be 5 mg/kg-bw/day and the lowest-observed-effect leveÏ (LOEL) was 25
mglkg-bw/day. The reference dose (RfD) recommended by U.S. EPA is determined by
dividing this NOEL by a safety factor of 100-fold to take into account the animal-to
human extrapolation and the inter-individual variability (U.S. EPA, 199$).
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RESULTS
field study
The amounts of triclopyr were measured, for each of the 10 workers, in the cumulative
urine collected during 22 hours following the onset of a work-day exposure. These data
and their body weight are presented in Table 2. The average of the measured urinary
amounts is 56.4 gIkg-bw.
Heatth Risk Anatysis
Table 3 presents the exposure parameters estimated from model simulations where the
contributions of the dermal absorbed route and the pulmonary route vary. Due to the
small rate of dermal absorption, the estimation on the peak of blood concentration is
lowest when the absorption occurs only via the skin whereas the estimations of the
daily absorbed dose and the area under the blood concentration time-curve are highest.
The two exposure scenarios, the one for the eight workers with a backpack unit and the
other for the two workers with tractor-mounted boom spray, were simulated with the
kinetics model presented in Fig. 1 and the appropriate input conditions presented in the
Appendix. For each exposure scenario, eleven time-courses of triclopyr urinary
excretion were calculated using each of the ten individual sets of model parametric
values and one set obtained from the average of these ten individual sets. These
simulations were carried out assuming that absorption occurred only through the skin,
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because as shown from Table 3, this assumption resuits in an estimated daily absorbed
dose that is the highest for a given urinary excretion of triclopyr. This ensures that the
worst case scenario is retained. Fig. 2 depicts the time-courses of the cumulative
urinary excretion of triclopyr expressed as the fraction of daily absorbed dose (i.e.,
Fexc(t)) predicted for the eight workers with a backpack unit. The curves shown in Fig.
2 are obtained from sets of model parametric values which give the lowest and highest
values of Fexc(22 hrs) and from the average parameter set. Fig. 2 exhibits the three
estimated values for the fraction of the absorbed dose recovered in the 22-hr urinary
samples: 0.259, 0.349 and 0.477. Similarly, simulating the work timetable of the two
workers who pulvenzed Garlon 4® with the tractor-mounted boom spray, the estimated
values 0f Fexc(22 hrs) are: 0.230, 0.3 14 and 0.433.
The absorbed dose for each worker was calculated starting from their urinary
biomarker level presented in Table 2 and the above estimations of Fexc(22 hrs). Table 4
gives the lower- and upper-bound estimates of the daily absorbed dose for each worker
in addition to the value obtained from the average parameter set. For each worker,
these three estimations of the daily absorbed dose were divided by their body weight,
for comparison with the rat NOEL. Table 5 presents the resuits of this comparison. The
upper-bound estimations of the workers daily absorbed doses were found to be 13.3%
or less of the rat NOEL. On the other hand, only the worker number 4 absorbed a daily
dose lower than the RfD, since there is a 100-fold safety factor included in this criteria.
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DISCUSSION
A novel strategy was presented in this study for biomonitoring occupational exposure
to triciopyr and for assessing the associated human health risks. While it is already
well-known that the kinetics of a substance is necessary for reconstruction of the
absorbed dose starting from excreted biomarkers (Carmichael, 1989; Lauwerys and
Hoet, 2001), rare are the biomonitoring studies that consider the graduai exposure
occurring in typical work shifts. When the work-schedule is known, the system of
differential equations with the appropriate input function allows simulations of the
time-course of the graduai absorption of the substance and the biomarker excretion rate
corresponding to that specific exposure scenario. The health risk assessment can
consequently be determined more accurateiy by taking full advantage of this
mathematical tool. To wit, if, instead of employing the specific input function govemed
by the given timetable of exposure, the daily absorbed dose had been estimated from
simulations of a bolus administration in the skin at the beginning of the work-day, the
daily absorbed dose estimations presented in Table 4 wouid have been reduced by a
factor of 1.3.
For the reconstruction of the daily absorbed dose, some assumptions were made to
avoid underestimations. For one, only the dermal route was considered, even if,
according to the study of Middendorf et al. (1994) on occupational exposure to
triclopyr, the pulmonary route accounts on average for 13.8% of the daiiy absorbed
dose and the dermal route for 86.2%. Model simulations with this combination show
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that the estimates of the daily absorbed dose would be approximately 1.2 times lower
than the estimates based on dermal absorption only. Given that in the study at hand it is
impossible to know the relative contributions of the two entry routes, the safest dose
estimates arise from the assumption that 100% of absorption is though the skin. Mso,
the estimates of daily absorbed dose carried out assume single day exposure. However,
as a result of the slow urinary elimination arising from the low dermal absorption rate,
an accumulation of triclopyr is expected to occur in the body of workers. Ibis slow
elimination was noticed by Carmichael et aÏ. (1989) where the volunteers stiil excreted
amounts of triclopyr three days after dermal administration of triclopyr. Therefore, the
amounts recovered in the urinary samples collected the last day of a 5 day work-week
stem flot only from the amounts of triclopyr absorbed during that day, but also from the
remains of amounts absorbed the previous days. Had the model simulations
incorporated this bioaccumulation phenomena by simulating 5 days of exposure
instead of single one, the estimates of the dose absorbed during the last day would have
been about 2 times lower.
It is interesting to compare the level of triclopyr exposure measured in the current field
study with other studies. In particular, the study of Middendorf et al. (1994) estimated
the daily absorbed doses of 21 workers who applied a diluted form of Garlon 4® with a
backpack unit. These workers coilected ail their urinary samples during 4 days
following the onset of a work-day. Middendorf et al. (1994) calculated their daily
absorbed doses by dividing the amounts of triclopyr measured in the urinary samples
by a factor of 0.789. This value is equal to the mean fraction of the absorbed dose
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found in urine (Fa) after a long time as determined from the volunteers orally exposed
to 0.5 mg/kg of triclopyr in Carmichael et al. (1989). According to these dose
estimates, the workers in Middendorf et aÏ. (1994) absorbed between 0.207 and 7.690
mg of triclopyr in the monitoring day, with a geometric mean value of 1.1 mg. The
comparison between these daily absorbed doses and the ones presented in Table 4
reveals that the workers in the current study were much more exposed; this is so even
from comparison using the lower-bound estimates of Table 4. This important
difference is possibly due to the different procedures used to reconstruct the absorbed
daily doses as well as from the different field conditions (e.g., mixing procedures,
equipment maintenance, work practices)
One of the advantages of simulating the time-course of the biomarker excretion rate for
a given exposure scenario is the opportunity to choose any convenient period of urinary
collection. In practice, it is important to specify a period which suits the workers as
well as the employers. Sensitivity tests carried out on the model parameters (kabs, k58,
k8s, ke, F) show that the longer the urinary collection period is, the smaller is the
impact of the human kinetics variability on the estimation of daily absorbed dose. 0f
course, for a collection period of 5 days or longer following the beginning of a single
exposure day, only the total fraction of the absorbed dose eventually excreted in urine,
F, affects the daily dose reconstruction. In addition to being very demanding for
workers, this long period is unfortunately flot suitable for employers because the
workers would have to cease exposure to triclopyr durïng the four days of the
collection period following their work day. Alternatively, a unique micturition at the
222
end of the work-shift, as ACGIH® proposed for almost BEI® (ACGIH, 2002), or a 12-
hr cumulative urinary excretion following the onset of exposure are flot suitable either
because, in both instances, estimations of the daily absorbed dose are too dependent on
the wide variability in dermal absorption rates. The latter are known to vary according
to the anatomical region of the skin exposed, the skin condition and the environmental
temperature and humidity (Bronaugh and Maibach, 1999). It is weÏl to remember that
urinary concentrations measured in a single micturition depend on the variable urinary
flow and also, the amounts adjusted on creatinine depend on the creatinine excretion
rates which are subject to inter-individual variations as well as to the intra- and inter
day variations (Boeniger et al., 1993). Consequently, the estimates from a single
urinary sample are less reliable. For the biomonitoring of triclopyr, urinary collections
of 24-, 48- or 72-hr following the onset of the last day of a week of exposure appear to
be the more appropriate periods.
For future field studies, biological reference values (BRV) should be established from
the present resuits to prevent adverse health effects at an early stage in workers
exposed to triclopyr. The BRV could take the form of amounts of triclopyr recovered
in urinary samples over a given period that correspond to an absorbed dose that is
considered safe. For the convenient collection periods proposed, 24-, 48- and 72-hr
following the onset of a work-day of exposure, the BRV amounts in urine
corresponding to a NOEL dose can be obtained by simulating a typical worker
exposure scenario and using the set of model parametric values which results in the
lowest cumulative urinary values. The typical exposure scenario retained is an 8-hr
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work-shift, without break time, where the NOEL daily dose (5 mg/kg-bw) is assumed
to be entirely absorbed through the skin ($ee Appendix for the input conditions). This
dose would resuit in a cumulative urinary excretion of triclopyr equal to 1.45 mgfkg
bw for a 24-hr collection, 2.63 mgfkg-bw for a 48-hr collection and 2.83 mg/kg-bw for
a 72-hr collection. However, since there is no observed effect in humans exposed to
triclopyr, no one can prove that the NOEL established for rats corresponds to a safe
dose for humans. Thus, the future biomonitoring studies can also be based on the above
BRV divided by appropriate uncertainty factors.
Comparisons between the estimated daily doses absorbed by the workers of this study
and the RfD show that there is a potential health risks for these workers under the
current conditions. The RfD used here was proposed by U.S. EPA to prevent
significant adverse health effects, assuming repeated daily exposure in the general
population over a lifetime (U.S.EPA, 1998). The default uncertainty factors of 100-fold
were used to established this RfD from the rat NOEL. However, according to WHO
(1994), it is often suitable for an occupational exposure to use lower safety factors than
the proposed default factors, since the occupational population does flot include the
more vulnerable persons (i.e., chiidren, sick and elderly). In the current study, to
bypass the interspecies uncertainty and the variability in the kinetics of triclopyr, the
model simulations were designed to result in the highest estimate of the daily absorbed
dose corresponding to a given cumulative amount in urine. Also, since the workers in
this field study are exposed only three months per year, Renwick (1999) judged that it
may be more appropriate to assess their health risks with a guidance value derived from
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a NOEL established for sub-chronic exposure rather than a NOEL established for
chronic exposure.
The resuits of this study were reported to the managers supervising these workers so
that tighter security measures may be implemented during manipulations of the product
in order to minimize worker contact with the product. Worker education and serious
supervision were also recommended to insure that neoprene gloves and rubber boots or
boot covers are worn at ail times. The company ensures that these recommendations
will be implemented.
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APPENDIX
fuitctionat represeittation of the kiitetics oftrictopyr
Differential equation system
Front Fig. 1, thefottowing dfferential equatians are obtained (see Table 1 for the
description ofeacÏz symbot):
dD(t)
= (t)kabs xD(t)
dB(t)
= glungs(t)+kabs xD(t)+ ksB xS(t) (ke +kBs)xB(t)
dS(t)
= kBs xB(t)-ksB xS(t)
dU(t)
dN(t) (lFu)XkeXB(t)
Input conditions
The following equations describe the input conditions of the time tables simulated by
the ldnetic model (see the description of variables and parameters in Table 1):
Dose input rate for the exposure scenario of workers with backpack units (amount of
the unit daily absorbed dose per hour):
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1skin for:(O< t<2hr),(2.25hr< t <4hr),(4.5•hr <t < 6hr)(6.25hr <t <8.hr)
g1j0(t)= 7xhr
O otherwise
— lxfiungs
for:(O<t<2hr),(2.25•hr<t<4•hr),(4.5•hr<t<6hr),(6.25’hr<t<8.hr)
giungs(t)
—
7xhr
o otherwise
with the initial conditions: D(O) = Q(O) = U(O) = N(O) = O.
Dose input rate for the exposure scenario of workers with tractor-mounted boom spray
(amount of the unit daily absorbed dose per hour):
lxfskjfl for:(O< t< 2 hr),(2.25 . hr< t <4. hr),(4.25 hr< t<8.75 . hr),(9.25• hT< t<11.5 •hr)
gk(t) 10.5xhr
o othenvise
lXfungs
for (0< t < 2hr), (2.25 hr <t <4hr), (4.25 hr <t <8.75•hr), (9.25 <t <1 1.5hr)
gigs (t) = 10.5xhr
0 otherwise
with the initial conditions: D(O) = Q(O) = U(O) = N(O) = O.
Dose input rate for the determination of the biological reference value (mg/kg-bw per
hour):
lxfskjfl for:(O<t<8hr)
gkfl(t)= 8xhr
O otherwise
lungs for :(0< t< 8.hr)
giungs(t)
= 8xhr
O otherwise
with the initial conditions: D(O) = Q(O) = U(O) = N(O) = O.
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Table 1. Symbols used in the conceptual and functional representation of the
modifled kinetics model of triclopyr developed by Carmichael et al. (1989)
Symbols Description
Variables
g1(t) Dermal dose bioavailable per unit of time which can describe different time tables of
exposure (mg/kg-bw/hr)
giun (t) Inhaled dose bioavailable per unit of time which can describe different Lime tables of
exposure (mg/kg-bw/hr)
D(t) Burden of triclopyr at the skin surface as a function of time (mg/kg)
B(t) Burden of triclopyr in blood and tissues in dynamical equilibrium with blood as a
function of time (mg?kg)
S(t) Burden of triclopyr in storage tissues as a function of time (mg!kg)
U(t) Cumulative excretion of triclopyr in urine as a function of rime (mg/kg)
N(t) Cumulative excretion of triclopyr flot observed in urine as a function of Lime (mgflcg)
Parameters
kabs Dermal absorption rate constant of triclopyr (i.e. transfer rate from skin surface to
blood) (hr’)
ks Blood to storage tissues transfer coefficient of triclopyr (hr’)
ksB Storage tissues to blood transfer coefficient of triclopyr (hr’)
lc Elimination rate constant of triclopyr (hr1)
Total fraction of the absorbed dose of triclopyr eventually excreted in urine
Vd Apparent volume of the blood compartment B(t) (rnllkg)
Fraction ofthe daily absorbed dose from the dermal route
Fraction of the daily absorbed dose from the pulmonary route
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Table 2. Amounts of triclopyr measured in the 22-hr cumulative urinary samples
(mg) of the workers and their body weights (kg)
Amount of triclopyr measured
. .
. Body weightWorkers in the 22-hr cumulative unne
sample (mg) (kg)
la 2.71 77
2a 2.40 77
3a 4.23 68
4a 1.04 81
5a 12.98 75
6a 1.36 73
7a 3.04 75
8a 5.54 91
9b 3.61 73
10b 5.27 66
Workers applying Garbo 4’ with the backpack unit.
b Workers pulverizing Garbo 4® with the tractor-mounted boom spray.
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Table 3. Effect of variations in the relative contributions of the dermal and
pulmonary routes on model predictions of dïfferent exposure parameters
following a $-hr exposure to triclopyr resulting in a 22-hr cumulative urinary
excretion of triclopyr equal to 56.4 gfkg
Fraction of the daïly absorbed dose from the dermal route (fk)
Exposure and from the pulmonary route (fiungs)
parameters
fsk1 fsjn:t0.75 fsun=O.S fsk=°.25 fkiO
fiungsO fiungsO. 25 fiungsO.5 fiungsO. 75 fiungs= 1
Daily absorbed
dose oftriclopyr 0.162 0.124 0.101 0.085 0.073
(mg/kg-bw)
Peak of blood
concentration of 0.077 0.088 0.106 0.118 0.127
triclopyr
(mg[L)b
Area under the
blood 2.802 2.156 1.751 1.474 1.273
concentration
time-curve of
Note: The model simulations were carried out with the parametric set obtained from
the average of each individual parametric set of Carmichael et ai’ (i.e., kabs0.04 hf’;
kBs= 0.14 hr’; ksB= 0.28 hf’; kBU=0.30 hr’; F=0.81, Vd=l94.l ml/kg).
a
O.56tgIkg-bw
Daily absorbed dose =
simulated fraction of the daily absorbed dose recovered in the 22 - hr urinary samples
b The blood concentration time-curve of triclopyr Cblood(t) is obtained by the following
equation:
B (t)
Cby(t)—————.
Vd
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The area under the blood concentration time-curve of triclopyr AUC is obtained by
the following equation:
AUC
= fb1ood (t)dt.
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Table 4. The lower-bound, the mean and the upper-bound estimates of daily
absorbed dose (mg) for each worker assuming that the absorption occurs only via
the skin
Estimates of the daily absorbed dose (mg) a
Workers
Lower-bound Mean Upper-bound
1b
5.69 7.77 10.46
2’’ 5.03 6.87 9.24
3b
8.88 12.13 16.32
4b
2.19 2.99 4.02
5b
27.23 37.18 50.04
6b
2.85 3.89 5.24
7b
6.37 8.70 11.71
8b
11.63 15.87 21.36
9C
8.33 11.49 15.69
1C1V 12.16 16.78 22.91
The estimations were calculated using the following equation:
amounts of triclopyr measured in the 22- hr urinary samples
Daily absorbed dose =
fraction of the daily absorbed dose recovered in the 22- hr urinary samples
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b The lower-bound, the mean and the upper-bound estimates of the absorbed dose
were calculated with three values of the simulated fraction of the absorbed dose
recovered in the 22-hr urinary samples: 0.477, 0.349 and 0.259.
The lower-bound, the mean and the upper-bound estimates of the absorbed dose
were calculated with three values of the simulated fraction of the absorbed dose
recovered in the 22-hr urinary samples: 0.433, 0.314 and 0.230.
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Table 5. Comparison of the lower-bound, mean and upper-bound estïrnates of
daily absorbed dose (mgfkg-bw) with the dose corresponding to the no-observed
effect levet (NOEL) observed in rats: 5 mg[kg-bw
Daily absorbed dosea/
Workers /NOEL
Lower-bound Mean Upper-bound
1 0.015 0.020 0.027
2 0.013 0.018 0.024
0.026 0.036 0.048
0.005 0.007 0.010
0.073 0.099 0.133
6 0.008 0.011 0.014
0.017 0.023 0.031
8 0.026 0.035 0.047
0.023 0.032 0.043
10 0.037 0.05 1 0.070
See Table 4 for the estimates of the daily absorbed dose of each worker.
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CAPTIONS TO FIGURES
Figure 1 : Modified model of the ldnetics of triclopyr developed by Carmichael et al.
(1989). Symbols are described in Table 1.
Figure 2: Model simulations of the time-course of cumulative excretion of triclopyr in
urine (expressed as a fraction of the daily absorbed dose) following the onset of an 8-
hour day with two 15-minute breaks in the moming and in the after-noon and a 30
minutes break for lunch with absorption only through the skin: ( ) kajs0.04 hf’,
k3s0.13 hr’, ksB=0.46 hf’, k= 0.19 hf’, F=O.74 ; () kajs0.06 hr, kBs=0.13
hr’, ksB=0.23 hr4, k 0.35 hf’, F0.90 ; ( ) kas0.04 hf’, kBs=0.14 hf’,
ksB=0.28 hf’, ke= 0.30 hf’, F=0.81.
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ABSTRACT
Signiflcant amounts of methylmercury (MeHg) can bioaccumulate in fish and sea
mammals. To monitor MeHg exposure in individuals, organic and inorganic mercury
are often measured in blood samples or in hair strands, the latter being by far the best
integrator of past exposure. With knowledge of the MeHg kinetics in humans, the
levels of both biomarkers can be related to MeHg body burden and intakes. In the
present study, we use the toxicokinetic mode! of Carrier et al. (2001), describing the
distribution and excretion of MeHg in humans, to reconstruct the history of MeHg
intakes of indigenous women of the Inuvik region in Canada starting from total
mercury concentrations in hair segments. From these reconstructed MeHg intakes, the
con-esponding simulated mercury biood concentrations are found to be good predictors
of the concentrations actuai!y measured in blood samples. An important conclusion of
this study is that, for aimost ail subjects, the reconstructed history of their MeHg
intakes provides much lower intake values than intakes estimated from questionnaires
on food consumption and estimated MeHg levels in these foods ; the mean value of
the reconstructed MeHg intakes is 0.03 ig/kg/day compared with the mean value of
0.20 g/kgIday obtained from questionnaires. The model was also used to back
calculate the MeHg intakes from concentrations in hair strands collected from
aboriginals of the Amazon region in Brazil, a population significantiy more exposed
than the population of the Inuvik region.
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INTRODUCTION
The 1956 industrial mercury spillage in the bay of Minamata in Japan has inefutably
demonstrated the harmful effects of acute methylmercury (MeHg) exposure on the
human nervous system (Tsubald and frukayama, 1977). In 1971, another major
incident of MeHg poisoning occun-ed in fraq; the use of barley and wheat seed treated
with mercury fungicides induced severe cases of poisoning following the consumption
of bread made from the contaminated grains (Baldr et al., 1973). This incident
confirmed the neurological effects of MeHg on the foetus of the exposed mothers
(Marsh et al., 1980, 1981).
Nowadays, the major source of MeHg exposure is through the consumption of
contaminated fish (World Health Organization (WHO), 1990). Populations that get a
substantial amount of their food through subsistence fishing, such as Canadian
aboriginals, have the potential to be highly exposed to MeHg. Many epidemiological
surveys have been conducted to monitor the level of MeHg exposure in these
populations with the aim of limiting the health hazards arising from their diet (Mc
Keown-Eyssen and Ruedy, 1983 ; Wheatley and Paradis, 1996 ; Dewailly et al., 2001
Muckie et al., 2001). The MeHg exposure can be inferred from biomarker levels
expressed as the concentration of total mercury (organic and inorganic form) in blood
andlor in hair samples. The MeHg consumption can also be assessed by estimating the
daily intake of MeHg by means of a questionnaire about the past ingestion of food
potentially contaminated with MeHg or from an analysis of a duplicate diet during a
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given period. In order to evaluate the associated health hazards of MeHg intake, these
MeHg exposure markers are compared with reference values proposed by public health
and environmental organizations (WHO, 1990; United States Environmental
Protection Agency (USEPA), 1997; Health Canada, 1998; Food and Agriculture
Organization of the United Nations (FAQ), 2003). These values, which are based on
scientific investigations of the plausible relations between the levels of MeHg
biomarkers and the harmful effects on human health, are considered acceptable by
those organizations.
To relate the levels of MeHg biomarkers to the corresponding daily intakes of MeHg,
an empirical one-compartment kinetic model describing the fate of MeHg in the human
body lias so far been used (WHO, 1990 ; USEPA, 1997 ; FAO, 2003). More often than
not, the steady-state conditions (i.e., the intake equals the excretion) are assumed in
establishing the relationship, resulting in a constant ratio between the MeHg daily
intake and the total mercury measured in the biological matrices. However, since the
amounts of MeHg measured in fish fluctuate greatly (Morgan et al., 1997) and the
consumption patterns of fish and sea mammals vary with seasons (Sherlock et al.,
1982), the MeHg exposure generally varies too much throughout tirne to satisfy the
conditions of steady-state. This exposure variation is identified by the variable total
mercury levels measured in sequential segments of hair strands of individuals from fish
eating populations (Phelps et al., 1980; Dolbec et al., 2001).
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Recently, a biologically-based dynamical mode! was developed by Carrier et al. (2001)
to predict in humans the distribution and elirnination of MeHg and its inorganic
metabolite for a variety of MeHg ingestion scenarios. This model can relate MeHg
daily intakes to the total mercury levels measured in accessible biological matrices.
The model follows the dynamics of intakes and elimination, without steady-state
assumptions, for any dietary exposure scenario and any data collection time. The
toxicokinetic model of Carrier et aI. (2001) is based on a system of differential
equations where each equation describes the evolution of the organic or inorganic
mercury burden in a compartment. Each compartment stands for either a single organ
or a group of organs or tissues. An input function incorporated in the differential
equation of the gastrointestinal compartment allows simulations of any oral MeHg
exposure scenario. This function represents the variable rate of MeHg daily intakes
during a chosen period, a daily intake being the total of the amounts of food ingested
multiplied by their respective MeHg concentrations. The values of the model
parameters in Carrier et aÏ. (2001) were determined using the available published data
of the in vivo time-profiles of total mercury in blood and in hair of volunteers orally
exposed to MeHg. These profiles were obtained from several experimental studies on
healthy men and women (Aberg et al., 1969; Miettinen et al., 1971; Birke et al., 1972;
Kershaw et al., 1980; Sherlock et al., 1984; Smith et al., 1994).
Before proceeding with the reconstruction of MeHg intakes in aboriginal populations,
the present study seeks to understand the impact of the toxicoldnetics of organic and
inorganic mercury on the determination of amounts of MeHg ingested that can be
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inferred from the concentrations of total mercury measured in biological matrices. For
this purpose, the model of Carrier et al. (2001) was used to investigate the relationships
between MeHg intake and biomarker levels for different exposure scenarios,
particularly those where steady-state conditions are far from being attained. Also, the
variability in MeHg biomarker levels stemming from the inter-individua! variability of
the MeHg blood elimination haif-life and of the ratio between the total mercury
concentration in hair and that in blood was assessed. Similarly, the effect of various
collection times post exposure on MeHg biomarker levels were examined.
Using the mode! and the measured concentrations of total mercury in sequential
centimeters of hair strands, reconstruction of the likeÏy monthly MeHg intalces was
carried out for indigenous populations of Canada and Brazil without the need for
knowledge of their dietary habits.
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METHODS
For the present study, the differential equation system of the toxicokinetic model of
Carrier et al. (2001) was prograrnmed in MathCad 2000 Professïonal (MathSoft Inc.,
Cambridge, MA). The mathematical resolution of the differential equation system, with
the input function describing an ascribed ingestion sequence, was based on the
numerical method of Runge-Kutta included in this software. Ail model simulations
were carried out with the mean parametric values presented in Carrier et al. (2001),
except when assessing the impact of the inter-individual variability of the elïmination
haif-life of MeHg in blood and of the ratio between totai mercury concentration in hair
and that in blood. Sïnce the model is based on the conservation of mass in the system at
ail times, it predicts initialiy the amounts of organic or inorganic mercury in each
model compartrnent. To convert mercury blood amounts to concentrations, biood
volume was taken to be 8.2% of the body weight (Brown et al., 1997). Also, to depict
the time-profiles of total mercury levels in hair, it was assumed that hair grew at the
rate of 1 centimeter (cm) per month (WHO, 1990).
Main factors governing tevets of methytmercury biomarkers
Methylmercury blood eliminatîon haif-life : Carrier et al. (2001) determined
averages for this parameter by fitting their kinetic model to time-proflie data observed
in controlied intake studies. Average MeHg blood elimination half-lives of 47.1, 50.2,
50.2, 51.7 and 54.8 days were respectively obtained from the data of Aberg et al.
(1969), Miettinen et al. (1971), Smith et al. (1994), Sherlock et al. (1984) and Kershaw
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et al. (1980). The underlying MeHg demethylation rate (Al-$hahristani and Shihab,
1974; Al-Shahristani et al., 1976) is subject to large variations among individuals and
is plausibly the most determinant parameter for the elimination of MeHg from blood
(WHO, 1990). To address this large variation, we allowed the MeHg blood elimination
haif-life to vary from 39 ta 70 days, based on the extreme values measured in subjects
under controlled and uncontrolled intake exposures (WHO, 1990). Its impact on the
maximum total mercury concentration in blood and, in tum in haïr, was examined for
individuals ingesting MeHg under different exposure scenarios.
Ingestion sequence : Before attempting reconstruction of individual intake histories, it
was deemed useful ta assess the impact of the time sequence of ingestion on the time
course of biomarkers. The kinetic profiles of total mercury concentrations in blood and
in hair were simulated for different durations of MeHg ingestion and different
ingestion rates. These template scenarios represent individuals consuming either a
single meal contaminated with MeHg, or the same meal every day for one week, one
month, 3 months and 21 months (only after this latter length of time is steady state
practically attained). The progression of total mercury in biological matrices was also
simulated for individuals ingesting one contaminated meal per week during 3 and 14
month periods. Every meal corresponded ta an arbitrary dose of 1 ,ig of MeHglkg of
body weight (BW) and the MeHg background before the onset of exposure was
considered nil. Also, the ratios of total mercury concentration in the 1st cm of hair
closest ta the root ta total mercury concentration in the corresponding blood sample
were evaluated as function of collection times and exposure scenarios. The
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concentration of total mercury in the 1st cm closest to the scalp was retained in the
analysis of hair-to-blood ratio because it is available in almost ail the exposed
individuals, also this concentration reflects the integration of blood exposure during the
month just prior to collection.
Ratio between the total mercury concentration in haïr and that in blood In
Carrier et al. (2001), the values of the transfer rates of organic and inorganic mercury
from blood to hair were determined from the mean data set of Kershaw et al. (1980) on
the time courses of total mercury in the hair and blood of exposed volunteers. Since
these model parameters mainly govern the ratio between the total mercury
concentration in hair and that in blood, sensitivity tests on these transfer rates were
implemented to establish the impact of variability of the hair-to-blood ratio on the
MeHg biomarker levels. Simulations of the exposure scenarios presented above were
executed by varying by ±50% the mean values presented in Carrier et al. (2001). This
variation was chosen based the data set of Walker et al. (2002) described in the section
below.
Reconstruction ofrnethytmercury intakes in indigenous populations
Two databases of MeHg biomarkers were supplied to our research team. These
databases originated from MeHg exposure studies on indigenous populations living in
Canada and in Brazil.
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Indigenous population from Canada From lune 1st 1998 to June 15t 1999, 104
pregnant Inuit women, between ages of 15 and 45 years, agreed to participate in a
biomonitoring study on environmentai contaminants (Walker et ai., 2002). These
women were from communities in the Inuvik region of the Northwest Territories,
Canada. The day of delivery, samples of maternai blood and strands of hair were
coÏlected. Total mercury concentration was measured in blood samples and in each
consecutive segment of 1 or 2 cm cut in the strand of hair. The limit of detection for the
concentration of total mercury in biood was 0.2 tig/1, for hair it was 0.4 gIg. In
addition, Walker et al. (2002) distributed to these women a dietary questionnaire about
their food consumption and estimated thereafter their average daily intake of MeHg
from the amount of each food item multiplied by its known MeHg concentration. The
avaiiable database provides the concentration in hair for 80 women, the concentration
in blood for 94 women and the average daily intake as assessed from the questionnaire
for 86 women.
Since the concentration of total mercury in each segment of hair represents an
integration over time of the mercury transferred from blood to hair roots during the
period corresponding to the segment growth, indirect information about past MeHg
exposure is thus available for women who provided hair samples. 0f course, the period
for which the exposure history can be estimated was determined by the ]ength of the
collected hair strand. In the present work, the model of Carrier et al. (2001) was used to
estimate the temporal profile of MeHg daiiy intakes starting from total mercury
concentrations in hair strands. These back calculations were carried out by iterations,
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varying the estimated MeHg intake rates until an optimal adjustment was achieved
between model simulations and actual data on the total mercury concentration in each
sequential segment of the hair strand. To fit the concentration of mercury in the
segment at the tip of the hair strand (i.e., the segment corresponding to the most distant
time for which past exposure to mercury can be estimated), the model simulations
assumed that, before that month, the MeHg exposure occurred under steady-state
conditions. Also, with the aim of not underestimating the MeHg intakes, the
concentration in the segments of hair with no detectable mercury was set to the limit of
detection. The MeHg daily intakes estimated through this back-calculation were later
compared with the ones estimated from the food frequency questionnaire.
Using the model, the reconstructed temporal profile of MeHg consumption gave, for
each woman providing a hair strand, an estimation of the total mercury concentration in
blood on the day of childbirth. This simulated blood concentration was compared with
the one measured in their blood sample. The comparison could meaningfully be done
only for women whose mercury level in the 1st cm of haïr cut closest to the root was
above the limit of detection.
Indigenous population from Brazil A study was undertaken in the Amazon in
Brazil with the aim of verifying the relationship between the nervous system
dysfunction and levels of MeHg exposure in a fish eating population (Lebel et al.,
1996, 199$; Dolbec et al., 2001). The targeted populations were natives that lived in
Amazonian villages situated on the edge of the river Tapajôs in Brazil. The MeHg
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exposure was evaluated by the total mercury concentration in collected hair strands.
These strands were cut in segments of 1 cm and, the total mercury concentration was
measured for every segment. The available database includes these concentrations for
108 aboriginals. For 45 of them, the hair was collected in 1995, for the other 63, in
2000.
In the current study, the temporal profiles of daily MeHg intakes of 20 natives men and
women (pregnancy status flot specified), were estimated by the same procedure as for
the Inuvik women. The 20 individuals were chosen to afford representative levels of
MeHg exposure in the cohort; to do so, two individuals were selected at random in
every decile group. These deciles were ranked according to the average concentrations
obtained upon pooling their hair segments.
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RESULTS
Main factors governing levets of rnethy!mercuiy biol?tarkers
Methylmercury blood elimination haif-life : Table 1 presents simulations of
biomarker levels in exposed individuals with varying MeHg blood elimination rates.
Increasing the residence time of total mercury in the body (longer MeHg blood
eliminatjon haif-lives) results in an increase in maximum biomarker levels. For a
chronic daily exposure, using a MeHg blood elimination haif-life of 70 days, the
maximums of the total mercury concentrations in hair and in blood are approximately
1.6 times higher than the ones obtained with a haif-life of 39 days. This increase is
however flot noticeable for short exposure periods. In addition, the model simulations
presented in Table 1 show that changing the MeHg blood elimination haif-life has little
impact on the hair-to-blood ratio.
Ingestion sequence : The simulations of the temporal profiles of the total mercury
concentration in blood show that the contaminated meals consumed during the days,
and even the months preceding a blood sampling, significantly influence the blood
concentration. For example for an individual ingesting a daily meal equivalent to a
dose of 1 g MeHglkg BW during one week, the model estimates the maximum
concentration of total mercury in blood immediately after ceasing ingestion at 6.2 LgR;
this is, respectively, 3.7 and 7.8 times Iess than the maximum concentration attained at
the end of one month or 3 months with the same daily dose. The model also showed
that to attain a steady-state blood concentration, the daily exposure needs to occur for
21 months, which would result in a blood concentration of 68.3 jg/l.
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According to the model simulations, the total rnercury concentrations in the l cm of
haïr cut closest to the foot increases following a kinetic pattem similar to the one in
blood. However, there is a time-delay between the mercury level in blood and the
concentration in the proximal cm hair segment as hair concentration stems from the
average blood levels in contact with hair roots over one month. This time-delay effect
diminishes only when the exposure conditions corne close to steady-state conditions.
The analysis of the tirne-profiles of total mercury concentration in hair simulated for a
single MeHg intake and for daily MeHg intakes during a week or a month shows that
the maximum concentrations in the proxirnal cm of haïr are reached about one month
following the end of MeHg exposure, whereas, for daily intakes over three months, the
maximum concentration in hair is reached 10 days after the end of exposure. Also, the
simulated time-profile of total mercury level in hair indicates that the steady-state is
attained after 21 months of a constant daily intake. If the ingestion of contaminated
foods stops when steady-state is reached, the maximum concentration in the proximal
cm is obtained when the hair strand is collected on the termination day.
Figure 1 presents the time-profiles of total mercury concentration in blood and in hair
following the onset of ingestion of one meal of 1 ug of MeHgfkg BW per week for
periods of 3 and 14 months. Between each ingested contaminated meal (seven days),
approximately 7% of total mercury in blood was eliminated; this appears in Figure 1 as
oscillations in the time-profiles of blood concentration. However, no osci]lation in the
hair concentration is observed given that the MeHg exposure remains the same month
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after month and the amount in each one-cm of the hair strand stems from the
integration of the total mercury levels in blood during the month corresponding to the
one-cm growth. As a resuit of the integration of MeHg biood exposure, the total
mercury concentration in hair is approximately the same as the concentration that
would be obtained following the daily ingestion of a meal of 0.14 ig of MeHg/kg BW
instead of 1 ig MeHg/kg per week (i.e., 1 ig of MeHg/kg of BW divided by 7).
Figure 1 illustrates a detectable time-delay between the maximum of the total mercury
concentration in blood and the maximum in the proximai cm of hair for the weekly
MeHg intakes throughout the three months intake, while no time-delay was detectabie
for the weekly exposures for 14 months. For both duration periods, after the first month
without MeHg ingestion, the concentrations in hair and biood follow similar decay
profiles, showing that after this initial time period, a dynamical equilibrium sets in
between blood and hair concentrations. This feature is also observed for ail the daily
exposure scenarios after one month following the last ingestion.
Ratio between the total mercury concentration in hair and that in blood
Simulated ratios between the total mercury concentration in the 1st cm of haïr closest to
the root and the concentration in blood are presented in Table 2 for different durations
of MeHg daily intake and time of collection. It can be seen that hair-to-blood ratio
depends on the duration of MeHg intakes; it increases when the duration of exposure
increases. The ratio is close to a constant value when exposure gets nearer to steady
state conditions, since the time-delay observed between the blood and hair
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concentrations then decreases. According to the model of Carrier et al. (2001) with the
mean parametric values, this constant steady-state ratio is equal to 342. Table 2 shows
that this value is only reached in the case of a chronic daily exposure. Even for a
chronic ingestion of one MeHg contaminated meal per week (see Figure 13), the hair
to-blood ratio is flot constant. Since the blood levels decrease during the days following
ingestion, this ratio depends on the day of blood collection, varying during the week
between 331 and 354.
Also from Table 2, the hair-to-b]ood ratio is much lower if the collection is carried out
on the termination day of MeHg exposure rather than if collection is done one month
after. One month after intake cessation, the ratio is close to a constant value because
the hair and blood concentrations are changing at a similar rate. In fact, the hair-to
blood ratio does flot necessarily depend on the duration of MeHg intakes when the
biological matrices are collected one month or more following the end of exposure, and
this is true even for the once a week exposure scenario. That ratio ranges from 406 to
431 (see Table 2)
The total mercury concentrations in blood predicted by the model of Carrier et al.
(2001) were flot sensitive to the presumed variability of the transfer rates of organic
and inorganic mercury from blood to hair because these transfer rates are relatively
small compared to the other blood elimination rates. However, concentrations in hair
were widely influenced by this variability; in fact, the total mercury levels in hair
varied proportionally to the value of these blood-to-hair transfer rates. As can be
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verified from the resuits presented in Table 2, this proportional response is true for any
ingestion sequences and collection ,times. Also, this Table shows that the exposure and
sampling scenarios are more important in determining the hair-to-blood ratio than the
values of the transfer rates of organic and inorganic mercury from blood to hair.
Reconstruction of methytmercury intakes in indigenous populations
Indigenous population from Canada : The construction of past daily MeHg intakes
in the 80 Inuvik women who supplied hair strands was estimated by adjusting possible
intake rates until an intake profile coupled with the model kinetics yielded a fit to the
measured total mercury concentrations in every consecutive segment of hair. The
estimations of intake rates from the data of four exposed women in the cohort are
illustrated in Figure 2A; they show that there is a reasonable adjustment between the
simulations of the model and the temporal profile of the mercury concentrations
measured in the hair of these women. Good fits were also achieved from total mercury
concentration measured in the hair of the other Inuvik women (results are flot shown).
Comparison of the time-profiles of intakes versus that of hair concentrations presented
in Figure 2A illustrates the delay between the MeHg daily intake rates and the total
mercury concentrations in hair. For example, MeHg daily intake bas to increase
substantially before the appearance of a detectable increase in the hair segment. This
time-delay between intake rates and hair concentrations stems from an important
mechanism at work: rising intake results in rapid rise in blood concentration (days), but
blood concentration needs to be high for a substantial amount of time (weeks) before
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the monthly average of blood-hair root contact, represented in a cm of hair, can rise
similarly. The dose rate reconstructions and the measurements of the total mercury
concentration in the hair segments in Figure 2A show wide variations in the monthly
levels of exposure; in none of the Inuvik women was steady-state ever attained.
For each of the 80 women who provided a hair sample, the reconstructed time-profile
of MeHg daily intakes allows estimation of their average MeHg daily intake for each of
the pregnancy trirnesters. Descriptive statistics on these intakes are presented in Table
3. Only 60 women supplied hair strands long enough to estimate the past exposure to
MeHg during the first trimester of pregnancy. There is, on average, little difference
between MeHg ingested during the trimesters.
In Table 3, descriptive statistics are presented for the average MeHg daily intakes
estimated from the dietary questionnaire of the 69 women who responded to the
questionnaire among the 80 women providing hair strands. The estimates of the MeHg
consumption based on the questionnaire were much higher than the ones based on the
previously described reconstruction of intakes from the total mercury concentrations in
consecutive segments of hair. In fact, the questionnaire gave higher intake estimations
in 58 women of the group of 69. For example, the questionnaire estimated an average
daily intake of 2.73 g of MeHg 1kg BW for a given woman whereas the highest dally
intake based on her reconstructed time-profile is 0.02 tig of MeHg /kg BW. However,
for the woman having the highest mercury levels in lier hair, average daily intake
estimated by the questionnaire is Jess than half of the intakes reconstructed with the
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model. Aiso, the woman with the highest daily intake as estimated by the questionnaire
presented no detectable mercury in her hair.
Figure 2B presents, for 4 women in the Inuvik cohort, the model simulations of the
temporal profile of their total mercury concentration in blood as well as the
concentration measured in the maternai blood sample coilected after childbirth. These
blood concentration simulations were determined using the model ldnetics and the
reconstructed time-profile of MeHg daily intakes based on the observed concentrations
in the consecutive segments of hair strands, independent of the mercury levels in blood.
Figure 2B shows that the simulated values for concentrations of mercury in blood at
the moment of chiidbirth are close to the values measured in the collected blood.
Figure 3 presents the relation between the simulated (x) and measured (y) total
mercury concentrations in blood for the 16 Inuvik women having total mercury
concentrations in the proximal cm of hair above the detection iimit. The points are
fairly close to the plotted une of a would be perfect simulation (y = x). A regression
for the linear function iog(y) = ni . log(x) was carried out by the least-squares method
on the logarithms of the measured and simulated blood concentrations. The logarithm
was used to avoid distortion of fit from high values because the difference between the
lower and higher concentrations (the measured as weii as the simulated) is more than
one order of magnitude. The slope estimator (m) is 0.86 and the 95% confidence
interval of this estimator is IC(95%)=(0.69, 1.02). The determination coefficient (r2) of
this regression is 0.90.
261
Indigenous population from Brazil : The adjustments of the model simulations on
the mercury concentrations measured in every segment of hair allowed reconstruction
of the variations in daily MeHg intakes for the 20 selected Amazonian aboriginals.
Figure 4 presents the resuits of only two simulations carried out: for the two
participants among 20 providing hair strands long enough to back calculate the MeHg
daily intakes for 16 months. This figure shows that a good fit can be obtained between
the model simulations and the measured values; which was also the case for the other
18 aboriginals (results no shown).
A comparison between the temporal profile of the mercury concentrations in hair and
that of daily MeHg intakes illustrates again the delay between the variations of these
two quantities. Also, as for the Inuvik women, the monthly levels of MeHg exposure
vary, so steady-state assumptions are also flot in order here. The variations in MeHg
levels for Amazon natives have been previously reported by Lebel et al. (1997) and by
Dolbec et al. (2001). These authors conclude that the variations are mostly due to
different MeHg content within the types of fish caught during the dry season and the
ones consumed during the rainy season.
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DISCUSSION
The toxicokinetic model of Carrier et al. (2001) was developed for the purpose of
simulating the fate of organic and inorganic mercury in humans exposed to MeHg via
the dietary route. II allows bilateral links between the MeHg dally intake and the
mercury concentration in blood and hair samples collected at any given time following
the onset of any MeHg ingestion period.
Main factors governiltg rnethytmercury tevels ofbiomarkers.
Due to the relatively long elimination haif-life of MeHg, the duration of exposure bas
an important influence on biomarker levels. The model simulations of total mercury
concentrations in blood as well as in hair showed that the MeHg daily intake necessary
to attain a specified maximum concentration has to be much higher for an exposure of
short duration (days or weeks) than for a chronic or extended exposure of several
months. For example, simulations show that, after ingesting each day for one week a
MeHg contaminated meal, the MeHg blood level would be just 10% of the level
reached at steady-state under identical daily intakes. Only after 21 months of constant
identical daily intakes are the conditions for steady-state met; these conditions are
rarely met in real life situations, hence there are dangers of severely biased estimations
if steady-state is assumed. The impact of temporal exposure scenarios may help explain
the large study-to-study difference between uncontrolled and controlled intake studies
with regard to the ratio: “mercury blood concentration / MeHg daily intake” (Sherlock
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and Quinn, 198$; WHO, 1990); these studies often surmise that the fish-eating
populations are exposed to MeHg under steady-state conditions, which is flot the case.
As already mentioned, inter-individual variabiÏity in the MeHg blood elimination haif
life was observed in controlled intake studies (Miettinen et al., 1971; Kershaw et al.,
1980; Sherlock et al., 1980; Smith et al., 1994). In the present study, the impact of this
variation on the biomarker levels was investigated for different durations of MeHg
daily intakes. Under chronic exposure, the simulated maximum total mercury
concentrations in blood and in hair are about twice as high when the elimination haif
life of MeHg in bïood is put equal to 70 days in comparison to 39 days. However, the
consequences of this variation are much less important if the daily exposure has only
occurred for a short period (see Table 1).
In addition to the inter-individual variability observed in MeHg blood elimination haif
lives and in mercury hair-to-blood ratio, there is study-to-study variations in the
observed hair-to-blood ratio: the mean hair-to-blood ratio reported by the observational
and controlling dosage studies vary between 140-370 (FAO, 2003). However, these
ratios must be interpreted very cautiously; as presented in Table 2, this wide range may
stem mainly from differences regarding the exposure scenarios and sampling
procedures. The variability due to the sampling procedure was observed in the study of
Kershaw et al. (1980) where volunteers had ingested a single MeHg contaminated
meal. These authors measured the total mercury concentration in blood sample and in
0.5-cm proximal segment of haïr for each 2 weeks following the ingestion; a 95%
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confidence range of 224-476 for the ratio was calculated for a volunteer who provided
six blood and six haïr samples. Nevertheless, model simulations show that the
variations produced by the exposure durations become negligible when the sampling
procedure is done one month after exposure cessation (see Table 2). Therefore, to
assess inter-individual variability in the hair-to-blood ratio, blood and hair samples
should be collected one month after cessation of MeHg exposure and the concentration
in hair should be based on the proximal segment of the hair strand.
Reconstruction of methylntercury intakes in indigenotts populations
Using the mode! of Carrier et al. (2001), it was possible to reconstruct the temporal
profiles of MeHg daily intakes of pregnant women in the Inuvik region starting from
the total mercury concentration in each segment of the hair strand. Consequently, the
reconstruction does flot require the knowledge of the amounts of contaminated food
consumed and their respective MeHg concentrations. While there is variability in the
parameters of the MeHg kinetics (Stem, 1997; ClewelI et al., 1999), the set of the mean
parametric values from Carrier et al. (2001) aÏlows for good predictïve values of intake
estimates, using as indirect validation the comparison between the simulated and
measured concentrations of total mercury in the blood samples of the 16 women at
child birth (see Figure 3). Despite these encouraging resuits, there stili exist
uncertainties conceming the real time-profile of MeHg intakes because the intra- and
inter-individual variability in the ldnetics of MeHg, in the blood volume and in the hair
growth rate were not accounted for in the modeling. There is also a possible
imprecision in mercury measurements in hair.
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When reconstructing the time-profiles of the MeHg intakes, the variability in the model
parameter values can however be considered. In fact, a range of MeHg daily intakes
couid be obtained by adjusting the model simulations to the hair concentrations using
different MeHg blood elimination rates and transfer rates of the organic and inorganic
mercury from blood to hair. Time-profiles of the MeHg intakes of the 16 women with
detectable mercury levels in the proximal cm of hair were estimated by the model
simulations with parametric values for the blood elimination haif-life of MeHg at the
extremes of the likely range, either 39 or 70 days. With the siower elimination rate (70
days), the estimates of MeHg intakes were reduced by factors ranging between 1.1 and
1.5 compared to the 50 day half-life, whereas they were multiplied by factors between
1.1 to 1.3 with the faster elimination rate (39 days). To assess the impact of variability
in the transfer rate of organic and inorganic mercury from blood to hair, a range of
MeHg daily intakes was back-caiculated for each of these 16 women, using the mean
transfer rate values ± 50%. This range of estimated intakes for a given women was then
applied to predict an interval for her total mercury concentration in blood at delivery.
k was found that the measured values of these blood concentrations were ah within the
simulated interv ais.
Even with the above mentioned uncertainties, the MeHg intakes estimated by adjusting
the model to the measured total mercury levels in the hair strands collected from the
Inuvik women seem more accurate than the estimates based on their answers to the
dietary questionnaire. In fact, the method proposed provides coherence between the
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reconstructed MeHg intakes and the measured biomarker levels, whereas there are
important inconsistencies between the questionnaire estimations and the amounts of
total mercury measured in biological matrices. These inconsistencies, as reported in the
Resuits section, iead one to doubt any inferences based on questionnaires. These
dietary estimations are probably biased by inaccurate recollection of the frequency of
fish and sea mammal consumption and from variations in the MeHg amounts in
traditional/country foods collected in different areas. These biases can have significant
impact when assessing heaith risks related to MeHg ingestion. For instance, the
average daily MeHg intakes reconstructed by the model are much lower than 0.2 g/kg
BW, the value recommended by Health Canada (Health Canada, 1998), whereas the
ones estimated by the dietary questionnaire are close to this recommended value (see
Table 3). Even when the extreme variability of both the MeHg blood elimination haif
life and the hair-to-blood ratio are taken in, the estimated MeHg daily intakes
reconstructed using the model by fitting on hair strand data was lower than the one
estimated through the questionnaires for almost ail women.
The back-calculations of the MeHg daiiy intakes based on the total mercury
concentration in hair strands are applicable to a large range of MeHg exposures.
Applied to data collected from the populations of the Amazon, the back calculations
show that the most exposed aboriginal in that cohort presented a mercury concentration
in the hair about 7 times higher than the most exposed woman in the Inuvik cohort.
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CONCLUSION
The resuits reported in this study may be useful in the design of further biomonitoring
studies. Most important, the probable time duration of MeHg exposure should be
carefully established when back-calculating with a model the MeHg intakes through
the total mercury measured in the biological matrices. It was shown in the present
study that mercury concentrations in every one-cm segment of hair are best to provide
indications of the historical exposure to MeHg; hence, biomonitoring studies should
give priority to hair sampling. The fit between the time-profiles of MeHg hair
concentrations simulated by the toxicokinetic model of Carrier et al. (2001) and the
observed hair concentrations allows good estimates of the daily intakes during the
exposure period to the extent of the length of the hair strand. However, if the collected
hair strand is flot long enough, a dietary questionnaire about eating habits could be
distributed to the exposed individuals just to decide whether the intake was constant,
intermittent or acute. This questionnaire does flot need to quantify the daily MeHg
intake; it is only important to know the period during which the indïvidual might have
consumed contaminated food.
An important advantage of collecting hair strands to monitor the MeHg exposure is that
the total mercury concentration in a one-cm segment is flot substantially influenced by
the most recent contaminated meal, contrary to the concentration in blood samples.
According to the temporal profiles of the total mercury concentration in blood of
volunteers in the study of Kershaw et al. (1980), the mercury level in blood is in
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equilibrium with the one in tissues after 30 to 40 hours following the ingestion of a fish
meal contaminated with MeHg. This implies that the mercury distribution from the
blood to tissues is complete after this period without MeHg exposure. Thus, field
workers collecting blood samples should ask the exposed individuals beforehand flot to
consume foods which miglit have been contaminated with MeHg for at least two days
prior to the blood test.
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Table 1: Effect on the maximum concentration of total mercury in blood QgR)
and in hajr (tgIg) of variations in the value of the assumed metabolic rate of
transformation of organic mercury into inorganic mercury.
Maximum total mercury concentration in blood and hair
Duration of Biological Elimination haif-lives of methylmercury from blood
methylmercury
. i matnxdaily intake
39 days 50 days 70 days
Blood 0.92 jcgll 0.92 ig/l 0.93 JLgfl
Unique dose
Hair 0.25 iigIg 0.26 cgIg 0.27 gIg
Blood 21.82 ig/l 23.01 ig/1 24.30 igR
1 month
Hair 6.53 gfg 6.81 tgIg 7.15 tg/g
Blood 42.30 g/l 48.39 g/l 55.99 tg/l
3 months
Hair 13.99 g/g 15.41 ,uglg 17.22 g/g
Blood 53.08 igf1 67.98 gR 95.09 g/l
21 months
Hair 18.85 g’g 23.28 ,iglg 3 1.34 g/g
Note: The concentrations are estimated from the mode Carrier et al. (2001) using the
parametric values presented by these authors, except for the values of the elimination
haif-Jife of MeHg from blood.
‘Bach ingested dose is equivalent to 1 g of methylmercury/kg body weight.
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Table 2 : Simulated ratio of total mercury concentration in flic 1st centimeter of
hair closest to the root Qig/g) and in blood (cg/mI) as function of collection times
and different durations of methylmercury daily intakes.
Ratio of hair-to-blood concentrations’
Collection tirnesDuration of (tirne elapsed since the cessation of exposure)
methylmercury
daily intake Day of One One Two Three
cessation week rnonth months rnonths
4.5 86 407 420 423Unique dose (2.2- 6.7) (43- 129) (209- 629) (210- 633) (21 1- 635)
39 124 419 421 423One week (19- 58) (62- 186) (209- 630) (210- 633) (211- 635)
179 267 420 422 4241 rnonth (90-269) (134-401) (210-631) (211-634) (212-636)
306 348 421 423 4253 months (153-459) (174-522) (210-633) (211-636) (212-639)
3422 372 425 428 43121 months (171-513) (186-558) (212-639) (214-643) (215-648)
The ratios were estimated from the Carrier et aI. (2001) mode! using the pararnetric
values presented by these authors (top). A variation of ±50% on the transfer rate of
organic and inorganic from blood to hair yields a range of hair-to-blood ratios (in
parentheses).
2 At the end of this exposure, the steady-state conditions are reached, but these
conditions are lost at times after exposure ceases.
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Table 3: Descriptive statistics on average daily intakes of metliylmercury Qglkg
body weight) for the women from the Inuvik cohort (Walker et aI., 2002): j)
estimated from the model simulations based on the total mercury concentrations
measured in the consecutive segments of hair; ii) average daily intakes as
estimated by the questionnaire.
Average daily intake of methylmercury
(cgIkg body weight)
Estimated by the model from hair
concentrations Estimated by
the1St trimester 2’trimester 3rd trimester of questionnaire
of pregnancy1 of pregnancy1 pregnancy
Arithmetic mean 0.04 0.03 0.03 0.20
Standard 0.07 0.07 0.05 0.35deviation
Minimum 0 0 0.015 0
Maximum 0.49 0.56 0.34 2.73
Number of 60 72 80 69individuals
‘Estimated by optimal adjustment of the simulations based on the Carrier et al. (2001)
model to fit the data on the mercury concentration in each consecutive cm of the hair
strand.
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CAPTIONS TO FIGURES
Figure L Model simulations of the lime-profiles of total mercury concentration in
blood t—) and in the 1st centimeter of hair closest to the root (----) following ingestion
of a once a week intake of 1 pg of methylmercuryfkg of body weight: 3-months
exposure (A) and 14-months exposure (B).
Figure 2. (j) Historical reconstruction of daily intakes of methylmercury (g/kg of
body weight) prior to the hair collection at time O () from model simulation (----) of
the measured data (n) on mercury concentration in successive centimeters of hair
(gIg) in 4 women from the Inuvik cohort (Walker et al., 2002). (ii) Simulated time
profile (--) of total mercury concentration in blood (ig/l) from the reconstructed
intake compared to measured data (x).
Figure 3. Comparison between measured and simulated total mercury concentration in
blood (tLg/l) for the 16 women from the Inuvik cohort with mercury levels in the
proximal cm of hair above the detection limit (Walker et al., 2002). The simulated
value for each woman was obtained using the model of Carrier et al. (2001) in
combination with their measured time-profile of total mercury concentration in hair.
The une () represents the linear equation yx.
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Figure 4. (j) Historical reconstruction of daily intake of methylmercury (jiglkg of body
weight) prior to the hair collection at time O (—) from model simulation t----) of the
measured data (o) on mercury concentration in successive centimeters of hair (tg/g) in
2 natives from the Amazon cohort (Lebel et al., 1998; Dolbec et al., 2001).
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CHAPITRE $ : CONCLUSION GÉNÉRALE
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Les travaux de cette thèse proposent aux intervenants de la santé des outils pour les
aider à évaluer l’exposition et prévenir les risques encourus par les personnes exposées
à cinq substances toxiques trois insecticides de la famille des organophosphorés
(parathion, malathion et chlorpyrifos), un phytocide largement utilisé comme herbicide
(triclopyr), et finalement le méthylmercure. L’approche consiste à mesurer les niveaux
de biomarqueurs de ces substances dans des matrices biologiques accessibles et à les
comparer à des valeurs repères pour estimer l’exposition individuelle et le risque pour
la santé associé à cette exposition. Les outils proposés possèdent toutes les qualités
recherchées dans un test de dépistage ils sont facilement applicables, ont un haut
degré de spécificité et de sensibilité et permettent la détection de l’exposition bien
avant l’apparition d’effets toxiques. En particu]ier, les mesures des métabolites des
organophosphorés permettent de déceler le niveau d’exposition bien avant qu’il y ait
inhibition détectable des cholinestérases. Le non-dépassement des valeurs repères,
présentées sous forme de valeurs de référence biologiques, devrait permettre de
prévenir les effets toxiques chez les individus les plus sensibles de la population ciblée.
Des stratégies d’échantillonnage adaptées aux diverses substances étudiées et aux
scénarios d’exposition les plus souvent rencontrés dans la réalité sont également
proposées pour permettre l’évaluation précise de l’exposition interne de chaque sujet.
L’utilisation des niveaux de biomarqueurs comme mesures de l’exposition et
indicateurs d’effets physiologiques de ces substances a été rendu possible grâce à une
approche qui consiste, dans un premier temps, à développer OLI à adapter des modèles
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mathématiques de la cinétique de ces substances et de leurs métabolites à partir de leurs
profils temporels dans des matrices biologiques collectées chez l’humain et, dans un
deuxième temps, à établir les relations de type « dose absorbée—réponse toxique » à
partir d’une revue de la littérature. La conjugaison de ces deux démarches a permis de
déterminer des niveaux de biomarqueurs en deçà desquels acicun effet ne devrait être
observé chez l’humain.
Cette approche permet d’utiliser des mesures de biomarqueurs en situations réelles
pour estimer une dose absorbée dans le passé ou le devenir d’une dose sans avoir
recours à des mesures de concentrations dans le milieu d’exposition et sans connaître la
fraction d’absorption des diverses voies d’entrée dans l’organisme. De plus, pour la
plupart des substances étudiées, les biomarqueurs sont sensibles et spécifiques,
augmentant ainsi la validité et la pertinence de la mesure de l’exposition. Le présent
travail fournit donc des outils très utiles à la réalisation d’études épidémiologiques qui
viseraient à évaluer l’impact d’une exposition à une ou l’autre des substances étudiées.
Pour les quatre pesticides, des simulations avec les modèles cinétiques ont permis
d’évaluer l’effet de divers scénarios temporels d’exposition, de diverses voies d’entrée
et divers taux d’absorption sur l’estimation de la dose absorbée qui est reconstruite à
partir des niveaux de biomarqueurs accumulés dans l’urine. Des tests de sensibilité ont
démontré que le paramètre cinétique qui a le plus d’influence sur l’estimation de la
dose absorbée est le taux d’absorption par voie cutanée, taux beaucoup plus faible et
plus variable que les taux des voies orale et pulmonaire. Ces tests ont montré que les
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résultats sont peu sensibles au taux de biotransformation et de distribution de la
molécule-mère, puisqu’ils sont environ 15 fois plus élevés que les taux d’absorption
cutanée et d’excrétion des métabolites qui s’avèrent déterminants pour la cinétique
observée. Considérant ce résultat, les valeurs de référence biologiques, jugées
sécuritaires pour une exposition professionnelle, ont été établies avec le scénario
d’exposition qui est le plus conservateur une exposition constante durant une période
de huit heures consécutives, uniquement par la peau et où la charge corporelle du
pesticide ou de ses métabolites au début de cette période est nulle. La marge de sécurité
induite par ce scénario est expliquée en détails dans les articles portant sur les
pesticides.
Une analyse a également été réalisée pour évaluer l’impact de différents scénarios
d’exposition sur les niveaux de biornarqueur du MeHg. En effet, pour cette substance,
le taux d’absorption n’a aucune influence sur les concentrations sanguines ni sur celles
dans les cheveux et ce, quel que soit le scénario d’exposition. Ceci s’explique par la
grande différence des échelles de temps gouvernant l’absorption et l’élimination ; la
demi-vie d’élimination du Met-1g est d’environ 50 jours alors que celle de l’absorption
est tout au plus de 3 heures pour une absorption orale. Des variations dans le taux
d’absorption ont alors peu de répercutions à moyen terme sur les niveaux de mercure
dans le sang et les cheveux. Par ailleurs, la fréquence de consommation de produits
contaminés au MeHg et la durée de l’exposition sont régies par des échelles de temps
mesurées en semaines, tout comme la demi-vie d’élimination; les scénarios temporels
de consommation ont donc un impact important sur les niveaux de biomarqueurs.
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Toutefois, les variations mensuelles dans la consommation ont plus d’influence sur les
niveaux biologiques que les variations de la demi-vie d’élimination du MeHg.
Une retombée importante de cette recherche touche les stratégies de collecte des
échantillons biologiques pour les diverses substances étudiées. Par exemple, pour les
pesticides étudiés, il ressort qu’une urine cumulative de 24 heures ou plus depuis le
début d’une période d’exposition est souhaitable pour reconstruire avec un bon degré
de précision la dose cumulative absorbée par les individus. Pour le Mel-lg. suite à de
courtes périodes d’exposition (i.e.. ingestion journalière durant un mois ou moins), il
est suggéré d’effectuer la collecte de cheveux un mois après la fin de l’exposition afin
de s’assurer que les cheveux aient eu le temps d’intégrer par leurs racines la présence
du mercure dans le sang durant une période assez longtemps pour que cela apparaisse
dans le centimètre proximal retenu pour le test.
L’utilisation du modèle cinétique du MeHg a permis une bonne adéquation entre les
niveaux de biomarqueurs mesurés chez un individu et les quantités de MeHg ingérées.
En effet, contrairement aux apports en MeHg estimés à partir d’un questionnaire
alimentaire et de la contamination mesurée dans la nourriture, les apports reconstruits à
partir du modèle de Carrier et coll. (2OO) assurent une cohérence entre les apports
estimés de MeHg et les quantités de mercure total mesurées dans les matrices
biologiques.
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L’application de l’approche proposée dans cette thèse à des données provenant de
travailleurs exposés au malathion et au triclopyr et à celles provenant de populations
autochtones exposées au MeHg montre bien l’utilité de ces outils dans un programme
de prévention. Leur principale qualité comme signal de risque est de détecter
l’exposition à des niveaux bien inférieurs à ceux induisant des effets toxiques et par le
fait même à un stage beaucoup plus précoce que celui obtenu en utilisant des
biomarqueurs d’effets.
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APPENDICE : CONTRIBUTION
JCONTRIBUTION SPÉCIFIQUE DE LA CANDIDATE À CHA CUN DES
ARTICLES DE CETTE THÈSE
Malathion (Article 1) et Parathion (Article 2)
• Contribution significative au développement du modèle cinétique
o Mise au point du système d’équations différentielles
o Détermination et validation des valeurs paramétriques
• Contribution significative à l’application du modèle cinétique
o Réalisation des tests de sensibilité
o Détermination d’un scénario d’exposition pour déterminer les valeurs de
référence biologiques
• Contribution à l’analyse de la littérature pour déterminer la DSEO
• Contribution significative à la rédaction des articles
o Ecrire l’article du parathion
o Correction de l’article du malathion écrit par Michèle Bouchard
Chlorpyrifos (Article 3)
• Contribution au développement du modèle cinétique
o Détermination et validation des valeurs paramétriques
• Contribution significative à l’application du modèle cinétique
o Réalisation des tests de sensibilité
o Détermination du scénario d’exposition pour déterminer les doses de
référence biologique
• Contribution à la rédaction de l’article
o Correction de l’article écrit par Michèle Bouchard
Triclopyr (Article 4)
• Contribution significative au développement de l’analyse des risques
toxicologiques chez les travailleurs de l’étude:
o Adaptation du modèle de Carmicheal et colI. (1989)
o Réalisation des simulations du modèle
• Reconstruction de leur dose absorbée à partir des urines
cumulatives collectées par Amssettou Dosso
• Tests de sensibilité
• Etablir les valeurs de référence biologiques
o Recherche de la dose sans effet nocif observé
• Ecrire l’article
Méthylmercure (Article 5)
• Contribution significative à l’application du modèle de Carrier et colI. (2001)
o Reconstruction de l’historique des apports quotidiens en méthylmercure
chez les autochtones ciblés
o Réalisation de simulations portant sur différents scénarios d’exposition
afin d’effectuer une analyse de sensibilité des paramètres et variables
i mpl iqLtés
• Écrire l’article
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